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ABSTRACT OF THESIS

EVOLUTION OF EQUINE ARTERITIS VIRUS DURING PERSISTENT INFECTION
IN THE REPRODUCTIVE TRACT OF THE STALLION AND THE MALE DONKEY

Equine arteritis virus (EAV) establishes persistent infection in the stallion
reproductive tract, and the carrier stallion continues to shed virus in semen for weeks to
years or lifelong. The objective of this study was to elucidate the intra-host evolution of
EAV during persistent infection in stallions. Seven EAV seronegative stallions were
experimentally infected with EAV KY84 strain and followed for 726 days post-infection,
and sequential clinical samples including semen were collected for virus isolation and
next-generation sequencing (NGS). In addition, archived sequential semen samples from
two stallions that were naturally infected with EAV KY84 for a long-period (up to 10
years) were also sequenced by NGS. The data demonstrated genetic bottleneck event and
selection during acute infection followed by intra-host quasispecies diversification during
persistent infection in the stallion reproductive tract.
Also, the full-length genome of a novel EAV donkey strain from Chile and a
noncytopathic bovine viral diarrhea virus-1 (ncpBVDV-1) strain contaminating rabbit
kidney-13 cells were also sequenced by NGS. The EAV donkey strain was genetically
distinct but antigenically cross-reacted with EAV antisera, and it was phylogenetically
closely related to the South African donkey strain of EAV. Genetic and phylogenetic
analyses demonstrated that ncpBVDV-1 belongs to BVDV-1b group.

KEYWORDS: Equine arteritis virus, equine viral arteritis, persistent infection, intra-host
evolution, quasispecies, bottleneck event
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CHAPTER ONE
Literature Review

1. Introduction
Equine arteritis virus (EAV) is a small, enveloped, positive-sense, single-stranded
RNA virus that belongs to the family Arteriviridae (genus: Equartevirus, order:
Nidovirales)1. Viruses in the order Nidovirales (Arteriviridae, Coronaviridae and
Roniviridae) have a similar genome organization and viral replication strategy, mainly
characterized by the generation of a nested set of subgenomic viral messenger RNAs (sg
mRNAs)

1–6

. Recently, the International Committee on Taxonomy of Viruses (ICTV)

reorganized the genus designation and proposed expansion of the family Arteriviridae, a
taxonomic group that includes EAV, porcine reproductive and respiratory syndrome virus
(PRRSV), lactate dehydrogenase-elevating virus (LDV) of mice, simian hemorrhagic
fever virus (SHFV), wobbly possum disease virus (WPDV) and African pouched rat
arterivirus (APRAV-1)6–8.
EAV is the causative agent of equine viral arteritis (EVA), which is a
reproductive and respiratory disease of the family Equidae that occurs worldwide9–13. In
1953, EAV was first isolated from the lung of an aborted fetus during an extensive
outbreak of respiratory disease and abortion on a Standardbred breeding farm near
Bucyrus, OH, United States of America (USA)9,14. While there is only one known
serotype of EAV, field strains of the virus can vary in virulence and neutralization
capabilities15–21. The clinical signs of EVA are variable depending on the age and
physical condition of the horse, route of exposure, virus strain, challenge dose and
environmental factors22,23. Most importantly, EAV can cause abortion in pregnant mares,

1

neonatal death in young foals, and establishment of persistent infection in 10-70% of
infected stallions (carrier state), with significant economic consequences for the equine
industry11.
This chapter provides a review of EAV (replication cycle, viral structure and
neutralization determinants) and of the disease it causes (EVA) including epidemiology,
modes of transmission, immune response, clinical signs, pathogenesis, persistent
infection in the stallion, diagnosis, treatment, prevention and control. Lastly, an overview
will be presented on RNA virus quasispecies structure and evolutionary mechanisms.

2

1.1. Equine arteritis virus (EAV)
1.1.1. Classification and genome organization
Table
TheNidovirales
new classification of the Order Nidovirales
Table 1.1.
1.1. Order
Order

Family

Subfamily

Genus
Dipartevirus
Equartevirus
Nesartevirus

Species
Wobbly possum disease virus
Equine arteritis virus
African pouched rat arterivirus
Lactate dehydrogenase-elevating virus
Porcine reproductive and respiratory syndrome virus 1
Porartevirus
Porcine reproductive and respiratory syndrome virus 2
Rat arterivirus 1
DeBrazza's monkey arterivirus
Arteriviridae
Free State vervet virus
Kafue kinda chacma baboon virus
Kibale red colobus virus 1
Kibale red colobus virus 2
Simartevirus
Kibale red-tailed guenon virus 1
Mikumi yellow baboon virus 1
Pebjah virus
Simian hemorrhagic encephalitis virus
Simian hemorrhagic fever virus
Alphacoronavirus 1
Bat coronavirus CDPHE15
Bat coronavirus HKU10
Human coronavirus 229E
Human coronavirus NL63
Alphacoronavirus Miniopterus bat coronavirus 1
Miniopterus bat coronavirus HKU8
Mink coronavirus 1
Porcine epidemic diarrhea virus
Rhinolophus bat coronavirus HKU2
Scotophilus bat coronavirus 512
Betacoronavirus 1
Hedgehog coronavirus 1
Human coronavirus HKU1
Middle East respiratory syndrome-related coronavirus
Nidovirales
Coronavirinae
Batacoronavirus Murine coronavirus
Pipistrellus bat coronavirus HKU5
Rousettus bat coronavirus HKU9
Severe acute respiratory syndrome-related coronavirus
Coronaviridae
Tylonycteris bat coronavirus HKU4
Bulbul coronavirus HKU11
Common moorhen coronavirus HKU21
Coronavirus HKU15
Munia coronavirus HKU13
Deltacoronavirus
Night heron coronavirus HKU19
Thrush coronavirus HKU12
White-eye coronavirus HKU16
Wigeon coronavirus HKU20
Avian coronavirus
Gammacoronavirus
Beluga whale coronavirus SW1
Fathead minnow nidovirus 1
Bafinivirus
White bream virus
Bovine torovirus
Equine torovirus
Torovirus
Torovirinae
Human torovirus
Porcine torovirus
Ball python nidovirus 1
Unassigned
Bovine dinovirus 1
Chinook salmon nidovirus 1
Alphamesonivirus 1
Alphamesonivirus 2
Alphamesonivirus Alphamesonivirus 3
Mesoniviridae
Alphamesonivirus 4
Alphamesonivirus 5
Mesonivirus 1
Unassigned
Mesonivirus 2
Roniviridae
Okavirus
Gill-associated virus

3

EAV was initially classified as a non-arthropod-borne togavirus along with LDV
and SHFV because of the similarity of their virion morphology and protein
compositions24–26. In 1984, the genus Arterivirus was established within the family
Togaviridae27,28. However, since neither togaviruses nor flaviviruses synthesize a 5′-3′coterminal set of nested sg mRNAs during viral replication, the replication strategy of
EAV was more closely related to that of coronaviruses, LDV, SHFV and PRRSV3,29–33.
Thus, the 6th ICTV report (1995) assigned all four viruses (EAV, LDV, SHFV and
PRRSV) to the genus Arterivirus, following which the 7th ICTV report (2000) announced
that the genus Arterivirus belongs to a new family (Arteriviridae) under a new order
Nidovirales34,35. Recently, the ICTV proposed a reorganization and expansion of the
family Arteriviridae. Under the new proposed classification, the genus designation
“Arterivirus” is now specifically divided into Dipartevirus, Equartevirus, Nesartevirus,
Porartevirus and Simartevirus27. Currently, there are four families (Arteriviridae,
Coronaviridae, Mesoniviridae and Roniviridae) within the order Nidovirales, and the
family Arteriviridae is formalized by five genuses: Dipartevirus, Equartevirus,
Nesartevirus, Porartevirus and Simartevirus (Table 1.1.).
The EAV virion is an enveloped, spherical, 50 to 65 nm particle with an isometric
core that contains a single-stranded, positive-sense ribonucleic acid (RNA) molecule
(Figure 1.1.B.). The EAV genome length varies between 12,704 to 12,731 bp among
different virus strains and includes a 5 leader sequence (224 nucleotides) and at least ten
open reading frames (ORFs; Figure 1.1.A.). The two large ORFs 1a and 1b occupy the 5′proximal three-quarters of the EAV genome and encode two replicase polyproteins (pp1a
and pp1ab) directly translated from the genomic RNA3. These two large replicase
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polyproteins are processed into at least 13 nonstructural proteins (nsp1-12, including
nsp7α/β) by three viral proteases (nsp1, nsp2 and nsp4)36,37. The 3′-distal quarter of the
genome consists of eight ORFs (ORF 2a, 2b, 3-4, 5a, 5b, 6 and 7), which encode for the
structural proteins E, GP2, GP3, GP4, GP5a protein, GP4, M and N proteins,
respectively5,38–41. The seven envelope structural proteins (E, GP2, GP3, GP4, GP5a
protein, GP5 and M) are classified into two major envelope proteins (GP5 and M) and
five minor envelope proteins (E, GP2, GP3, GP4 and ORF5a protein)1. The structural
proteins are expressed from a 3′-coterminal nested set of six sg mRNAs (2-7) that have a
common 5′ leader sequence and transcription regulating sequence (TRS) at the 5′-end of
each sg mRNA (Figure 1.1.A.)29,42,43. The sg mRNAs function monocistronically, except
for the bicistronic sg mRNAs 2 and 5. The protein translation of sg mRNAs 2 (E and GP2
proteins) and 5 (ORF5a protein and GP5) is expressed by leaky scanning of the 5′proximal end of the same sg mRNAs39,40.

5

Figure 1.1. Schematic representations of EAV genome organization and gene
expression and of the EAV virion particle. (A) The ORFs 1a/b are located at the 5′-end
of the genome and are translated into two replicase polyproteins (pp1a and pp1ab) and
further processed into at least 13 nsps by three viral proteases (PCPβ, CP and
3CLSP)3,36,37 (B) The EAV virion particle contains seven envelope structural proteins: E,
GP2, GP3, GP4, ORF5a protein, GP5 and M. The N protein encapsulates the linear,
positive-sense, single-stranded RNA genome. This schematic representation was
modified from Balasuriya et al. (2013) from Elsevier with permission1.
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1.1.2. Nonstructural proteins of EAV
The replicases pp1a and pp1ab encoded by ORF1a/1b undergo proteolytic
processing at 11 cleavage sites by viral proteases (two papain-like cysteine protease
domains: “accessory protease” nsp1, nsp2 and a chymotrypsin-like serine: “main protease”
nsp4 which is encoded by ORF1a) and results in 13 nsps (nsp1-12, including
nsp7α/β)1,36,37. The ORF1a protein is comprised of eight cleaved end products, nsp1-8
including a number of processing intermediates44–46.
The nsp1 is an “accessory protease” that functions in virion biogenesis and
processes the replicase polyprotein to produce sg RNA47,48. The nsp2 is another
“accessory protease” responsible for the cleavage of the nsp2/3 site through auto-protease
activity and the cofactor for processing of the nsp4/5 site44,48,49. The nsp3 is a
transmembrane protein involved in double-membrane vesicle formation48,50. The nsp4 is
the “main protease” that plays a significant role during the cleavage of nsp3-8 and nsp31244,48. The nsp5 participates in the formation of the EAV replication complex44,48. The
nsp7 is further processed into nsp7α/β; the functions of nsp6-8 are undetermined44,48,51.
The ORF1b translation (expression of pp1ab) occurs through a -1 ribosomal
frameshift mechanism by a “slippery” sequence localized in the overlapping region of
ORF1a/1b3,36,37,44,45,49,52–62. The ORF1b generates four major protein products after
processing mediated by nsp4 that include the RNA-dependent RNA polymerase (RdRp,
nsp9) and the NTPase/RNA helicase domains (nsp10), which are necessary for viral
RNA replication and mRNA transcription3,44,48,63,64. The nsp11 has endoribonuclease
activity important for viral RNA synthesis

48,65

. Lastly, the function of nsp12 has not yet

been determined1. The mature nsps are also involved in the constitution of the membrane-
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anchored replication/transcription complex (RTC) that promotes viral genome replication
and synthesis of the nested set of sg mRNAs for the expression of the viral structural
proteins66,67. Previous immunofluorescence studies have demonstrated that the ORF1bencoded replicase subunits are observed in the perinuclear region of EAV infected cells;
this suggested that the ORF1b-encoded replicase subunits might be associated with
intracellular membranous compartments in the endoplasmic reticulum (ER)61.

1.1.3. Structural proteins of EAV
1.1.3.1. Minor envelope proteins
The EAV virion contains five minor envelope proteins: E, GP2, GP3, GP4 and
ORF5a protein encoded by ORF2a, ORF2b, ORF3, ORF4 and ORF5a, respectively
(Figure 1.2.)1. The unglycosylated envelope protein E is highly hydrophobic and
predicted to be a type III integral membrane protein and is intermediately abundant in the
virion40. The E protein is essential for the production of infectious progeny 40,41. The GP2
is a type I transmembrane minor envelope protein that is highly conserved on sequence
comparison analysis68. Although GP2 is not essential for viral RNA replication and
transcription40,69, it is essential for the production of infectious progeny40,48. According to
Wieringa et al. (2002), suppression of ORF3 expression restrains the production of
infectious virus particles, which implies that GP3 membrane-associated envelope
glycoprotein is essential for viral replication48,70. The GP3 is predicted to be either a type
II protein or a class IV protein70,71. Although the function of GP4 is not fully understood,
it is predicted to be as essential for viral replication as GP348,70. The ORF5a protein is a
novel structural protein encoded by an overlapping region in the 5′-end of ORF539,72. The
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ORF5a protein is a type III membrane protein that is expressed from the same sg mRNA
as GP5 and is possibly involved in the leaky ribosomal scanning1. The function of ORF5a
protein is not fully understood, but it is predicted to be essential for viral replication and
infectivity 1,39.

Figure 1.2. Predicted membrane topology of the minor envelope proteins (E, GP2,
GP3, GP4 and ORF5a protein). Two alternative topology predictions for E and GP3
enveloped membrane proteins are demonstrated above. Predicted N-glycosylation sites in
these proteins are shown in yellow circles with corresponding amino acid positions.
Modified from Balasuriya et al. (2013) from Elsevier with permission1.

The minor envelope proteins GP2, GP3 and GP4 are abundantly expressed in
EAV

infected

cells

and

covalently

form

a

GP2/GP3/GP4

heterotrimeric

complex38,41,70,73,74. The GP2 and GP4 proteins are both type I integral membrane
proteins that contain one and four functional N-glycosylation sites, respectively (Figure
1.3.)1,70,75. The intermolecular cysteine bridges with intra-chain disulfide bonds play a
significant role in the conformation and stabilization of the GP2/GP3/GP4 heterotrimeric
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complex (Figure 1.3.)74. The E protein may act as an intermediate receptor and is
associated with the GP2/GP3/GP4 heterotrimeric complex during the process of viral
attachment/entry and production of infectious viral progeny1,76.

Figure 1.3. Predicted alternative topology models of the GP2/GP3/GP4 heterodimer
complex. The GP3 envelope membrane protein is predicted to be either a class II
membrane protein (A) or a class IV membrane protein (B). The intermolecular cysteine
bridges are predicted with the covalently-linked disulfide bonds (S-S) at the Cys positions.
Putative N-glycosylation sites are shown in yellow circles with corresponding amino acid
positions. Modified from Wieringa et al. (2003) with permission74.

1.1.3.2. Major envelope proteins
The membrane glycoprotein GP5 and nonglycosylated membrane (M) protein are type IV
integral membrane proteins encoded by ORF5b and ORF6, respectively38,77. The GP5
and M large envelope proteins form disulfide-linked heterodimers in the virus particles
(Figure 1.4.B.). There are four major neutralization determinants of EAV that have been
identified in GP5, located at aa 49 (site A), 61 (site B), 67-90 (site C) and 98-106 (site D)
10

(Figure 1.4.A.)15,16,20,78–81. Site D expresses overlapping linear epitopes that may enable it
to interact with three other neutralization sites (A-C) to establish conformational
epitopes15,16,81,82. The nonglycosylated M protein acts as an important scaffold for the
correct folding of GP5 in order to generate the neutralizing epitopes1.

Figure 1.4. Schematic membrane topology of GP5 and M heterodimer structure. (A)
Four major neutralization determinants of EAV are shown at aa 49 (site A), 61 (site B),
67-90 (site C) and 98-106 (site D) in the GP5 protein. (B) The covalently-linked
heterodimer complex is formed by a disulfide bond (S-S) between Cys-34 in the GP5
protein and Cys-8 in the M protein. Putative N-glycosylation sites are shown in yellow
circles with corresponding amino acid positions: Asn-56 and Asn-81. Another Nglycosylation site (Asn-73) that was recently found in isolates from an EVA outbreak in
North America21 is shown in a blue circle. Modified from Balasuriya et al. (2013) from
Elsevier with permission1.
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In EAV infected cells, the newly synthesized GP5 proteins recruit existing M
proteins from the ER to form a disulfide-linked heterodimeric complex1,75. The disulfidelinked heterodimeric complex of the two major envelope proteins are formed by the
disulfide bridge between two cysteine (Cys) residues at amino acid position Cys-8 of M
and Cys-34 of GP573. The heterodimerization of the GP5 and M is indispensable for viral
infectivity and production of infectious virus particles41,69,83. The GP5/M disulfide-linked
heterodimer complex acts as a bridge between the nucleocapsid and the viral envelope
during viral assembly83,84. Lastly, the GP5/M heterodimerization complex plays an
essential role in post-translational modification (i.e. glycosylation) and conformational
maturation of the neutralization determinants in the GP5 ectodomain82,85.

1.2. The replication cycle of EAV
The EAV life cycle begins with the infection of susceptible cells with EAV
(Figure 1.5.). EAV can be replicated in various primary cell cultures including equine
endothelial cells, equine kidney cells, monocytes, macrophages and a small
subpopulation of CD3+ T cells1,86–88. EAV has tropism for a broad range of host cell types,
and it can be propagated in several continuous cell lines such as baby hamster kidney
(BHK-21), African green monkey kidney (Vero, MA-104), rabbit kidney (RK-13) and
human kidney cells1,89–91. EAV infection is highly cytocidal in both primary and
continuous cell lines, and it replicates to produce high titered virus causing cytopathic
effect (CPE)89,90.
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Figure 1.5. Schematic diagram of EAV replication cycle. ER: endoplasmic reticulum;
ERGIC: ER-Golgi intermediate compartment; NC: nucleocapsid. Modified from
Balasuriya et al. (2013) from Elsevier with permission1.

1.2.1. Virus attachment and entry
The replication cycle of EAV involves virus attachment and entry, biosynthesis
(viral genome replication, mRNA transcription and viral protein synthesis [translation]),
virus assembly, budding and release92. Asagoe et al., (1997) have shown that heparin,
which is a glycosaminoglycan (GAG), can inhibit EAV infection of RK-13 cells but the
mechanism of the inhibitory activity by heparin was not elucidated93. The first step in the
virus replication cycle is viral attachment and entry that is mediated by a specific receptor
on EAV-susceptible cells92. Heparin sulphate (HS) is commonly used as an attachment or
13

binding molecule for numerous viruses and other pathogens as it is ubiquitously present
on the surface of animal cells and in the extracellular matrix, where the initial interactions
of viruses and target cells occur. Thus, EAV may also be using HS on cell surfaces as the
initial attachment molecule94.
Recently, Sarkar et al. (2016) identified EqCXCL16S as an EAV entry receptor
on EAV-susceptible cells95,96. CXCL16S protein has scavenger receptor properties and is
expressed on equine endothelial cells, a subpopulation of CD3+ T cells and a
subpopulation of CD14+ monocytes; its distribution in cells of the reproductive tract has
not however been determined. The EqCXCL16 gene is located on equine chromosome 11
(ECA11; positions 49572804 to 49643932), and encodes a type I glycosylated
transmembrane protein95,97. Two isoforms of EqCXCL16 have been identified
(EqCXCL16S and EqCSCL16R). Interestingly, the protein isoform EqCXCL16S but not
EqCXCL16R can function as an EAV cellular receptor. Although both molecules have
equal chemoattractant potential, EqCXCL16S has significantly higher scavenger receptor
and adhesion properties compared to EqCXCL16R. However, EqCXCL16S is certainly
not the only receptor because EAV can infect not only equine cells, but also a wide range
of commonly used laboratory continuous cell lines from other species of animals1,86–91.
Similar to other enveloped viruses, EAV tends to bind to a cell surface receptor followed
by membrane fusion95,98; it is assumed to enter the cell via clathrin-dependent
endocytosis99,100. However, EAV attachment and entry mechanisms still need to be
further investigated. This should include investigation of the possible role of other virus
attachment molecules on the cell surfaces, unknown receptors and co-receptors in
different cells and the mechanism of fusion between EAV and the target host cell.
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Specific viral proteins involved in EAV attachment and entry are not well
characterized. However, there have been several studies that investigated the role of
major (GP5 and M) and minor envelope (E, GP2, GP3 and GP4) proteins of the virus in
EAV attachment and entry. Firstly, GP5 protein was assumed to be a virus attachment
protein and acts as the receptor recognition. However, an in vitro reverse genetics
experiment using a chimeric EAV construct in which the ectodomain of the EAV GP5
protein was replaced by that of other arteriviruses (e.g. PRRSV or LDV) resulted in no
alteration in the viral cell tropism101. This chimeric virus was still able to propagate in
BHK-21 and RK-13 cells. Thus, the ectodomain of the GP5 protein was not the major
determinant of EAV tropism in cell culture101. A similar study was performed with the
ectodomain of the M protein of a PRRS mutant virus, where its exchange for that of EAV
or LDV did not alter the tropism for porcine alveolar macrophages. It was concluded that
the M protein of arteriviruses is not responsible for receptor binding84. Secondly, the E
protein is noncovalently associated with the minor structural proteins that integrate the
GP2/GP3/GP4 heterotrimeric complex41. Although the association of this complex is
essential for viral infectivity, it is not required for the formation of EAV particles; studies
have suggested that the GP2/GP3/GP4/E complex might be involved in the EAV
attachment and entry process and that the virus uses more than one attachment molecule
for binding to the host cell41,69. Thirdly, EAV was presumed to attach and enter the host
cells via a mechanism of receptor-mediated clathrin-dependent endocytosis similar to
PRRSV99,100,102. There are no definitive studies however that have identified the EAV
viral proteins involved in virus attachment and entry or, for that matter, the detailed
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mechanisms of viral entry and release of the EAV genome into the cytoplasm to initiate
viral replication.

1.2.2. Post-translation in processing of replicase polyproteins
Translation of the EAV replicase polyproteins (pp1a and pp1ab) generates at least
13 nsps after cleavage mediated by three ORF1a-encoded proteases (nsp1, nsp2 and nsp4)
(Figure 1.6.)36,37,103. The pp1a is translated directly from ORF1a and processed at seven
cleavage sites into eight end products, nsp1 to nsp8, with several processing
intermediates44–46. Expression of ppa1ab requires a -1 ribosomal frameshift mechanism
and is processed into four major end products including viral RdRp and RNA helicase by
nsp4 proteases3,63.

Figure 1.6. Schematic representation of post-translational processing of EAV
replicase polyproteins. The order of nsps of the EAV replicase polyproteins is numbered;
their distinct characteristics are abbreviated as follows: leader sequence Mpro: 3C-like
serine proteases (3CLSP); ZF and Z, zinc-finger and zinc-binding domain, respectively;
C/H: cysteine/histidine-rich clusters; TM: predicted transmembrane domains; N and HEL:
N-terminus and the nucleoside triphosphate-binding/helicase (HEL), respectively; and U:
nidoviral-endonuclease specific for U (NendoU) domain. The PCP1β and CP cleavage
sites are shown by black arrows. Multiple 3CLSP cleavage sites are located under the
black triangle points. The structural proteins are highlighted in black. Modified from Van
Hemert and Snijder. (2008) with permission104.
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The nsp1 is characterized by a zinc finger (ZF) domain and papain-like cysteine
protease (PCP) with inactive PCP1α and active PCP1β37,105. Although EAV PCP1α
becomes inactive by the loss of an active Cys-site during virus evolution53, the PCP1β
acts as a platform for the ZF domain during transcription57. The nsp1 is released from the
replicase polyprotein by the autocatalytic activity of PCP1β resulting in the cleavage of
the nsp1/2 site at its C-terminal domain for the purpose of viral sg mRNA
synthesis44,47,105. Secondly, the N-terminal domain of nsp2 acts to activate the cysteine
protease (CP) that releases the nsp2 from the replicase polyprotein after the cleavage of
the nsp2/3 site by the internal cysteine autoprotease44,49. Furthermore, the mature nsp2 is
responsible for the processing of the nsp4/5 site through either the major or minor
processing pathway (Figure 1.7.). Thirdly, the N-terminal domain of nsp4 has
chymotrypsin-like serine protease (SP) activity52. The nsp4 is the “main protease”, also
known as a 3C-like serine protease (3CLSP), responsible for the production of the viral
RdRp and NTPase/RNA helicase (nsp9 and nsp10, respectively)37,46,106. After nsp1 and
nsp2 have been autocatalytically released from pp1a, nsp4 initiates further processing,
cleavage of the polypeptides: five cleavage sites in nsp3-8 of pp1a and three cleavage
sites in nsp3-12 of pp1ab via two alternative pathways (Figure 1.7.)44–46,49,62,105.
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Figure 1.7. Two alternative proteolytic processing pathways of EAV replicase
polyprotein pp1a. The important characteristics of EAV replicase polyproteins are
abbreviated by P and P*: papain-like cysteine protease (PCPα/β) and cysteine protease
(CP), respectively; Mpro: 3C-like serine protease (3CLSP); C/H: cysteine/histidine-rich
clusters; and TM: predicted transmembrane domains. The PCP1β and CP cleavage sites
are shown by black arrows. Multiple 3CLSP cleavage sites are located under black
triangle points. Modified from the Nidoviruses book chapter: Van Hemert and Snijder.
(2008) with permission104.

As mentioned above, EAV PCP and EAV CP are responsible for processing the
cleavage sites nsp1/2 and nsp2/3, respectively, to release nsp1 and nsp2 from the
replicase polyproteins. The 3CLSP processes the rest of the polypeptides in the EAV
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pp1a and pp1ab at the EAV 3CLSP-specific known cleavage sites: four at Glu|Gly site
(nsp3/4, nsp5/6, nsp7/8/9 and nsp11/12), three at Glu|Ser sites (nsp4/5, nsp6/7 and
nsp9/10), and one at Gln|Ser site (nsp10/11) (Figure 1.6.)37,45,46,62. There are two
alternative (major and minor) pathways that have been identified in the processing of the
carboxyl-terminal part of pp1a (nsp3-8) (Figure 1.7.)45. In the major processing pathway,
the mature nsp2 acts as a cofactor that strongly associates with the processing of nsp3 or
nsp3-carrying precursors including nsp3-8 required for further processing the nsp4/5 site
by the nsp4 3CLSP45. The EAV 3CLSP first cleaves the nsp4/5 site, then processes the
nsp3/4 and nsp7/8 sites which results in the rest of the remaining nsp5-7 intermediates
remaining uncleaved (Figure 1.7.)44,46. However, in the case of the nsp2, this is absent
and the 4/5 site cannot be cleaved; in which case the alternative minor processing
pathway takes responsibility for further processing45. In the minor processing pathway,
the nsp4/5 site remains uncleaved; instead, the cleavage processing occurs at the nsp5/6
and nsp6/7 sites45. Then, further processing may occur at the nsp3/4 and 7/8 sites (Figure
1.7.)45.

1.2.3. Genome replication
The typical feature of EAV and other arteriviruses is the formation of paired
membranes and double-membrane vesicles (DMVs) after 3 to 6 hour post-infection
(hpi)107–111. Expression of EAV nsp2-3 is essential for formation of DMVs56,112. Pedersen
et al., (1999) demonstrated that EAV replicase subunit nsp9, which contains RdRp
function, assembles the viral replication complex through membrane-associated DMVs
where the RNA synthesis takes place. The outer membranes of EAV-induced DMVs
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closely interact with the ER membranes of the target host cells and result in the formation
of a reticulovesicular network (RVN)113. Electron spectroscopic imaging of DMVs has
revealed the presence of EAV RNA genomes and has identified a network connection
between EAV-induced RVN and nucleocapsid assembly114. Similarly, the presence of
newly synthesized viral RNA genomes and many replicase subunits with numerous
amounts of DMVs were observed near the perinuclear region in nidovirus-infected
cells112,115,116.
The viral replicase polyproteins are visualized by immunoelectron microscopy to
be part of the RTC, and DMVs are closely associated with newly synthesized viral RNA
genomes112,116–118. Thus, DMVs are predicted to comprise the enzyme complex that plays
an important role in viral replication and sg mRNA synthesis56,112. The EAV replicase
subunits including nsp2-3 and nsp5 that have hydrophobic regions are predicted to impact
the structural function of the anchored-RTC by inducing DMV formation44,45,56,119.
Moreover, a recent study has shown that the isolated RTC-comprised replicase subunits
are involved in DMV formation (nsp2-3) or viral replication (nsp9-10) with the
accumulation of newly synthesized viral RNA genomes120, indicating the association
with DMV and its essential role in RTC function1. As described above, the assembly of
the EAV replication complex is based on the expression of replicase polyproteins and the
membrane of viral induced- and host cell-derived DMVs that lead to viral RNA
synthesis92.
The EAV genome is a polycistronic RNA molecule that consists of a 5′ cap and 3′
poly (A) tail structures33. While the EAV RdRp replicates (+) the viral genomic strand
into full-length (-) viral strands (or anti-sense genome) as full-length (-) strand templates
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synthesize more (+) viral genomic strands92, the subgenomic-sized (-) strands are
produced to synthesize sg mRNAs during a process of discontinuous RNA synthesis as
with other nidoviruses39,66,102,121. The recognition of signals at the 3′-end of the full-length
(-) strand viral templates is required for the production of new genomic RNA122,123.
During viral RNA synthesis, more (+) strands are generated than (-) strand RNA
genomes124.

1.2.4. Viral sg mRNA transcription
The EAV genome has a 5′ UTR of approximately 225 nucleotides (nts) that
prevents exonuclease-mediated degradation125. Furthermore, the 5′ UTR contains a
common 5′ leader sequence (211 nt in length)33. As in the case of other nidoviruses, EAV
sg mRNAs synthesis involves a discontinuous transcription mechanism121. This
discontinuous extension of (-) stranded RNA is controlled by the transcription regulatory
sequence (TRS; Figure 1.8.), a short and conserved sequence element (5′-UCAACU-3′),
which is essential for leader-to-body joining via a base-pairing interaction between (+)
and nascent (-) stranded RNAs126–128. The leader TRS is located in a hairpin loop
structure at the 3′-end of the leader sequence129 and several body TRSs are found
upstream of structural protein genes, except for ORFs 2b and 5a29,39,40,43. The primary
sequence of the body TRS located at an active site in each of the six sg mRNAs will be
transcribed; it plays a significant role in discontinuous RNA synthesis66,126,127,130,131. The
existence of TRSs was also found in the replicase genes43.
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Figure 1.8. Illustration of the replication and transcription model in nidoviruses. (A)
After viral replication, the “discontinuous extension of (-) strand RNA model” occurs by
using the sg (+) strand as a template for sg mRNA synthesis121. The process by which
translocation of the nascent (-) strand to the leader TRS region occurs is called RNA
strand transfer127,128. The (-) strand RNA synthesis reinitiates by base pairing interaction
between the antisense body TRS and sense leader TRS added to the anti-leader sequence.
The sg-length nascent (-) strand RNA is used as a template strand for sg mRNA synthesis.
The (+) and (-) strand RNAs are shown in white and black, respectively. The sense leader
and body TRSs are indicated in red and yellow boxes on the (+) strand RNA and
antisense leader and body TRSs are shown as black boxes on the (-) strand RNA. (B)
Like viral genomic replication, the viral sg mRNA transcription is regulated directly by
the RdRp complex. LTH: leader TRS hairpin; The figure (A) modified from Pasternak et
al. (2006) with permission from the Journal of General Virology and figure (B) is
reprinted from van den Born et al. (2005) with permission66,129.
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The sg (-) strand RNA genomes are used as templates for further sg mRNA
synthesis124. During discontinuous transcription, the viral RdRp controls termination and
reinitiation of transcription, indicating that the nidovirus transcription model assembles
by a similar-assisted, copy-choice RNA recombination (Figure 1.8.B.)128,132,133. The
RdRp complex and 3′-end of nascent (-) strand transcript are released and translocated
from the body TRS at the leader sequence region in the 5′-end of the (+) strand genomic
template where transcription is reinitiated. During (-) strand synthesis reinitiation, a
nested set of sg-length nascent (-) strand templates are extended with the complement of
the genomic leader sequence for the subsequent synthesis of the various sg mRNAs1.
This leader-to-body joining via base-pairing interaction between antisense body TRS at
the 3′-end of the nascent (-) strand and the sense leader TRS in the (+) genomic template
generates the additional anti-leader sequence and has an impact on RNA strand transfer
(Figure 1.8.B.)127,128. Additionally, the predicted secondary structure of the leader
sequence located at nucleotide position nt 1-211 is also important for the sg RNAs
synthesis129,134. The leader sequence forms a hairpin structure called leader TRS hairpin
(LTH) (Figure 1.8.B.)128,134. The synthesis of (-) strand RNA started from the 3′-end of
the EAV genome becomes attenuated at one of the body TRS regions66,67. If attenuation
does not happen, (-) strand RNA synthesis continues to generate a full-length
complement of the genome as the intermediate step in EAV replication121. Like viral
genomic replication, the viral sg mRNA transcription is regulated directly by the RdRp
complex and occurs on the membrane of virus-induced and host cell-derived DMVs92.
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1.2.5. Virus assembly, budding and release
The newly synthesized viral RNA genome is encapsulated by nucleocapsid
formation1. EAV obtains its envelope containing viral envelope proteins through the
internal membranes of infected cell, and assembly takes place in the cytoplasmic region
near the ER135. The budding and maturation processes happen at the ERGIC1. The
completely formed EAV virions mature in the Golgi complex and are released via an
exocytic pathway from the infected host cells (Figure 1.5.)1.
As previously described, the seven envelope structural proteins (E, GP2, GP3,
GP4, ORF5a protein, GP5 and M) are essential for the production of infectious progeny
virus40,73,136. Moreover, the major envelope proteins (GP5, M and N) form virus-like
particles (VLPs)41. However, producing VLPs by the cotransfection of infected cells with
plasmids encoding EAV GP5, M and N proteins was unsuccessful, indicating that
additional factors are involved in virus assembly40,41. EAV assembly occurs in
association with nucleocapsid formation, and thus EAV assembly will not take place
without it40,41. However, the interaction between EAV N protein and viral genomic RNA,
the formation of icosahedral nucleocapsid, and the copy numbers of EAV N proteins
required to form the nucleocapsid remain unknown92.
The EAV nucleocapsid becomes enveloped though the GP5/M disulfide-linked
heterodimer complex which acts as a mediator between the nucleocapsid and the viral
envelope

during

viral

assembly83,84.

This

also

suggested

that

the

GP5/M

heterodimerization complex forms the basic protein matrix of the envelope77. From the
individual expression of these major enveloped proteins, EAV GP5 and M proteins were
observed only in the ER; however, co-expression of the M and GP5 proteins resulted in
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the M protein presenting both in ER and ERGIC and the GP5 protein co-localized with
the M protein only in the ERGIC85. This result suggested that transport of EAV GP5 and
M proteins from ER to the ERGIC depends on the formation of a GP5/M
heterodimerization complex85. Snijder et al. (2003) further confirmed this by genetic
engineering introducing mutations of Cys residues at amino acid position Cys-8 of M
protein and Cys-34 of GP5 protein. As a result, mutations caused the blocking of the
GP5/M heterodimerization complex and virus assembly, interrupting the transport of both
GP5 and M from Golgi to the ERGIC and production of infectious viral progeny83. The
authors concluded that the GP5/M heterodimerization complex is a prerequisite for virus
assembly and occurs in the ER. Additionally, the interaction between cytoplasmically
exposed domains of the GP5/M heterodimerization complex and the synthesized
nucleocapsid suggested that EAV nucleocapsids bud in the ERGIC by acquiring lipid
membrane-carrying viral envelope proteins92.
After EAV nucleocapsid formation, the minor envelope proteins (E, GP2, GP3
and GP4) also gather at the lipid membrane of the ERGIC and bud into the lumen92. The
minor enveloped proteins form a GP2/GP3/GP4 heterotrimeric complex and along with
the E protein, they participate in the process of viral attachment/entry and production of
infectious viral progeny1,76. GP2 and GP4 form a heterodimer, which subsequently
covalently associates with GP3137. The intermolecular cysteine bridges with an intrachain disulfide bond at the amino acid position Cys-48, 102 and 137 play a significant
role in the conformation and stabilization of the GP2/GP3/GP4 heterotrimeric complex
(Figure 1.3.)74,75,137. When a protein subunit of the GP2/GP3/GP4 heterotrimeric complex
is missing, the formation of the heterotrimeric complex fails and the amount of E protein
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in the viral envelope decreases41. Furthermore, the absence of E protein will entirely
block the formation of the GP2/GP3/GP4 heterotrimeric complex in the EAV particle41.
With the formation of the EAV nucleocapsid bud into the ERGIC, the virus
obtains a lipid membrane consisting of viral major and minor envelope proteins to form
the virus particles. The newly produced EAV particles are transported from the
intracellular compartments to the plasma membrane of the EAV-infected cell, and then
finally, the virus particles exit the cell through exocytosis92.

1.3. Equine viral arteritis
1.3.1. Epidemiology
EVA is a reproductive and respiratory disease of equids caused by
EAV16,9,13,18,138–141. EAV was first isolated from the lung of an aborted fetus during an
extensive outbreak of the respiratory disease and abortion at a Standardbred breeding
farm near Bucyrus, Ohio, in 19539,14. EAV causes a significant economic impact on the
equine industry due to the occurrence of abortion, neonatal death and establishment of
persistent infection in stallions9,14,139,142,143. According to serological surveys, EAV has a
worldwide distribution that includes North and South America, Europe, Australia, Africa
and various countries in Asia11. Iceland, Japan and New Zealand are known as free from
the disease144. EAV seroprevalence varies according to age and breed. For instance, in the
United States a very high percentage of adult Standardbred and Saddlebred horses are
seropositive (70-90% and 8-25%, respectively) while a low serprevalence is observed in
the Thoroughbred population (<5.4%)11,145–148. The 1998 National Animal Health
Monitoring System (NAHMS) equine study reported only 0.6% EAV seropositivity in
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the Quarter horse population in the United States149, but an extensive EVA occurrence
involving multiple states during 2006 to 2007 probably increased the seroprevalence in
the Quarter horse population150. In Europe, a high seroprevalence is observed among
Warmblood stallions and Spanish purebred horses (55-93% and 17.3%, respectively)151–
153

. Variability in EAV seroprevalence is correlated with age and sex154. Recent studies

have suggested the linkage of a specific dominant haplotype of the EqCXCL16 gene
located in ECA11 at positions: 49572804 to 49643932 with the susceptibility of CD3+ T
lymphocytes to in vitro EAV infection and the establishment of persistent infection86,87,155.
It has been shown that those stallions with CD3+ T lymphocyte susceptiblity phenotype
have a higher risk of becoming long-term EAV carriers than those that lack this
phenotype155.

1.3.1.1. Transmission
Transmission of EAV between horses occurs by the horizontal, venereal and
vertical routes11,14,138,139,156,157. Horizontal transmission happens by the aerosolization of
respiratory secretions or fetal fluids at time of abortion. During the acute phase of
infection, the virus spreads via the respiratory route by the aerosolization of respiratory
secretions13,138,141,152,158–160. Nasal shedding continues for 7 to 14 days with viral titers
ranging from 10 to >2 x 103 plaque-forming units per mL (PFU/mL)138,161,162. Venereal
transmission occurs through infective semen during natural breeding, artificial
insemination (AI) and embryo transfer. The venereal transmission happens via the semen
of both acutely and persistently EAV-infected stallions by natural or artificial breeding157.
Most EVA outbreaks are caused by venereal transmission after a naïve mare is bred to an
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EAV carrier stallion163,164. Approximately, 10 to 70% of EAV infected stallions can
become persistently infected and continuously shed EAV in their semen for several
weeks to years or lifelong with the presence of high levels of neutralizing antibodies in
serum11,156,157. The establishment and maintenance of the EAV carrier state in the stallion
is testosterone-dependent and the virus mainly persists in the ampulla of the vas
deferens165. Carrier stallions constitute the natural reservoir of EAV and are responsible
for

the

maintenance,

perpetuation

and

evolution

of

EAV

in

equine

populations11,17,19,21,142,146,164,166. Previous studies have demonstrated that EAV evolves in
the stallion reproductive tract resulting in the emergence of novel viral genetic variants
with neutralizing phenotypes that allow for viral immune escape17,142,164,166. EAV can also
be spread from donor mares inseminated with EAV-contaminated semen to naïve
recipient mares through embryo transfer167. Vertical (transplacental) transmission occurs
from pregnant mares to the fetus during the latter stage of pregnancy168. Congenital
infection of foals results in development of rapid progressive, fulminating interstitial
pneumonia and fibrinonecrotic enteritis169–173. Lastly, the lateral transmission of EAV can
also take place through contact with EAV-contaminated fomites that include personnel,
clothing, vehicles and equipment such as artificial vaginas and phantoms11,146,160.

1.3.1.2. Immune response to EAV infection
EAV infection induces a strong and protective immune response in the host154.
Even though the innate immune response has not yet been fully understood, recent
studies have demonstrated that EAV regulates the innate immune response by blocking
type I interferon (IFN) production174. Specifically, the three EAV nonstructural proteins
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(nsp 1,2 and 11; mainly nsp1) have the ability to inhibit IFN synthesis. After EAV
infection, the horse develops EAV-specific complement-fixing (CF) and viral
neutralizing (VN) antibodies154,175,176. These CF and VN antibodies are initially detected
within 7 to 14 days post-infection (dpi) and reach their peak by 2 to 3 weeks or 2 to 4
months post-infection, respectively162,176–179. Although CF antibodies decrease by 8
months post-infection, VN antibodies last for 3 years or longer180. Foals receive VN
antibodies through the colostrum of immunized mares, which provide them with
protection against EAV infection. Although high neutralizing antibody titers remain in
serum, EAV still persists in the stallion reproductive tract97,98. Recently, it has also been
shown that EAV also induces a mucosal antibody response in the reproductive tract with
shedding of virus-specific immunoglobulins (IgA, IgM, IgG1, IgG3/5 and IgG4/7) into
the seminal plasma as well as the homing of plasma cells in the accessory sex glands165.
However, despite the systemic neutralizing antibody, local inflammatory and mucosal
antibody responses, EAV evades local host immunity mechanisms and persistence is
maintained.

1.3.2. Clinical signs
Most primary EAV infections are subclinical or inapparent. However, when
clinical signs of EVA develop, they present as an influenza-like illness in adult horses,
abortion in pregnant mares and interstitial pneumonia or pneumoenteritis in young
foals11,13,171,181182. The range and severity of the clinical signs depends on various factors
including an individual’s genetic background, age, physical and environmental conditions,
route of exposure, challenge dose and viral strain11,140. Field strains of EAV can vary in
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virulence and in the clinical severity of the disease they cause. For instance, some field
strains cause moderate to severe disease (e.g. EAV KY84, AZ87, IL93 and PA96 strains),
moderate disease (e.g. EAV PA76 and KY77 strains), mild disease (e.g. EAV SWZ64,
AUT68, IL94 and CA97 strains) or asymptomatic infection (e.g. EAV KY63 and CA95
strains)15,16,21,23,96,183–190. While the highly virulent experimentally-derived horse-adapted
Bucyrus strain of EAV (EAV VBS) can cause high morbidity and mortality in healthy
mature horses following infection, in natural outbreaks of EVA caused by field strains of
EAV, mortality is very uncommon11,183.
Acutely infected animals may develop a wide range of clinical signs154. The
average incubation period is 3 to 14 days (6 to 8 days after venereal transmission
exposure). Infected horses may develop respiratory disease and reproductive
consequences including the development of pyrexia of up to 41°C (39-41°C) which may
last for 2 to 9 days. Infected animals may also develop all or any combination of the
following clinical signs: depression, anorexia, nasal and/or ocular discharge,
conjunctivitis, rhinitis, leukopenia, periobital or supraorbital edema, edema of the limbs,
edema involving the scrotum and prepuce of the stallion and mammary glands of the
mare, urticarial around the head, sides of neck and/or body and abortion of pregnant
mares9,11,140,191–193. Other less frequent clinical signs include icterus, photophobia, corneal
opacity, coughing, dyspnoea, colic, diarrhea, ataxia, petechiation of the nasal mucosa,
conjunctiva

and

oral

mucous

membranes,

submaxillary

and

submandibular

lymphadenopathy and adventitious edema in the intermandibular space, beneath the
sternum or in the shoulder region9,139,180,191,193–195. The most frequent clinical signs of
EVA include pyrexia and leukopenia. Most naturally infected horses recover

30

spontaneously. Abortion in pregnant mares may occur from early to late gestation (3 to
over 10 months of gestation) and abortion rates have varied from less than 10% to >70%.
Congenitally infected foals develop a rapidly progressive pneumoenteric syndrome and
severe fulminating interstitial pneumonia169–171.

1.3.3. Pathogenesis
The pathogenesis of EVA has been studied by following natural outbreaks or by
experimentally

inoculating

horses

with

different

EAV

strains9,14,138,138,139,159,161,177,183,184,193,196–199. Following initial infection, viral replication
occurs within alveolar macrophages and bronchiolar epithelial cells, with subsequent
spread to regional (respiratory tract-associated) lymph nodes within 42 hpi138,146,200.
Within 72 hpi, a cell-associated viremia develops and frequently lasts for 3 to 19 dpi.
During the viremic phase, the virus spreads throughout the body replicating in pulmonary
macrophages, vascular smooth muscle cells and endothelial cells and causing a systemic
panvasculitis1,138,183,194,198,201–203. The severe systemic panvasculitis of small vessels with
endothelial cell injury increases vascular permeability and leukocyte infiltration. This can
cause foci of intimal, subintimal and medial necrosis with hemorrhage, edema and
permeation with lymphocytes and neutrophils in the muscular arteries183,189,197,198,201,202.
The endothelial cells and macrophages are recognized as the principal target cells as well
as all the epithelial, mesothelium and smooth muscle cells of the tunica media of smaller
arteries, venules and the myometrium179,202. However, the relative roles and importance
of direct virus-mediated endothelial cell injury and increased vascular permeability in the
pathogenesis of EAV infection have not yet been clearly defined179.
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Recent studies of the pathogenesis of EAV infection have demonstrated that the
virus localizes in CD3+ T lymphocytes, CD172a+ myeloid cells and a small population of
IgM+ B lymphocytes in the connective tissue204. Interestingly, the virus was not detected
in epithelial cells in the upper respiratory tract during the acute infection period204. The
nasopharynx and tubal-nasopharyngeal tonsils are suggested to be important primary sites
of EAV replication189. Previous in vitro and in vivo studies with EAV have suggested that
increased transcription of genes encoding the proinflammatory interleukin (IL) mediators
IL-1β, IL-6, IL-8 and tumor necrosis factor (TNF-α) play a significant role in determining
the severity of the disease186. Recently, Go et al. (2012) demonstrated experimental
inoculation of horses with in vitro CD3+ T cell susceptible and resistant phenotype with
EAV generate different levels of proinflammatory and immunomodulatory cytokine
mRNAs. Additionally, horses with in vitro CD3+ T lymphocyte resistant phenotype
developed more severe clinical signs than the horses with the susceptible CD3+ T
lymphocyte phenotype205.
EAV infection can result in abortion in pregnant mares. Fetuses and placentas
may be partially autolyzed at the time of expulsion9,14,193. Johnson et al. (1991) suggested
that abortion in mares is caused by systemic vascular necrosis that weakens uterine and
placental blood supply. It has also been suggested that the abortions are caused by the
vasculitis of myometrial blood vessels with placental dysfunction202. MacLachlan et al.
(1996) have suggested that abortion happens due to EAV infection directly affecting the
fetus causing stress and interfering with the fetal hypothalamic-pituitary axis. There are
no pathognomic gross or histopathological lesions associated with abortion. Interlobular
pulmonary edema, pleural and pericardial effusion, and petechial and ecchymotic
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hemorrhages on the serosal and mucosal surfaces of the small intestine were observed on
necropsy of an aborted fetus202.
With the exception of persistently infected stallions, viral clearance from serum
and body tissues usually occurs at ~28 dpi and coincides with an increase in serum
neutralizing antibodies206,207. However, an in vivo study by Vairo et al. (2012) recently
reported that the virus could still be demonstrated in the tonsil at 28 dpi. In the carrier
stallion, EAV primarily persists in the ampullae of the vas deferens165,189,208,209. Recently,
Carossino et al. (2017) has determined the specific tropism of EAV for stromal cells and
identified that the virus primarily persists in fibrocytes and T (CD2+, CD3+, CD5+ and
CD8+) and B (CD21+) lymphocytes in the ampullae165. The study indicated that EAV
expresses different host-cell tropism depending on the tissue compartment and duration
of infection (i.e. acute vs. chronic)165. For instance, EAV infects CD3+ T lymphocytes
and CD14+ monocytes, but does not infect CD21+ B lymphocytes in the accessory sex
glands of the stallion reproductive tract87. The authors concluded that EAV persistence
may drive immunosuppression and/or T cell exhaustion to suppress the host immune
response165. The viral strategy of host immune evasion has to be further determined.
Recently, Carossino et al. (2017) investigated the EAV tissue and cellular tropism
in the reproductive tract and the inflammatory response induced during persistent
infection. They used reproductive tract tissues from normal, short-term and long-term
EAV carrier stallions in their studies. EAV tissue and cellular tropism was determined by
virus isolation, nucleocapsid-specific single and dual immunostaining (IFA/IHC) and
transmission electron microscopy (TEM). The inflammatory response was characterized
by histopathology and IHC using a panel of differentiation (CD) markers. The ampulla
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was demonstrated to be the tissue with the highest viral titer (1.0 x 103 – 1.7 x 105 PFU/g)
among the accessory sex glands of carrier stallions. Dual IFA/IHC demonstrated the
presence of viral antigen in fibrocytes and lymphocytes (mainly CD3+ [CD8+] and CD21+)
within the lamina propria and inflammatory infiltrates in the ampullae. The virus was not
detected in the epithelium of the ampullae or any other accessory gland. The
inflammatory response was characterized by multifocal lymphoplasmacytic ampullitis
which included moderate and high infiltration of CD4+/CD25+ and CD8+ T lymphocytes,
respectively; clusters of CD21+ B lymphocytes and moderate Iba-1+ and CD83+
macrophage and dendritic cell infiltration. Evidence of CD25+ and FOXP3+ T regulatory
lymphocytes with lack of expression of IFN-gamma and limited expression of granzyme
B in CD8+ T lymphocytes indicate that immunoregulatory mechanisms in conjunction
with CD8+ T cell exhaustion are likely involved in maintenance of persistent infection. In
summary, EAV was demonstrated to be primarily lymphotropic (including T and B
lymphocytes with a restricted homing pattern to the ampulla) and fibrocyte-tropic
(vimentin+). Despite the strong local inflammatory and serum neutralizing antibody
response, EAV evades host immunity in a tissue under immune surveillance and is
capable of establishing long-term persistence in the male reproductive tract. Furthermore,
EAV was not detectable in lymphoid tissues including those associated with lymph
drainage from the reproductive tract, suggesting that infected T and B lymphocytes
exhibit a specific homing pattern to the reproductive tract and restricted migration from
reproductive tract tissues to secondary lymphoid organs.

34

1.3.4. Persistent EAV infection
As previously mentioned, EAV persists exclusively in the reproductive tract of
infected stallions. During the acute phase of the disease (average range of first 21 days),
the stallions show decreased libido and reduced sperm motility, concentration and
percentage of morphologically normal sperm cells156,190,191. Subsequently, 10 to 70% of
infected stallions and sexually mature colts remain persistently infected and continuously
shed EAV in their semen for weeks, months, years or lifelong without alteration in the
semen quality143,156,157. Viral shedding appears in semen at 5 dpi and is associated with
the sperm-rich fraction of the ejaculate157,210,211. Viral titers in seminal plasma show a
broad range (101 to >107 PFU/mL)209,211. Although the duration of the carrier state can
vary, it has been arbitrarily divided into three categories: short-term carrier state (several
weeks), intermediate carrier state (3 to 7 months) and the long-term persistent or chronic
carrier state (years and even lifelong) 11,156.
The mechanism(s) involved in EAV persistence and the factors that lead to viral
clearance in stallions is not yet defined. However, the establishment and maintenance of
the EAV carrier state in the stallion is testosterone-dependent11,209,212. Thus, surgical
castration of carrier stallions is the only certain method to cause cessation of viral
shedding212. Previous studies have suggested that testosterone is strongly associated with
an interaction between the host immune response and EAV in the reproductive tract such
as immunosuppressive activities or maintenance of a susceptible host cell population that
results in maintenance of EAV persistence208,213–216. It is proposed that high levels of
testosterone in the stallion reproductive tract are important during long-term EAV
persistence, but not for viral replication or persistence of intermediate duration217. An in
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vivo study of attempted establishment of persistent EAV infection in prepubertal and
peripubertal colts has demonstrated that the carrier state could not be established without
the presence of testosterone during intermediate duration217. Thus, the carrier state of
EAV infection is androgen-dependent, and so persistent infection cannot occur in
prepubertal colts, mares, geldings and fetuses11,140,156,209,212.
As indicated above, carrier stallions provide the means by which EAV
evolves11,17,19,21,142,146,164,166. EAV continuously evolves via genetic divergence called
EAV quasispecies during persistent infection in the stallion reproductive tract142,163,164.
EAV quasispecies generate novel genetic variants with phenotypic diversity that
contributes to the occurrence of EAV142,163,164,218. Significant nonsynonymous
substitutions at high rates were observed in GP3 and GP5 proteins suggesting that ORF3
and ORF5 are under strong selective pressure in persistently infected stallions16,17,142. A
limited number of critical amino acid substitutions were especially observed in the V1
variable region of the GP5 protein (aa 61 to 84)16,218. The emergence of viral variants
from EAV quasispecies present in the long-term carrier may be endowed with novel
genetic and phenotypic properties (i.e. neutralization) and could be susceptible for new
outbreaks of EVA17,142,156.

1.4. Diagnosis of EAV infection
1.4.1. Appropriate specimen collection for examination
Equine viral arteritis clinically mimics a number of other infectious and noninfectious diseases and therefore, it is not possible to establish a diagnosis of EVA based
solely on the nature of clinical signs89. Thus, the clinical diagnosis of EVA should be
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confirmed by laboratory diagnosis. During the acute phase of the disease, the most
appropriate specimens include nasopharyngeal swabs or washings, conjunctival swabs
and

blood

samples

for

separation

of

buffy

coat

cells

(citrated

or

in

ethylenediaminetetraacetic acid [EDTA]) for virus isolation (VI) or PCR219. From
infected stallions, semen samples containing the sperm-rich fraction are essential for VI
or PCR11. During the necropsy of aborted fetuses, clinical specimens including placenta,
fetal fluids, lung, spleen and lymphoid tissues should be collected for VI, PCR or
immunostaining to confirm cases of EAV-induced abortion219. All clinical samples listed
should be stored and submitted under conditions of refrigeration via overnight delivery
for laboratory testing. After a necropsy, tissue samples should be fixed and placed in 10%
neutral buffered formalin for virus detection, histopathologic examination and
immunohistochemical staining220. In suspicious cases of EVA in young foals, various
organs and lymph nodes associated with the gastrointestinal and respiratory tracts should
be collected219. Serum samples are collected for serologic diagnosis, and paired samples
obtained at least 14 days apart or preferably a 21-to 28-day interval are recommended219.

1.4.2. Virus isolation in cell culture
VI is the World Animal Health Organisation (OIE)-approved “gold standard” test
for EAV detection, especially in semen samples from stallions and is the prescribed test
for international trade221. VI should be attempted from specimens collected from clinical
or fatal cases using rabbit, equine or monkey kidney cell cultures in accordance with
established procedures222. The cell system of choice for VI is the rabbit kidney cell line
(RK-13), and generally EAV can be isolated on first or second passage. However, some
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strains may require additional blind passages in cell cultures169. Virus isolates should be
further confirmed by cross neutralization assay using EAV-specific equine antiserum or
specific standard or real-time RT-PCR223.

1.4.3. Molecular diagnosis (nucleic acid detection by RT-PCR)
Molecular testing (i.e. detection of viral nucleic acids) has several advantages
including high sensitivity, rapid turnaround, convenience and cost224. Several molecular
diagnostic assays (reverse transcription polymerase chain reaction [RT-PCR]) have been
developed including RT-PCR and RT-nested PCR (RT-nPCR), real-time RT-PCR (rRTPCR) and insulated isothermal RT-PCR (iiRT-PCR) assays for EAV nucleic acid
detection from clinical specimens225–231. The primers/probes have been designed to target
conserved regions of the viral genome, and especially target the 3′-end of ORF1b of the
viral polymerase gene and ORF7 (encoding N protein)225,226,228,229.
The RT-nPCR assay is more sensitive than the standard RT-PCR but it tends to
give false positive results due to cross contamination of a sample219. In light of this, the
rRT-PCR which avoids handling of PCR amplicons has replaced gel-based assays219.
Previous studies evaluated the rRT-PCR assay and proved an equal or higher sensitivity
than VI for EAV detection232. Recently, a TaqMan® probe-based iiRT-PCR assay has
been developed for qualitative detection of EAV nucleic acid from clinical
specimens233,234. This system is based on the use of the field-deployable POCKITTM
Nucleic Acid Analyzer (GeneReach USA, Lexington, MA, USA) which allows point-of
need use234,235 including veterinary clinics, racetracks, breeding facilities and diagnostic
laboratories233.
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Recently, two RNA in situ hybridization (ISH) assays (conventional and
RNAscope® ISH) for the detection of EAV RNA in formalin-fixed paraffin-embedded
(FFPE) tissues have been described236. The conventional RNA ISH assay had a
significantly lower sensitivity as compared to the RNAscope®. The use of oligonucleotide
probes along with a signal amplification system (RNAscope®) can enhance detection of
EAV RNA in FFPE tissues.

1.4.4. Antigen visualization by immunohistochemistry
EAV antigen can also be demonstrated in FFPE tissues from aborted fetuses using
nucleocapsid-specific monoclonal antibody (immunohistochemistry [IHC])236. Evaluation
of 80 FFPE tissues collected from 16 aborted fetuses showed that IHC had a similar
sensitivity to RNAscope®. The conventional RNA ISH assay had a significantly lower
sensitivity as compared to the RNAscope® and IHC assays.

1.4.5. Serological diagnosis
The virus neutralization test (VNT) is the current OIE-approved “gold standard”
test for EAV antibody determination required for international trade221. Although the
VNT is highly sensitive and accurate, it has a few disadvantages including cost, labor,
turnaround time and variability among different laboratories. It requires standardized
reagents and protocol224. Furthermore, serum cytotoxicity due to anti-cellular antibodies
directed against RK-13 cells can interfere with test interpretation at lower serum
dilutions224. Also, the VNT cannot distinguish antibody responses between vaccinated
and naturally infected horses224. To get over the disadvantages of VNT, several enzyme-
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linked immunosorbent assays (ELISA) have been developed and evaluated to detect
EAV-specific antibodies using whole virus, synthetic peptides or recombinant viral
proteins (e.g. GP5, M and N) as antigens215,219,237–243.
The GP5 is the major target as an antigenic protein of virus neutralization that has
the potential for development of serological diagnostic assays224. Since the M and N
proteins consist of conserved sequences among different EAV strains and isolates, these
proteins also have the potential to be used as antigens for diagnostic purposes244. Firstly,
an ELISA using a recombinant fusion protein expressing GP5 (aa 55-98) had a sensitivity
and specificity of 99.6% and 91.1%, respectively239. Another ELISA based on the
ovalbumin-conjugated synthetic peptide containing amino acids 81-106 of GP5 had a
sensitivity and specificity of 96.7% and 95.6%, respectively237. Secondly, an ELISA
using sera from naturally or experimentally infected horses against a cocktail of
recombinant GP5, M and N proteins expressed in baculoviruses resulted in a sensitivity
and specificity of 100% and 92.3% respectively; it was not able to detect antibodies in the
sera from the vaccinated horses215. Thirdly, a blocking ELISA using partially purified
EAV and MAb against the GP5 protein was developed, and it provided a sensitivity and
specificity of 99.4% and 97.7%238. Fourthly, an ELISA using the carboxyl terminus of
the M protein (aa 88-162) is frequently recognized by EAV-specific equine sera245.
Lastly, a microsphere immunoassay (MIA) has been developed using a combination of
microspheres and three well-developed technologies: bioassays, solution-phase
microspheres and flow cytometry224. However, all of the above mentioned ELISA assays
were neither sensitive nor specific enough to replace the VNT. Recently, a commercial
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cELISA assay (VMRD, Pullman, WA) was developed that showed high sensitivity and
specificity compared to the VNT, but this needs further evaluation219.

1.4.6. Differential diagnosis
A range of viral (e.g. equine herpesvirus 1 and 4 infections and equine influenza),
and bacterial (e.g. Streptococcus) respiratory diseases that commonly affect horses cannot
be distinguished clinically from EVA. Other infectious diseases that can cause systemic
signs of illness resembling EVA are equine infectious anemia, dourine, African horse
sickness fever and Getah virus infection. EVA also bears many many clinical similarities to
the syndrome caused by hoary alyssum (Berteroa incona) toxicosis. Abortions or deaths in
foals due to EAV need to be differentiated in particular from those caused by equine
herpesvirus 1 as well as other infectious causes of abortion in the mare97,98.

1.5. Treatment of EVA
1.5.1. Antiviral therapy
Even though several antiviral medications have been investigated, there is still no
effective antiviral treatment for EAV infection150,219,246 A potential antiviral compound
(phosphorodiamidate morpholino oligomers [PMOs]) has been evaluated150,246. PMOs are
20-25 bases in length of single-stranded DNA analogues that tend to be water-soluble and
nuclease-resistant247,248. PMOs form base pairs with complementary viral RNA target
sequences to interfere with viral gene expression and its translation248,249. Additionally,
peptide-conjugation to the PMO (P-PMO) is involved in transporting more PMO into
infected cells250. The 5′ UTR of the EAV genome is the most sensitive target site of P-
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PMOs246. According to in vitro studies, 5-10 uM of antisense P-PMO was able to target
the EAV 5′ terminus from persistently infected HeLa cells150. However, the in vivo
efficacy of P-PMO therapy needs to be evaluated.

1.5.2. Anti-GnRH vaccination and GnRH antagonists
Previous studies have demonstrated that the application of gonadotropin-releasing
hormone [GnRH] antagonists, anti-GnRH vaccination and single-layer centrifugation251–
259

can facilitate viral clearance in some stallions or eliminate semen infectivity in some

cases. However, none of them has 100% efficacy in inducing complete viral clearance
from the reproductive tract154. For instance, Burger et al. (2006) have demonstrated in a
vaccination study in EAV carrier stallions injecting twice 4 weeks apart with anti-GnRH
vaccination resulted in cessation of virus shedding in semen 4 to 6 months after the first
immunization and from all subsequent semen collections154,255. However, all the
vaccinated stallions developed reduced libido, scrotal size, total sperm number and
percentage of normal sperm indicating that this protocol would not be a suitable
treatment for EAV-infected breeding stallions154.

1.6. Disease prevention and control
The purpose of EVA control and prevention strategies is to prevent the risk of
spread of EAV in horse populations149,260,261. In the USA, the standards of EVA control
and prevention are described in the Equine Viral Arteritis: Uniform Methods and Rules
developed by the USDA-APHIS260. Several European countries: United Kingdom (UK),
Ireland, Germany, France and Italy established a Code of Practice which provides
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guidelines for the control and prevention of several equine diseases including EVA262.
Globally, the OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals and
the Terrestrial Animal Health Code261,263 provides standards for EVA laboratory testing
procedures for international trade of horses and semen. Detailed information on the
application of this testing process is also available at the American Association for
Equine Practitioners (AAEP) (www.aaep.org).
It is important to correctly identify carrier stallions by determining their
serological status and whether they have a prior history against EVA154. All stallions
should be tested for the presence of serum neutralizing antibodies at least 60 days before
the breeding season154. If the stallion is seropositive (neutralizing antibody titer ≥ 1:4)
without a vaccination history or confirmation of seronegative status prior to vaccination,
virological assessment of semen is required to determine its status154. The collection of
two semen samples containing the sperm-rich fraction of the ejaculate is required154. The
test can be performed on samples obtained on the same collection day, consecutive days,
or after an interval of several days or weeks154. Another way of identifying EAV carrier
stallions is to perform test breeding by which two seronegative mares are bred or
inseminated twice, each on two consecutive days, for a total of four covers154. These
tested mares will be isolated for 28 days until checked for the presence of neutralizing
antibodies154. If one or both mares show seroconversion after being bred, this is
indicative that the stallion is persistently infected or the semen used is infective154.
Carrier stallions can still be used for breeding purposes under strict conditions: physical
isolation and breeding to seropositive mares only as indicated previously11,157,264–266. With
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exception of the USA, other countries do not accept the introduction of EAV carrier
stallions or EAV-infective semen154.
It is highly recommended to vaccinate horses against EVA if they frequently
travel and interact with other horses at competitions154. The OIE Terrestrial Animal
Health Code provides the general recommendations for the international movement of
horses and importation of equine semen154. Horses should be subjected to a quarantine
period of 28 days without clinical signs of EVA, a stable or declining EAV antibody titer
or a seronegative status between two serum samples collected at least 14 days apart154.
When the state veterinarian receives the notification of EVA outbreak, it is important to
suspend the routine activities (training or breeding) and animal movement and isolate all
of the clinically affected or in-contact animals by following AAEP guidelines. The
immediate quarantine will allow vaccination and laboratory confirmation to prevent
wider spread of EVA, associated abortions, neonatal death and persistent infection in
stallions from the horizontal mode of transmission of EAV21,154,267. Appropriate clinical
sample collection should be immediately performed with the cooperation of farm
managers and veterinarians for laboratory testing154. Disinfection of stalls and equipment
is recommended using a disinfectant including phenolic, chlorine, iodine and quaternary
ammonium compounds to inactive EAV154. The quarantine will be continued for 3 to 4
consecutive weeks after the last confirmed case is reported154.
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1.6.1. Vaccine
There are two commercially available vaccines for the prevention of EVA, a
modified live attenuated (MLV; ARVAC®) and an inactivated product (Artervac®). The
MLV vaccine was developed by serial passage (P266) of the VBS strain in horse kidney
(HK-131), rabbit kidney (RK-111) and equine dermal (ED-24) cells. It has been used
since 1985 in the USA and Canada146,154,159,161,206,268,269 The MLV vaccine has been
proven to be safe and effective in providing protective immunity in vaccinated
horses161,175,206,268. However, MLV vaccination does not necessarily prevent reinfection
of first-time vaccinated horses so that revaccination is encouraged146,161,188. The MLV
vaccine induces neutralizing antibodies within 5 to 8 days post-vaccination, with a peak
in antibody titers occurring between 7 to 14 days post-vaccination146,161,175,188,206,268–270.
Neutralizing antibodies may last for at least 2 years. It has been determined that a titer of
at least 1:64 is required for protection271. Few vaccinated horses may develop fever with
transient lymphopenia, and the attenuated virus can be detected from nasal secretions and
buffy coat cells up to 7 days post-vaccination in the vast majority of the horse
population146,146,159,268,270,272,273. Additional to the MLV product, an inactivated EAV
vaccine (Artervac®) has been developed and is licensed in several European countries
including the UK, Ireland, France, Hungary and Denmark154. As Artervac® has a lower
immunogenicity compared to the MLV vaccine, a booster vaccination 3 to 4 weeks after
the primary vaccination is recommended with semiannual revaccinations. Although this
vaccine stimulates neutralizing antibodies, its efficacy against EAV infection and
prevention of the establishment of persistent infection in stallions is substantially less
characterized than the MLV vaccine154.
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In the USA, it is highly recommended to immunize seronegative stallions with the
MLV vaccine (ARVAC®) at least 28 days prior to the breeding season, followed by an
isolation period of 21 days after the primary vaccination to allow maximal development
of the VN antibody response and to avoid exposure of other animals during the transient
shedding period of the vaccine virus260. An in vivo study reported that a low level of
vaccine virus (<1 PFU/mL) was detected in the semen of one stallion at 4 to 6 days postvaccination270. Annual revaccination prior to the breeding season is highly
recommended154. Unfortunately, vaccinating persistently infected stallions will not
induce clearance of the carrier state154. Most importantly, the current VN test is not able
to distinguish between vaccinated and naturally infected horses, thus it is critical to
confirm the stallions’ seronegative status before primary vaccination. The MLV vaccine
is effective in the prevention of EVA outbreaks and establishment of carrier state in
stallions154.
Carrier stallions should only be bred to EAV seropositive mares which were
naturally infected or vaccinated against EVA146. The mares should be vaccinated at least
3 weeks before breeding followed by a 21 day period of isolation after breeding as
previously indicated154. Neutralizing antibody titers should be determined (≥ 1:64) in
EAV seropositive mares at least 30 days before breeding to a persistently infected stallion
or using infective semen for artificial insemination or embryo transfer274,275. Following
breeding, the mares should be kept in isolation for at least 21 days away from EAV
seronegative horses154. The use of the MLV vaccine is not recommended in pregnant
mares especially in the last 2 months of gestation to avoid abortion276. Vaccination is also
not recommended in foals less than 6 weeks old; they should be vaccinated at ~6 months
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of age when maternal acquired antibodies are no longer detectable154. So far, the efficacy
of the MLV vaccine has been proven in the prevention of EVA outbreaks and persistent
infection in stallions154.
As previously mentioned, the currently available VN test is not able to
differentiate vaccinated from infected animals (DIVA). The development of a DIVA
vaccine would contribute to the equine industry by facilitating the serological
identification of infected from vaccinated animals and supporting surveillance programs
for national and international movement of horses154. Even though several studies have
been undertaken to develop new vaccines, none of them have thus far reached the market.
The development of an infectious cDNA clone of the MLV strain (pEAVrMLVB)
showed itself to be safe and capable of stimulating protective immune response
comparable to the MLV vaccine (ARVAC®)188. This infectious clone has the advantage
that it could be further manipulated by genetic engineering to generate a secondgeneration DIVA vaccine154. The development of subunit vaccines would also be another
suitable alternative as a second-generation DIVA224. DNA vaccination has been tested in
mice277. The vaccine with plasmid DNA encoding ORF5 generated the highest VN
antibodies in vaccinated animals277. A DNA vaccine expressing a combination of viral
genes (ORFs 2, 5 and 7) and equine IL-2 was also tested in horses resulting in high VN
antibodies titers, which lasted for at least a year278. Lastly, Balasuriya et al. (2002) used
alphavirus replicon particles (VRP) to co-express the major viral envelope proteins (GP5
and M) as a recombinant vaccine candidate. The in vivo study using mice established
VRP co-expressing GP5/M heterodimer that was able to induce neutralizing antibodies
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against EAV177. However, all of the above vaccine candidates require further testing to
determine their safety and efficacy.

2. Evolution of RNA viruses
Where did viruses come from and how did they survive? Unfortunately, very few
records of viruses are available unlike the situation for other cellular organisms about
which we are able to infer from fossils279. However, the application of modern
technologies such as next-generation sequencing (NGS) and reverse genetic engineering
has helped to provide some answers concerning the origins and evolution of viruses279,280.
By comparing the sequences of viral genomes, it is now possible to estimate the degree of
evolutionary relationship between ancestral viruses using bioinformatics, mathematical
and phylogenetic techniques279,280.
Viruses evolve as a result of reassortment or recombination between virus strains
in addition to nucleotide substitutions introduced during the replication cycle279. RNA
viruses in particular rapidly produce large populations in a short period of replication281.
Most RNA viruses encode for a low fidelity RNA-dependent RNA polymerase (RdRp)
enzyme that can result in a mutation rate of 103 to 105 errors per nucleotide per
replication cycle. This rate is 10,000-fold lower than that which occurs during DNA virus
replication282–284. As a result, DNA viruses evolve more slowly than RNA viruses279.
A continuous process of genetic variation in RNA viruses is responsible for
heterogeneous mutant distributions also termed “mutant swarms or mutant clouds or
quasispecies”280,281. Viral quasispecies allow RNA viruses to adapt to a given
environment with the advantages of dynamics of infection, virus spread, attenuation and
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virulence, complexity and self-organization285,286. The main features of viral quasispecies,
biological implications of quasispecies dynamics and the specific viral system related to
viral quasispecies will be further discussed. RNA viruses evolve by four mechanisms in
nature and each of these are described in detail below.
The accumulation of nonsynonymous mutations in the genome will lead to
antigenic drift which is one of the main mechanisms involved in the evolution of
influenza viruses287. Antigenic drift is the result of point mutations in influenza virus
gene, encoding HA and NA that cause alternations in the structure of the main viral
surface antigens. This is a slow process that is on-going and which causes antigenic
differences in strains of influenza virus288. The evolutionary process sometimes is under
certain limitation; for example, the viral attachment proteins must maintain the eligible
configurations and catalytic abilities for the virus to be able to bind to the target host’s
cell receptor and enzymes (e.g. reverse transcriptase)279. The RNA viral genome
undergoes virus evolution via the quasispeices effect (the establishment of mutant
spectra)280. Once the RNA virus enters the susceptible host cell, the virus replicates itself
rapidly and generates numerous numbers of virus population. Due to lack of proofreading
capability of RdRp, the RNA viruses generate numbers of mutations in the virus
population that is called mutant spectra (mutant swarm or mutant clouds). The mutant
spectrum is the ensemble of genomes that forms a viral quasispecies, and its complexity
and formation are closely related to its biological environment. The complexity of a
mutant spectrum can be demonstrated in the nucleotide sequences obtained either by
classic molecular cloning and Sanger sequencing or by next-generation sequencing
(NGS)285.
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2.1. Mechanisms of virus evolution
2.1.1. Accumulation of mutations
RNA viruses mainly evolve through mutation errors that are generated during
viral replication. Although all polymerases cause errors by inserting incorrect nucleotides
into the template during viral replication, the DNA-dependent DNA polymerases have
proofreading ability in their exonuclease activities that enable them to modify or correct
any such mistakes. In contrast, RdRp does not have proofreading ability as previously
mentioned284. If the errors are located in the protein-coding sequences, then it introduces
random substitutions in the encoded amino acid sequence279. The theory of Darwinian
natural selection applies to the mutations that ensure the continuous survival of the
viruses279.

2.1.1.1. Concept of viral quasispecies
Manfred Eigen and Peter Schuster developed the quasispecies theory by looking
at the quasispecies (dynamic mutant distributions) which are displayed as a dominant
master sequence of the virus population289. Then, Wiessmann and his colleagues
provided the first evidence of quasispecies distribution in RNA viruses by the
bacteriophage Qβ virus using T1 oligonucleotide fingerprinting through reverse genetics.
Serial passages of bacteriophage Qβ virus clones in E. coli demonstrated competition
between wild-type virus and mutant clones290,291. Interestingly, the rate of mutation of
bacteriophage Qβ virus was 104-fold constantly higher than the values of DNA
bacteriophage292. This was the first calculation of the rate of mutation for an RNA virus
that demonstrates the quasispecies dynamics using bacteriophage Qβ virus. The
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quasispecies theory formulates an error-threshold relationship at the maximum error rate
compatible with maintaining genetic complexity in a replicative system289. The value of
the error-threshold is determined by the replication accuracy and the virus fitness of the
dominant or master sequence corresponding to the mean fitness value of the error
copies289. Eigen and other authors proposed that the quasispecies contains the finite
replicon populations expanded under nonequilibrium conditions of variable fitness
landscapes293–304. The quasispecies theory can be mathematically determined based on
the dynamics of error copy production and the error threshold relationship and that
describes the evolutionary dynamics model305. The quasispecies theory introduces a
molecular view of evolutionary biology as well as viral quasispecies evolution285. The
alternative terms for quasispecies include “Mutant swarm, intrahost variation, intrahost
diversity, mixture of mutants, nucleotide degeneracy, hyperploidy, heterospecies and
heteropopulations”306.

2.1.1.2. Major characteristics of viral quasispecies
Viral quasispecies is defined as the continuous process of genomic distributions
of genetic variation, competition and selection307,308. There are two types of selection:
positive and negative that influence the generation of viral quasispecies in the virus
population. Positive selection is the process of a dominant genotype resulting in the
positive evolution of phenotypic traits expressed by the individuals of the evolving
population285. For instance, the viral quasispecies of a reconstructed foot-and-mouth
disease virus (FMDV) generate a dominant mutant distribution by antibody selection309.
Negative selection is the process of removing a genotype in an evolving population that

51

causes the negative evolution of phenotypic traits expressed by individuals285. However,
the outcome of negative selection is sometimes the same as positive selection or vice
versa during a competition process285. During replication of a viral subpopulation,
positive selection increases frequency of subsets of genomes with a net fitness gain310–312.
This increased fitness of the resulting subpopulations is maintained as memory
genomes313. The quasispecies memory is present in the mutant spectrum at higher
frequencies than mutation rates313,314. There are two parameters related to
characterization of the viral quasispecies: mutation rate and mutation frequency285.
Mutation rate is the frequency of occurrence of a mutation during genome replication that
can be calculated by mutations per site per replication. It is a value that is independent of
the fitness of the parental and mutated genomes285. Mutation frequency is the proportion
of mutant viruses in a population and is affected by many biochemical and environmental
selective factors285.
Additional to variation and continuity of core information of a biological adaptive
system, the viral quasispecies tends to maintain its memory of past events313. Evolving
viral quasispecies maintains the molecular memory as a form of minority components in
their mutant spectra and it is called viral quacispecies memory313. The viral quasispecies
memory plays an important adaptive role in the host environment such as the immune
system and results in the quasispecies dynamics285. During viral replication, memory
genomes with fitness gain in the most frequent genomes of the same quasispecies is
subjected to the Red Queen hypothesis315,316. This hypothesis defines that the continuous
selection of the most fit genomes in competing viral populations317–321. However, the
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quasispecies memory level can be gradually lost in the parallel lineages of replicating
populations and that is called memory decay321.
The viral fitness and the effect of population size, known as bottleneck events, are
another important characteristic of viral quasispecies285. Viral fitness is a major parameter
which results in a viral population adapting to a specific environment and producing
infectious progeny under the formulation of quasispecies theory and the error threshold
relationship282,285. Cristina Escarmís and her colleagues have demonstrated the molecular
basis of fitness loss associated with successive bottleneck events in biological clones of
FMDV. Some numerous, unusual mutations were observed in the large viral population
following in vitro passage of FMDV; these were not found in any field isolates or
clones322–324 Hundreds of bottleneck passages have driven an evolution of noncytopathic
variants of FMDV to be capable of establishing persistent infections in BHK-21 cells325–
327

. The constant steady replication of large viral populations result in a consequence of

high fitness called adaptation to new environment; in contrast, the repeated bottleneck
events with accumulation of mutations result in low fitness, is called de-adaptation in the
environment280 As the result of a reduction in fitness and the biological changes in
viruses, repeated bottleneck event transfers mediate distributions of neutral mutants in
mutant spectra285,328,329. There are two types of population bottleneck events called
plaque-to-plaque transfers and intrahost bottleneck intensity. In the case of plaque-toplaque transfers, a single infectious genome undergoes replication and diversification285.
Depending on a different intensity, the number of genomes from a larger ensemble starts
replication. Following which, a small number of genomes from the larger ensemble will
have limited variants by selective constraint285. During the replication cycle of a virus,
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viruses infect through host-to-host interaction as well as intrahost bottleneck intensity
that influences the intrahost evolutionary events330–340. The bottleneck events happen to
modify viral population sizes resulting in the heterogeneous and dynamic nature of viral
populations that are suitable in the environment by fitness gain341–343. Bottleneck events
occur in both short-term and long-term periods of virus evolution285.
Virus evolution does not always occur by modifications in consensus sequence, it
also happens through non-equilibrium of a mutant spectrum in variable fitness landscapes,
a theoretical construction of the evolutionary process285,344. In contrast, population
equilibrium plays an important role in maintaining a constant consensus sequence in viral
populations345,346. The positive selection influences the subpopulation of viral genomes in
the mutant spectrum increasing in frequency or replacing the previous distribution and
this results in a new consensus adapted to the biological environment285. The virus
undergoes the evolutionary process in a dynamic mutant spectrum either by evolutionary
stasis (rates of evolution of around 10-4 substitutions per site per year or lower) or rapid
evolution of its consensus sequence (rates of evolution of about 10-1 to 10-2 substitutions
per site per year) depending on its given environment286. In the case of avian influenza
virus, the evolutionary stasis in the natural target host will not give rise to a disease
outbreak, but the rapid evolution of the same virus will cause a disease outbreak in
different mammalian hosts when the virus starts to replicate347. Another viral
quasispecies parameter is the rate of evolution, which is the number of accumulated
mutations in viral genomes through a time point285. The major difference from the
previously mentioned mutation rate and frequency is counting the time factor285. The unit
of rate of evolution is expressed as the number of substitutions per site per year. This may

54

affect replication of a viral population during short-term (intrahost) or long-term
(interhost) virus evolution285.

2.1.1.3. Biological outcomes of quasispecies dynamics
As previously mentioned, the major characteristics of viral quasispecies produce
several outcomes in the virus-host relationship including host range mutant and viral
emergence, escape mutant, mutagen-resistant mutants, virus extinction and long-term
virus evolution285. Firstly, the viral quasispecies dynamics influence modifications in the
cell tropism and host range during virus evolution285. Viruses use cellular receptors which
are composed of different macromolecules such as proteins, lipoproteins, glycoproteins,
glycolipids and glycosoaminoglycans to attach and enter the host cells 348–353. For instance,
canine parvovirus-2 (CPV-2), which causes highly contagious after fatal disease in dogs,
is closely related to feline parvovirus (FPV) and therefore assumed to be a host variant of
FPV354–356. As the result of continuous genetic variation, two or three genetic mutations
in FPV caused the emergence of a novel strain of CPV and allowed it to expand its host
range to infect dogs357. Either amino acid substitutions on external surface proteins or
exchange of modules such as encoding relevant protein motifs by recombination affects
the modification of the host cell tropism285. Presence of a single or few amino acid
substitutions in a mutant spectrum may influence the host cell tropism and define the
phenotypic characteristics of a virus285. After serial passage of FMDV in cell culture,
amino acid substitutions were observed in the capsid surface that allows FMDV binding
to heparan sulfate (HS) on the cellular surface348,349,358–360. These HS-binding variants of
FMDV are also present in infected cattle tissues361. Modification of antigenic sites also
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impact the antibody dependent enhancement (ADE) of viral infection, a mechanism used
by several viruses362. Depending on the cross-linking of complexes of virus-antibody or
virus-activated complement components through infection with cellular molecules such
as Fc receptor on certain immune cells, the virus uses ADE mechanism to enhance its
infectivity to the susceptible host cells362. Analysis of the mutant spectrum composition
may enable one to predict the potential evolutionary outcomes related to receptor
recognition285. Interestingly, host cell tropism and viral pathogenicity are closely
associated with substitutions in the level of the structural or nonstructural viral proteins285.
For instance, amino acid substitutions in the polymerase subunit PB2 of influenza virus
promotes adaptation to alternative hosts and enhances the viral replication cycle363–367.
Secondly, viral quasispecies facilitate the emergence of escape mutants which are
the subset of mutants observed in the viral population that are associated with continuous
viral replication despite the presence of selective constraint in the host environment285. A
virus may generate mutations for the purpose of defending itself against the host immune
responses or selective constraints. Selective constraints include antiviral drugs, immune
components of the innate or the adaptive immune response including those induced by
vaccination and interfering RNAs285. By considering frequency factors of inhibitorresistant amino acid mutants, genetic barriers and the fitness cost represented in mutant
spectra, the frequency of inhibitor-resistant mutants of viruses is about in the range of 103

to 10-5

368–371

. Similar to the positive selection events, one or a few point mutations or

multiple mutations by recombination events can initiate resistance to an antiviral drug285.
According to Domingo et al. (2012), the drug resistance for human immunodeficiency
virus 1 (HIV-1), hepatitis B virus (HBV) and hepatitis C virus (HCV) is systematically
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reviewed as follows285: (i) Drug resistance is a general phenomenon and the selection of a
drug-resistant mutant

against a specific antiviral drug is evidence of the

phenomenon368,371–373. (ii) Multiple different mutations or combinations of mutations
called mutational pathways can lead to drug resistance374,375. For instance, multiple amino
acid replacements at different sites in the protein may decrease affinity for a drug or a
target protein complex285. (iii) High-level resistance to a drug may require mutations that
are different from mutations associated with low-level resistance. Different frequencies
of these mutations have been identified to the same drug376–379. (iv) Substitutions that are
influenced by drug resistance increase viral fitness and absence of the drug decreases
fitness285. (v) When multiple drug-resistant mutations occur, only some mutations are
selected for a fitness-enhancing effect, but not all of the mutations will be directly
involved in reducing affinity to the drug285. Vaccination is another selective constraint
that exerts evolutionary forces on viruses380. For instance, Hepatitis A virus (HAV) has a
single serotype, and its vaccine escape mutants have been identified in the complex
mutant spectra of the viral population381–384. HAV requires rare codons in the capsidcoding region to regulate ribosomal traffic for proper capsid folding proteins and to
prevent antigenic variants producing a new serotype317,385. However, the HAV escape
mutants

continuously

evade

adaptive

immune

responses

of

vaccinated

immunocompromised individuals348,386,387. Multiple selective constraints establish the
adaptive immune response in the host to block virus replication and remove infected cells
through neutralizing antibodies derived from virus specific T cells285. Also, investment in
immunotherapeutic approaches has the potential of eliminating viruses by targeting
highly conserved epitopes or neutralizing antibodies in the conserved regions of the viral
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proteins388,389. The development of effective antiviral drugs, vaccinations and
immunotherapeutic approaches is a challenge when it comes to inhibiting mutant viruses.
Thirdly, evidence of virus extinction observed in mutant spectrum complexity
occurs by an increase in the mutation rate above an extinction threshold. This suppresses
the replication of high fitness variants through a process called lethal mutagenesis390.
The hallmarks of lethal mutagenesis are increased frequency of defective genomes and a
constant consensus sequence391–393. The types of defective mutants are called defectors
and are associated with virus extinction caused by lethal mutagenesis280. This could be a
potential approach for antiviral protocols by targeting mutagenic agents285. During lethal
mutagenesis of viruses, there is evidence of a precarious mutant spectra suppressing the
virus replication of high fitness variants390. For example, populations of FMDV that are
resistant to polyclonal antibodies tend to have reduced fitness compared with wild types
of the virus394. The mutant spectrum interactions are affected by the interaction between
mutagenic agents and also by potential inhibitors of sequential treatments which can be
focused on lethal mutagenesis280. Combination therapies with two or more inhibitors are
generally used to prevent or reduce the production of inhibitor-resistant mutants280.
Additionally, combination of therapeutics of mutagenic agents and inhibitors will have
the advantage of reducing viral load and further result in virus extinction280.
Lastly and most importantly, the viral quasispecies dynamics will drive long-term
virus evolution in vivo285. While reviewing published information about the evolution of
RNA viruses and quasispecies evolution, two questions arise285. Firstly, does the outcome
of experimentally designed evolution studies reflect the viral population dynamics in the
natural environment? Fortunately, the findings suggest there is no discrepancy in virus
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behavior between experimental and natural infections in terms of genetic variation,
selection competition within the mutant spectrum or selection of genome subsets285.
Secondly, why should the consequences of quasispecies dynamics be considered for
understanding long-term virus evolution? This is because the mutant spectra determine
which type of genomes will be spread into susceptible target hosts285. Frequent complex
cycles of the quasispecies swarm and transmission influence long-term evolutionary
patterns by alternating the constitution of mutant spectra285. Viral lineages can undergo
slow or rapid evolution; these are related to pathogenicity395. For example, the genetic
diversity generated by a high polymerase error rate impacts the pandemic occurrence of
norovirus396. Also, viral fitness level determines the severity of dengue disease397. The
quasispecies dynamics proposes that RNA viruses evolve as a consequence of
disequilibria in mutant distributions instead of linear accumulation of mutations285.
However, there are contradictions concerning dating of viral ancestors and rates of codivergence between viruses and hosts398,399. A study involving phylogenetic analyses of
divergence has been conducted on HIV-1 and HIV-2 based on the common ancestor of
retroviruses and using strict or relaxed clock models that sometimes give conflicting
results400. The steady accumulation of mutations has randomly selected from the
quasispecies that was amplified in the susceptible hosts401. From the average rates of
virus evolution in the range of 1x10-1 to 3x10-5 substitution per site per year402,
phylogenetic analyses interestingly showed that the virus isolated in a short time span
presented a higher rate of evolution than isolates after a long time402,403. The operation of
a molecular clock follows the neutral theory of molecular evolution that means the rates
of evolution reflect mutation rates285. However, this does not support the quasispecies
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dynamics concept with reference to dating of viral ancestors, rates of co-divergence of
viruses and their hosts398,399. These discrepancies might arise because of insufficient data
concerning the population disequilibria to support the short-term and long-term evolution
under the assumption of a linear accumulation of mutations285. Overall, the quasispecies
dynamics through disequilibria of mutant swarms plays an important role during shortterm intrahost and long-term evolution285. In conclusion, the virus evolution and viral
population biology require continuous investment with regard to a rapidly replicating,
error-prone, viral quasispecies in integrated biological systems285.

2.1.2. Reassortment
RNA viruses with segmented genomes such as reoviruses, bunyaviruses and
influenza viruses evolve through a process called reassortment279. When a susceptible
host cell is coinfected by two strains of a virus, the progeny virus may have mixture of
genome segments from the two parental strains of a virus that are called reassortants279.
For instance, a susceptible cell is infected by two strains of influenza A virus that have
unique envelope glycoproteins: hemagglutinin (H) and neuraminidase (N). After
replication, the combination of parental RNA segments encoding H and N proteins now
produce new progeny viruses279. This continuous reassortment process results in new
reassortants of influenza A viruses that were responsible for three pandemics of influenza
during the 20th century279. The largest scaled pandemic known as “Spanish Flu” occurred
in 1918-19 resulting in the number of people killed by this influenza virus “H1N1” was
greater than the number of deaths during the First World War279.
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2.1.3. Recombination
Many RNA viruses exchange nucleotide sequences among RNA molecules of
different genomes producing new genomes284. This process is called RNA recombination;
RNA viruses evolve by rearranging their genomes or functional parts among different
viruses284. Recombination also occurs in DNA viruses279. There are two mechanisms of
recombination, namely base-pairing dependent and base-pairing independent. Basepairing dependent occurs between identical nucleotide sequences and base-pairing
independent happens between variable nucleotide sequences284. Recombination plays a
role in viral pathogenesis; for example, the noncytopathic bovine viral diarrhea virus
(BVDV) can become cytopathic BVDV causing severe fatal gastrointestinal disease in
cattle. The nonstructural protein 3 (NS3) synthesis of BVDV is critically associated with
pathogenicity, and the base-pairing independent RNA recombination generates extra
protease cleavage sites at the N terminus of the NS3 proteins284. Both DNA and RNA
viruses use recombination mechanism for their evolution279. Many DNA viruses usually
do not enter the nucleus during viral replication, except for herpesviruses that enter into
the nucleus closely interacting with target host cells to mimicking cellular proteins. For
instance, human herpesviruses can similarly modulate the host immune system including
major histocompatibility complex proteins and cytokines (e.g. IL-10)279.

3. Research objectives
Viruses have coexisted with human and animal populations on the earth for
millions of years. They are considered a parasite, because the virus cannot replicate itself
without the host organism. The virus is a causative agent of infectious disease in allliving
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organisms. Most virus infections in mammals are cleared following development of the
host immune response. However, some viruses have evolved to establish long-term
persistent infection in their natural hosts in the presence of strong host immune response.
Such viruses could either establish latent infection (dormant infection) or produce
smoldering infection in a specific tissue or organ and continue to produce infectious
progeny virus (persistent infection), which can be transmitted to susceptible naïve
animals. These viruses have evolved mechanisms to evade the host immune response. In
addition, these viruses tend to evolve during persistent infection generating novel genetic
and antigenic variants that can precipitate new disease outbreaks. EAV is one of the
classic examples of persistent viral infections in the natural host. Following natural and
experimental infection, the virus establishes persistent infection in the stallion
reproductive tract. Interestingly, 10% to 70% of the stallions that are infected with EAV
become persistently infected carriers and continue to shed the virus in semen for several
weeks to years to lifelong11. The primary objectives of the this research is to study EAV
evolution during persistent infection by determining the full-length genome sequences of
sequential EAV isolates present in the semen of long-term EAV carrier stallions by nextgeneration sequencing (NGS). We have included virus strains from both experimentally
(49 sequential isolates over a two-year period from seven experimentally infected carrier
stallions) and naturally infected (4 sequential isolates over a period of 10 years) stallions.
Both experimentally and naturally infected stallions were exposed to the KY84 strain of
EAV (EAV KY84). We used next-generation sequencing (NGS) to determine the
complete genome sequence of each strain. Subsequently, the annotated full-length
genome sequences were obtained, processed and subjected to complex bioinformatics
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analyses. In this study, we investigated the intra-host evolutionary dynamics during acute
and persistent infection periods. Furthermore, we characterized the virus quasispecies
diversity, rate of evolution and selective pressure during the different time periods (e.g.
acute and chronic) of EAV infection. Chapter two focuses on the evolution of EAV
KY84 strain during acute and persistent infection in the stallion.
EAV infection is highly species-specific and only infects members of the family
Equidae such as horses, donkeys, mules and zebras10,11. Recently, we have isolated a
strain of EAV from a feral donkey in Chile. The second objective of this research was to
obtain the full-length genome of this EAV donkey isolate using NGS. Thus, the second
objective of this study is to analyze genomic, phylogenetic and antigenic characterization
of this field strain of EAV from a donkey, which is a different member of the family
Equidae. Comparative nucleotide and amino acid sequence analysis and phylogenetic
analysis demonstrated that there is a unique relationship between EAV strains from
horses, as well as other donkey isolates from Italy and South Africa. Subsequently, EAV
strain-specific antisera and neutralizing monoclonal antibodies against the prototype
EAV Bucyrus strain were used to determine the antigenic variation of the Chilean donkey
isolate. Chapter three is focused on the molecular characterization and evolution of the
Chilean donkey strain.
As previously mentioned, virus isolation is the OIE-approved “gold standard” test
for EAV detection221. It is known that the high passage rabbit kidney (RK-13) cell line
that is used for EAV isolation is contaminated with noncytopathic bovine viral diarrhea
virus 1 (BVDV). During NGS sequencing of the EAV isolates from RK-13 cells, we
were able to obtain the full-length genome of the contaminating BVDV. The third
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objective of this research was to assemble the complete genome sequence of BVDV-1
strain contaminating the RK-13 cells. Chapter four is dedicated to the comparative
nucleotide amino acid sequence analysis of the BVDV-1 strain.
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CHAPTER TWO
Genetic Bottleneck and Selection of Equine Arteritis Virus During Acute Infection
and Intra-host Quasispecies Diversification During Long-term Persistent Infection
in the Reproductive Tract of the Stallion

2.1. Summary
Equine arteritis virus (EAV) is a small enveloped, positive-sense, single-stranded
RNA virus in the Arteriviridae family. It infects the upper respiratory tract of equids
(horses, donkey and zebra) with initial replication in nasopharyngeal epithelium and
alveolar macrophages. Systemic spread is through infection of cells of the monocyte
lineages and CD3+ T lymphocytes. It establishes persistent infection in the reproductive
tract of 10 to 70 % of infected stallions. Such stallions continually shed EAV in the
semen ensuring successful transmission of EAV to susceptible naïve horses. In this study,
seven EAV seronegative stallions were experimentally inoculated with EAV KY84
strain and followed for 726 dpi. Nasal secretions (swabs), unclotted blood and semen
were sequentially collected, and a total of 53 sequential viruses were deep sequenced to
elucidate the intra-host micro evolutionary process of EAV after a single transmission
event. In addition, the viruses from two long-term EAV carrier stallions (seven to ten
years duration) were deep sequenced; these carrier stallions were naturally infected with
the same KY84 strain of EAV. The intra-host viral population dynamics of the
experimentally infected stallions were compared and contrasted with the two naturally
infected stallions. In this study, the analysis of viral sequences in nasal secretions and
buffy coat cells showed a lack of extensive positive selection; however, characteristics of
the mutant spectra were different in the two sample types. By contrast, semen virus
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populations during acute infection had undergone a strong selective bottleneck as
reflected by a reduction in population size and multiple sites of the viral genome that was
under diversifying selection. During the period of persistent infection, virus solely
evolved inside the reproductive tract of the stallions in the presence of strong
neutralizing antibody response, resulting in a non-stochastic evolutionary process with a
number of atypical high frequency minor variants being identified. This indicates that an
active selection pressure continually morphs EAV quasispecies population structures and
dynamics during persistent infection. Comparative analysis of the experimental
evolution with that of naturally infected stallions showed a higher degree of correlation
in the rate of sequence divergence through time with mirroring patterns of selection
between experimental and naturally infected stallions.

2.2. Introduction
Equine arteritis virus (EAV) is the causative agent of equine viral arteritis
(EVA), a reproductive and respiratory disease of horses, donkeys, mules and
zebras10,11,97,154,404–406,406. EAV was first isolated from the lung of an aborted fetus
during an extensive outbreak of respiratory disease and abortion storm on a
Standardbred breeding farm near Bucyrus, OH, USA, in 19539–11,14,194. Depending on
the host’s age, physical condition, immune status and the strains of virus, EAV infection
causes mild to moderate clinical signs including leukopenia, pyrexia, depression,
anorexia, dependent edema (scrotum, ventral trunk, and limbs), stiffness of gait,
conjunctivitis, lacrimation and swelling around the eyes (periorbital and supraorbital
edema and urticaria)11,97,154,168. EAV infection can also cause abortion in broodmares
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and congenital infection can lead to interstitial pneumonia in young foals and death in
newborn foals171. Most importantly 10-70% of acutely infected stallions become
persistently infected carriers and can continue to shed virus in semen for a long
time11,157,158,208. The carrier state is testosterone-dependent and can last from several
weeks (short-term carrier state), 3 to 7 months (intermediate carrier state) and years or
even lifelong (long-term persistent or chronic carrier state) despite the development of a
strong serum neutralizing antibody response1,11,97,98,143,154,156,157,407.

EAV primarily

persists in the ampulla of the vas deferens in the reproductive tract of carrier stallions165.
Persistently infected stallions play a central role in the maintenance, perpetuation and
evolution of the virus in the horse population142. An increase in the incidence of the
disease has been observed in the past twenty years, associated inter alia with increased
national and international movement of horses and shipment of frozen or chilled semen
19,21,142,160,164,167,184,265–267,408

.

EAV is a small, enveloped, positive-sense, single-stranded RNA virus that
belongs to the family Arteriviridae (genus: Equartevirus, order: Nidovirales), which
includes lactate dehydrogenase-elevating virus (LDV), simian hemorrhagic fever virus
(SHFV), porcine reproductive and respiratory syndrome virus (PRRSV), wobbly
possum disease virus (WPDV) and African pouched rat arterivirus (APRAV-1)1,409. The
EAV genome contains approximately 12.7 kb with at least 10 known open reading
frames (ORFs). The ORFs 1a and 1b are located in the 5′-three quarter of the genome
and encode for two polyproteins (1a and 1ab), which are subsequently processed into 13
nonstructural proteins (nsp1-13; including nsp 7α and 7β) by viral proteases1. The ORFs
2a, 2b, 3, 4, 5a, 5b, 6 and 7 are located at the 3′-distal quarter of the genome
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38,40

and

encode seven envelope proteins (E, GP2, GP3, GP4, ORF5a protein, GP5 and M) and
the nucleocapsid (N) protein, respectively. The GP2, GP3 and GP4 are minor envelope
glycoproteins and form a heterotrimer; whereas GP5 and M are the major envelope
proteins of the virus and are assembled into a heterodimer in the virus particle. The
major neutralization determinants of EAV are located in the N-terminal ectodomain of
the GP5 major envelope glycoprotein of EAV. Studies using neutralization-resistant
variants to monoclonal antibodies (MAbs) and polyclonal equine antisera in
combination with reverse genetics have identified four major neutralization sites in the
N-terminal ectodomain of the GP5 major envelope glycoprotein of EAV GP5 (site A
[aa 49], site B [aa 61], site c [aa 67 to 90], and site D [aa 98-106])1,82. The changes in
conformational neutralization epitopes is influenced by the GP5 interaction with the M
protein16,82. Although there is only one known EAV serotype, field strains differ in their
virulence and neutralization phenotypes

21,23,155,162,177,179,183,184,188,189,199

. Phylogenetic

analysis based on partial ORF5 sequences segregated EAV isolates from around the
world into North American (NA) and the European (EU) lineages, and each lineage is
further subdivided into two North American (NA-1, NA-2) and European (EU-1 and
EU-2) clades21,408,410–412.
The lack of proofreading capability of the viral RNA-dependent RNA
polymerase (RdRp) enzyme leads to a high mutation rate in the EAV genome resulting
in the occurrence of viral quasispecies282. Often times, a novel virus variant arises from
the quasispecies pool under conditions that regulate the frequency of minor variants. A
number of studies have demonstrated intra-host quasispecies variation and the resultant
genomic diversity in a number of important human and animal viruses361,413–417.
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Establishment of EAV-persistent infection in the reproductive tract of stallions has been
known for decades but very little work has been performed to better understand the
molecular basis of natural evolution of this virus during long-term persistent infection in
infected stallions. Earlier findings from T1 oligonucleotide fingerprinting analysis
demonstrated the presence of a population level diversity in naturally infected stallion418.
Furthermore, partial sequence analysis (ORFs 2-7) of sequential viruses from two
persistently infected stallions following the 1984 outbreak in Kentucky have shown
marked genetic divergence over time with emergence of new phenotypic variants142.
However, these initial studies on EAV evolution during persistent infection were
hampered due to the limitations in sequencing technology and data analysis capabilities
17,19,21,142,164,410

. In recent years, next-generation sequencing (NGS) technologies have

improved the processing capacity and allowed for high throughput analysis of viral
genomic data361,419. This allowed identification of low frequency variant populations in
unprecedented detail and opened the door for more precise characterization of viral
qausispecies population and its evolution during acute and persistent viral infections.
In this study, the comprehensive analysis of the dynamic events associated with
EAV evolution was reported by following intranasal inoculation of seven
experimentally inoculated stallions and two naturally infected stallions. The data
showed successful transmission of EAV founder populations with distinct evolution
during acute and persistent infections and also demonstrated the temporal regulation of
variant populations following a single transmission event driven by genetic bottlenecks
and episodic selections.
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2.3. Materials and methods
Cells and viruses
The high passage (HP) rabbit kidney cell line RK-13 (KY), passage level 399409, was maintained in Eagle’s minimum essential medium (EMEM; Mediatech,
Manassas, VA, USA) supplemented with 10% ferritin-supplemented bovine calf serum
(Hyclone Laboratories, Logan, UT, USA), 100 U/mL penicillin/streptomycin
(Mediatech, Manassas, VA, USA) and 1 μg/mL amphotericin B (Sigma-Aldrich, St.
Louis, MO, USA). Equine pulmonary artery endothelial cells (EECs) were maintained
in Dulbecco’s modified essential medium (Mediatech, Herndon, VA, USA) with
sodium pyruvate, 10% fetal bovine serum (Hyclone Laboratories, Inc., Logan, UT,
USA), 100 U/μg per mL of penicillin/streptomycin and 200mM L-glutamine68.
The KY84 strain of EAV was originally isolated from pooled blood collected
during the 1984 EVA outbreak (5/1984) from three stallions acutely infected with EAV
(stallion E and two other stallions) and was serially passaged three times in horses and
subsequently once in EECs to make the working virus stock419. This moderately
virulent EAV KY84 strain was used as the challenge virus in this study22,420. The KY84
strain of EAV has been shown to establish persistent infection in the reproductive tract
of stallions and to cause moderate to severe clinical signs of EVA in infected
horses156,208,420. Tissue culture fluid (TCF) containing the commercial live attenuated
vaccine strain of EAV (ARVAC®; Zoetis, Kalamazoo, MI, USA) was used as reference
virus to determine the serum neutralizing antibody responses during acute and persistent
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infection of the stallions in accordance with the World Organisation for Animal Health
(OIE) standardized virus neutralization test (VNT) protocol421.

Ethics statement
This study was performed in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health.
The Institutional Animal Care and Use Committee (IACUC) at the University of
Kentucky, Lexington, KY, USA approved this protocol (number 2011-0888). Stallions
were humanely euthanized by pentobarbital overdose following the American
Veterinary Medical Association (AVMA) guidelines for the euthanasia of animals, and
all efforts were made to minimize suffering.

Stallions used for experimental infection
Seven sexually mature (4 to 16 years of age) stallions of mixed breed were
included in the study (stallion IDs: L136 to L142). Horses were obtained from a local
commercial vendor and acclimated to their new environment for approximately two
months before the study commenced. During this period, animals were accommodated
in individual paddocks and trained to mount a mare or a phantom for collection of
semen into an artificial vagina. All stallions exhibited good libido and normal sexual
behavior and were seronegative (titer <1:4) for EAV neutralizing antibodies several
times prior to intranasal inoculation with the EAV KY84 strain using a previously
described protocol405. The animals were housed in individual stalls in an isolation
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facility for the duration of the study at the University of Kentucky Maine Chance Farm,
Lexington, KY, USA.

Experimental infection of stallions with EAV KY84 strain and clinical examination
Stallions were inoculated intranasally with 3.75 × 105 plaque-forming units
(PFU) of the EAV KY84 strain in 5.0 mL of EMEM (inoculum) using a fenestrated
catheter passed via the posterior nares into the nasopharynx as previously described 199.
All stallions were examined and clinical parameters were recorded by the same
veterinarian. Pre-inoculation (7, 5 and 2 days before experimental challenge) clinical
examinations were performed once daily to determine baseline values for body
temperature and also to certify that the parameters were within normal limits before
experimental challenge of the stallions. Specifically, fever and scrotal edema were
monitored twice daily (every 12 hours) for the first 15 days after infection, and the
highest value of the day was recorded. Clinical signs continued to be monitored once
per week during the following four weeks of the experiment (at 21, 28, 35 and 42 dpi).
Blood samples were collected at 0, 2, 4, 6, 8, 10, 12, 14, 21, 28, 35 and 42 dpi to
determine individual serum neutralizing antibody responses to EAV. The neutralizing
antibody titers were determined as per the OIE-prescribed test263.

Semen collection from experimentally infected stallions
Two ovariectomized mares previously vaccinated with the commercial MLV
vaccine against EVA (ARVAC, Zoetis Animal Health, Inc., Kalamazoo, MI, USA)
(serum neutralizing antibody titers ≥1:256) were used to “tease” the stallions. Each

72

stallion was allowed to mount either one of the mares or a breeding phantom to enable
semen collection in an artificial vagina (Botucatu model, Botupharma, Botucatu, SP,
Brazil). The artificial vagina was disinfected with a disinfectant (Roccal®-D Plus,
Pfizer Inc., New York, NY, USA) between collections. A disposable liner lubricated
with sterile lubricant (Priority Care, First Priority Inc., Elgin, IL, USA) was used to
collect semen from each stallion to avoid cross-contamination between ejaculate
samples. A pre-semen sample was collected and evaluated 2 days before challenge, and
then the samples were collected on days 1, 3, 5, 7, 9, 11, 13, 15 and 23 during acute
period of infection. Once the stallions became persistently infected, semen samples
were collected from each stallion once per month up until 726 days and processed to
evaluate the samples. Specifically, the numbers of sequential EAV isolates from each
stallion were selected at 5, 9, 107, 170, 345, 380, 548 and 726 dpi (Figure 2.1.).

EVA outbreak in 1984 and semen collection from two naturally infected stallions
(D and E)
An extensive outbreak of EVA occurred in Central Kentucky in 1984158. This
outbreak was the first recorded occurrence of EVA in the North American
Thoroughbred population, and subsequent investigation established that stallions could
be persistently infected with EAV; furthermore, carrier stallions were critical to the
epidemiology of EAV infection146,156,157. Two stallions from the index premises
(designated D and E) were infected during this outbreak and subsequently became longterm EAV shedders. Semen was collected from the two stallions at regular intervals
(stallion D, 6/84 [month/year], 9/85, 12/86, 9/87, 7/88, 1/89, 1/91, 9/92 and 8/94 [seven
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sequential samples] and stallion E, 6/84, 9/85, 11/86, 2/88, 1/89 and 1/91 [six sequential
samples]) following initial infection of the stallions, which occurred in May 1984.
Semen was collected until the stallions ceased shedding EAV, as determined by virus
isolation as previously described157.

Virus isolation
Virus isolation from raw gel-free semen samples was attempted in the RK-13
(KY) cell line according to a standard protocol used by the OIE Reference Laboratory at
Maxwell H. Gluck Equine Research Center, University of Kentucky, USA222. Briefly,
after sonication, serial decimal dilutions (10-1 to 10-4) of each sample supernatant were
prepared in EMEM (Cellgro®, Mediatech, Inc, Manassas, VA, USA), and 1 mL of each
dilution was inoculated into each of two 25-cm2 flasks containing a confluent
monolayer of RK-13 (KY) cells grown in supplemented EMEM and overlaid with the
supplemented EMEM containing 0.75% carboxymethylcellulose (CMC; Sigma-Aldrich,
St. Louis, MO, USA). Flasks not showing cytopathic effect (CPE) after 4 days were
subinoculated onto new RK-13 (KY) monolayers using 1 mL of culture supernatant as
the inoculum. Tissue culture fluid (TCF) was harvested and stored at -80°C for viral
RNA extraction. First and second passage flasks were stained with a 0.2% crystal violet
solution in buffered formalin on day 4 post-inoculation to count plaques and calculate
virus titers. The same individual performed all attempted virus isolations. Virus isolates
were, confirmed later by an EAV-specific TaqMan® real-time RT-PCR assay as
previously described223.

74

Phenotypic characterization of EAV isolates against neutralizing monoclonal
antibodies and equine sera
The EAV microneutralization assay was performed as previously described15,16.
Neutralization titers were determined for each virus isolated from the semen of
individual carrier stallions using a panel of EAV-specific MAbs and polyclonal equine
antisera422.

Real-time RT-PCR
Briefly, viral RNA was directly isolated from 50 µl of tissue culture fluid (TCF)
using a commercial RNA isolation kit (MagMAXTM -96 Viral RNA Isolation Kit,
Applied, Foster City, CA, USA) according to the manufacturer’s instructions. Viral
RNA was eluted in 50 l of nuclease-free water and stored at -80°C. RNA extracted
from TCF derived from RK-13 (KY) cells inoculated with semen samples that were
negative for EAV, as well as from nuclease free water were included as negative
controls. Viral RNA extracted from TCF containing the KY84 strain of EAV was used
as a positive control. A one-tube TaqMan® real-time RT-PCR assay was performed as
described by Miszczak et al.223

Next-generation and Sanger sequencing
The total viral RNA was extracted from the TCF containing EAV KY84 strain
(inoculum) or from the cell lysate following freeze-thaw of HP RK-13 (KY) cell
monolayer (P1) in 25 cm2 flasks using a total RNA purification kit (Catalog no. 17200,
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Norgen Biotek Corp., Ontario, Canada). The RNA was quantified using a Qubit 2.0
spectrophotometer (Life Technologies, Carlsbad, CA, USA). The cDNA libraries were
constructed from 100 ng of total RNA using a TruSeq Stranded total RNA sample
preparation kit (Illumina, San Diego, CA, USA) according to the manufacturer’s
instructions. Multiplex libraries were prepared using barcoded primers and a median
insert size of 340 base pairs (bp). Libraries were analyzed for size distribution using a
Bioanalyzer and quantified by quantitative RT-PCR using a Kapa library quantification
kit (Kapa Biosystems, Boston, MA, USA), and relative volumes were pooled
accordingly. The pooled libraries were sequenced on an Illumina MiSeq platform with
150 bp end reads following standard Illumina protocols. The Sanger sequencing was
performed by RT-PCR amplification of the entire EAV genome in multiple overlapping
segments using high-fidelity DNA polymerase enzyme as previously described. Primer
sequences used for RT-PCR amplification and sequencing will be available upon
request from the corresponding authors17,21,150. The nucleotide sequences of the 5'
untranslated region (UTR) and 3' UTR termini region were further confirmed by
standard Sanger sequencing of the reverse transcription-PCR products. Overlapping
sequences were analyzed and assembled into a full-length genome sequence using the
Geneious 7.0.6 software (Biomatters Ltd., Auckland, New Zealand).

Read mapping and variant calling
Raw reads in FASTq formats were imported into a CLC Genomics Workbench
Version 8.5.1 (CLCBio, Aarhus, Denmark) after quality associated trimming; reads were
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paired using the Illumina short read default parameters. Paired reads were then mapped to
the reference genome (EAV KY84 in the inoculum) and the frequency of viral
quasispecies population in individual samples, were called from reads coverage. The
mapping procedures were normalized by subsampling of the reads across data sets using
samtools 1.1 to 1000 x coverages to avoid the biases from a high and low read coverage
across samples sets. Mapped files in (BAM) were imported back to CLC genomic
workbench and numbers of single nucleotide variants (SNVs) were estimated by applying
a minimum frequency filter of 1% and ignoring broken reads and nonspecific matches.
Reference masking was set up for reads coverage >100,000 and < 100 in individual
samples. A technology-associated filter was used to remove any pyro error variant with a
minimum length of 3 and a frequency below 0.8.

Nucleotide diversity and evolutionary selection analysis
The statistical measure of nucleotide diversity (∏), which quantifies the average
number of pairwise differences within a sample, was calculated using open-source
software SNPGenie (https://github.com/chasewnelson/snpgenie). SNPGenie is a Perl
script which analyzes SNV caller results to calculate an evolutionary parameter, such as
nucleotide diversity (nonsynonymous and synonymous diversity, ∏n and ∏s). Reference
sequences in FASTA format, SNV report from CLC Genomics Workbench were used as
input files. To produce GTF formats, the script snpgenie-gb2gtf.pl. was used and an
estimation of nucleotide diversity ∏ was performed by running snpgenie.pl. from the
command line. Values generated for the whole genome were used to show the diversity
estimate at different time points. Individual ORFs were used to calculate ∏n
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(nonsynonymous diversity) and ∏s (synonymous diversity). A ratio of ∏n/∏s > 1 was
considered indicative of positive selection, <1 means purifying selection and 1 indicates
neutrality.
For selected ORFs with evidence of positive selection, the codon level was
estimated to investigate particular areas under selection pressure. In this analysis for each
codon, estimates of the numbers of inferred synonymous (s) and nonsynonymous (n)
substitutions are presented along with the numbers of sites that are estimated to be
synonymous (S) and nonsynonymous (N). These estimates are produced using the joint
maximum likelihood reconstructions of ancestral states under a Muse-Gaut model of
codon substitution and model of nucleotide substitution. For estimating maximum
likelihood values, a tree topology was automatically computed. The test statistic dN - dS
is used for detecting codons that have undergone positive selection, where dS is the
number of synonymous substitutions per site (s/S) and dN is the number of
nonsynonymous substitutions per site (n/N). A positive value for the test statistic
indicates an overabundance of nonsynonymous substitutions. Normalized dN - dS for the
test statistic is obtained using the total number of substitutions in the tree (measured in
expected substitutions per site) and used for making comparisons across data sets.
Maximum likelihood computations of dN and dS were conducted using hypothesis
testing and the phylogenies (HyPhy) software package.
In addition, the presence of selection pressure at the codon level is further
assessed using an online server at http://www.datamonkey.org. Fast unconstrained
Bayesian analysis for inferring selection (FUBAR) algorithms was used to characterize
selective pressure that are aggregated in all the branches of the constructed phylogenies,
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and the mixed effect model of evolution (MEME) was used to identify individual sites
subject to episodic positive selection along a subset of phylogenetic tree branches.

Sequence analysis and SNV detection from consensus sequences
Reads from individual samples were assembled de novo as indicated above using
ABySS (vb1.3.7). The highest-ranking base at a position and with highest quality scores
(highest calculated Q-score) were used to determine the consensus sequence. Once the
consensus sequence was determined for each sample, the annotation of individual ORFs,
and other genomic features was conducted using an automated gene transfer algorithm,
Glimmer 3. The EAV reference genome in the NCBI database (NC_002532) was used to
benchmark this procedure. The annotated ORFs and nonstructural proteins encoding
regions were manually inspected and curated for correct enzyme cleavage sites,
translation frame, start and stop codon coordinates.
Finally, the full genome nucleotide sequences (derived from the consensus) and
parts representing a genomic region were aligned using Clustal W plugin in Geneious
V6.1.7. For the nucleotide analysis, a default setting was in Clustal W cost matrix, a gap
opening cost 15 and gap extension cost of 6.6. For translated amino acid sequence
alignment, the GONNET cost matrix was used with a gap opening cost of 10 and a gap
extension cost of 0.1. The original EAV KY84 strain used for the inoculum was the
reference sequence for multiple sequence alignments. Single nucleotide variants (SNVs)
in positions were identified using Geneious V6.1.7 and the effect of each SNP on
translation (synonymous and nonsynonymous) was calculated for individual ORFs.
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Phylogenetic analysis
A phylogenetic tree was constructed using the same parameters described by
Guindon et al. (2010)423. Evolutionary and genetic divergence analyses were performed
by estimating the maximum likelihood of phylogenies using the PhyML program as a
plugin for Geneious V6.1.7. These trees were constructed based on the GTR model, with
1000 bootstrap replicates. In addition, trees for molecular evolution were assessed using
the maximum likelihood method based on the Tamura-Nei model as implemented in
MEGA 7.0.21. Maximum likelihood trees were also generated using TempEst-v1.5
(formerly known as Path-O-Gen) to investigate the temporal signals (clock-likeness) of
the sequential genomes generated in this study. These trees were used to estimate the root
tip distance by regression analysis. The relationship between root to tip divergence and
sample collection date supports the use of molecular clock trees in this study. Molecular
clock trees were generated by Bayesian inference analysis, as implemented in MrBayes
version 3.2.2424. These trees were estimated using the GTR substitution model and
gamma distribution rate of variation. The posterior probabilities were calculated using
MCMC chain length generating 1,000,000 trees and sampling every 100th tree. The
initial 25% of trees were discarded as a burn-in, and the others were used to construct a
majority rule tree.
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2.4. Results
Establishment of EAV persistent infection in experimentally infected stallions
A major aim of this study was to investigate intra-host evolutionary dynamics of
EAV during acute and persistent infection in stallions. To achieve this goal, an
experimental model of persistent infection was established by using the moderately
virulent EAV KY84 strain. The selection of this strain was based on two important
phenotypic traits relevant to this study, one is a moderately virulent phenotype which
can be used to assess clinical and behavioral parameters following infection and the
second is a demonstrated ability to establish long-term persistent infection in the stallion
reproductive tract.
Following infection, all seven stallions developed moderate to severe clinical
signs. The detailed description of the clinical signs, virus effect on semen quality, as well
as its tissue and cellular tropism have been previously described211. Briefly, clinical signs
started at 2 dpi, with signs that included fever (38.7°C to 40.8°C [101.7°F to 105.6°F]),
leukopenia, ocular, scrotal, preputial and limb edema, nasal and ocular discharge,
congestion and petechial or ecchymotic hemorrhages on the oral mucosal membrane and
decreased libido. These clinical signs lasted for up to 20 days, and the peak
manifestations occurred at a median of 7 dpi. Once stallions recovered from these signs
there were no recurrences of signs up to the conclusion of the experimental study (726
dpi). Viral shedding in nasal secretions was detected as early as 2 dpi and lasted up to 19
dpi. Viral titers varied from ≤10 – 5.7 x 104 PFU/mL (mean viral titer of 4.36 x 103
PFU/mL). Similarly, viremia was detected in buffy coat cells at 2 dpi but was extended to
between 28 and 42 dpi, and a mean viral infectivity titer varied from ≤10 – 5.1 x 103
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PFU/mL (mean viral titers 2.35 x 102 PFU/mL). The peak for both nasal shedding and
viremia occurred at a median of 6 dpi. The clearance of virus from blood mononuclear
cells coincided with the appearance of neutralizing antibodies.
All experimentally infected stallions exhibited decreased libido during the acute
phase of infection. However, neither clinical signs of EVA nor reproductive dysfunction
were observed in any of the experimentally infected stallions (n=7) following recovery
from acute infection. Viral shedding in semen started at 5 dpi, except for one stallion
(L141) where it was detected at 3 dpi. Viral infectivity titers in semen varied from 1.0 x
101 to 1.88 x 107 PFU/mL during the acute infection (up to 21 dpi), with a mean titer of
7.85 x 105 PFU/mL. A peak in viral infectivity titer in semen occurred at a median of 9
dpi. Stallions seroconverted from 8 dpi and maintained high serum neutralizing antibody
titers until the end of the study (1:64 to >1:512 [median titer of 1:256]).
Two out of seven experimentally infected stallions (L136 and L140) continued to
shed EAV in their semen for ≥ 726 dpi (i.e. long-term persistently infected stallions). By
the end of the study, viral titers in semen of these two stallions were 6.5 x 103 and 7.8 x
103 PFU/mL, respectively165, but infectivity titers in these stallions fluctuated from 1.2 x
103 to 8.8 x 105 PFU/mL during persistent infection in the reproductive tract (Figure 2.1.).
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Figure 2.1. Schematic presentation of the experimental design for this study. Darker
horses were used to represent experimentally infected stallions (n=7), arrow showing
timeline of sampling. Grey shaded horses were used to represent naturally infected
stallions and arrow showing timeline of semen collection for isolation of the sequential
viruses.

Persistent EAV infection in naturally infected stallions
Stallions D and E were naturally infected and became persistently infected during
the extensive outbreak in 1984142. These stallions have been monitored up to ten years,
and during this period, EAV was shed in semen with titers ranging from 10 x 103 to 1.0 x
105 PFU/mL (Figure 2.1.). There were neither apparent clinical signs nor any evidence of
reproductive dysfunction in these stallions during the follow up to the conclusion of the
study142.
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Complete genome sequence of EAV KY84 strain used for experimental infection
The complete genome sequence of EAV KY84 strain used as inoculum was
determined using two methods. Consensuses derived independently from Sanger and
NGS were compared and showed a 100% pairwise nucleotide identity. A fully annotated
and complete sequence of EAV KY84 strain is deposited in GenBank with the accession
number (MG137429).

Virus population in the inoculum
In order to understand the transmission dynamics of EAV quasispecies population
following experimental infection, the quasispecies population was first characterized in
the inoculum (original EAV KY84) by investigating the SNV present at minimum allelic
frequency of 1%. The analysis showed that a genetically more homogenous viral
population with structure constituted by a major variant (consensus virus; with ≥77% in
frequency) and minority SNV population that was circulating from 13 to 25 %. However,
this is likely to represent only a subset of the true variation present within the viral
inoculum and characterizes the variants present at a frequency of >1% (Figure 2.2.).

84

Figure 2.2. SNV population in the inoculum used for experimental infection. Each
dot in the figure represents a major and minor SNV population (nucleotide numbers
A407G, A2337G, T4616C, T7414C, A8759C and C12582T). Population frequencies on
y-axis and genomic position on x-axis are plotted in 2000 bp intervals. Blue dot (a
synonymous SNV), red dot (nonsynonymous SNV) and light green (major variant).

The minor variant populations in the inoculum were dominated by synonymous
substitutions that are distributed evenly along the EAV genome. One exception to this
was a SNV population with nonsynonymous substitution from A->G (T->A) at genomic
position 2,337 corresponding to nsp2. The allelic frequency for this specific substitution
in the virus inoculum was 13.5 %; whether this substitution is associated with specific
adaptive function in cell culture is hard to predict in the absence of experimental data.
However, a higher degree of conservation in the dominant nucleotide “A” across cell
culture-passaged EAV field isolates (data not shown) suggest that it is unlikely that this
substitution is associated with any specific advantage in the cell culture.
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Founder virus analysis and nucleotide diversity during acute infection period
Viruses isolated in the first nine days of the experimental infection were uniquely
positioned to provide information on the mechanism of adaptive evolutionary process of
EAV in a variety of host cells following initial infection. During this period, the virus
present in the inoculum had successfully established infection in the respiratory
epithelium and blood cells of all seven experimentally inoculated stallions. Virus
shedding in the nasal secretions and viremia in blood (virus in buffy coat cells) were
detected as early as 2 dpi, and then appeared for the first time in the semen at 5 dpi,
suggesting an initial infection of the stallion reproductive tract where EAV established
persistent infection.
This adaptation to infect and replicate in various tissues along with an active
challenge from host innate and fledgling adaptive immune responses could constitute
evolutionary bottlenecks that select specific viral variants to shape an effective
population size. In order to test this hypothesis and also elucidate the early event of
quasispecies dynamics, representative viruses from time points of highest nasal shedding
and viremia (6 dpi) and the initial semen isolates (5 and 9 dpi) were deep sequenced from
viral RNA derived in the first TCF passage 1 (P1) in RK-13 (KY) cells. Thus in this
section, results from deep sequencing of 28 sequential viruses are systematically
presented to highlight the early events in EAV KY84 infection.
First, the variant population present in the inoculum was compared with the 14
sequential viruses from nasal swab and buffy coat samples. For this, the SNV populations
(A407G, A2337G, T4616C, T7414C, A8759C and C12582T) were identified in the
inoculum and were traced in the nasal swab and buffy coat viruses. Each of these six
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minor variant populations was detected at least in five of the seven experimental stallions
without causing a major shift in the population frequency (Figure 2.3.).

T

T

Figure 2.3. Mapping of SNV in nasal secretions (NS), buffy coat (BC) cells and
semen (S) in seven experimentally infected stallions during acute infection (0 to 9
dpi). (A) Frequencies of the six SNV (represents variants in the inoculum) in an
individual stallion. (B) Average detection frequencies of the six mapped SNV were
steady in nasal secretion and buffy coat cells at 6 dpi. However, the SNV populations in
the S (semen) at 5 and 9 dpi had undergone a shift in frequencies, which resulted in the
fixation of T7417C at 5 dpi and A407G, T4616C, A8759C and C12582T at 9 dpi. The
nonsynonymous substitutions from A2337G were below the detection limit at 5 dpi and
then attained its average detection frequency at 9 dpi.
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These results have confirmed transmission of all virus populations present in the
inoculum and successful establishment of infection. Then, the overall similarities were
identified between the major variants in the inoculum and initial viruses from the
experimentally inoculated stallions by constructing phylogenetic trees and assessing
consensus level. The results as demonstrated by the star-like phylogenetic tree structure
and a 100% consensus agreement between the virus inoculum and the seven viruses from
nasal secretions indicating that a single major founder virus population was responsible
for establishment of the experimental infection

(Figure 2.4.). However, there were

marked differences in quasispecies population composition and structure between the
virus inoculum and viruses derived from nasal swabs. In this regard, nasal swab viruses
have shown an expansion of the minor variant population by accumulating mutations that
were not present in the inoculum. As a result, the quasispecies population frequencies
were increased by more than 20-fold in the nasal swab viruses (Figure 2.5.A and B.).
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Figure 2.4. Maximum likelihood phylogenetic trees showing a star-like network,
which demonstrates the presence a major founder population in the experimental
stallions similar to the stock virus. (A) Viruses from nasal secretions and buffy coat at 6
dpi; (B) tree showing divergence of initial semen viruses from the major founder
population at 5 dpi; and (C) at 9 dpi, the virus from semen was shown to evolve further in
the stallion reproductive tract. The rates of evolution (nucleotide substitutions / site) in
each tree are indicated under the bar.
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Figure 2.5. SNV population and structure during the acute phase of infection (0 to 9
dpi). Each dot in the figures represents a major and minor variant population. Population
frequencies on y-axis and genomic position on x-axis are plotted in 2000 bp interval.
Blue dot (synonymous SNV) and red dot (nonsynonymous SNV). (A) Less
heterogeneous population in viral inoculum used for experimental infection of stallions,
(B) nasal swab viruses at 6 dpi, (C) buffy coat viruses at 6 dpi, (D) semen viruses at 5 dpi
and (E) semen viruses at 9 dpi.
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To evaluate the level of polymorphism in this expanded quasispecies population,
the nucleotide diversity was estimated within the nasal swab viruses by computing
nucleotide diversity (∏) statistics. In this method, SNV are weighted at the population
level and high frequency polymorphisms will be considered to be more diverse than
populations with the same number of low frequency variants. The method also allowed us
to calculate within the sample nonsynonymous nucleotide diversity ∏n and synonymous
diversity ∏s separately. The ratio of the two estimates was performed to evaluate the
presence of a selective pressure. A value of 1 suggested neutrality or absence of selection
pressure, whereas a value of >1 suggested the presence of positive selection and a value <
1 suggested a purifying type of selection. Based on these analyses, a higher nucleotide
diversity was detected in nasal swab (1.9 x10-4) viruses than in the inoculum virus (1.3 x
10-5). The ∏n/∏s ratio for nasal swab viruses was 3.1 x 10-1, suggesting a dominant
purifying type of selection across the entire viral genome. However, during the SNV
enumeration, the most nonsynonymous mutations were aggregated in nsp9 and nsp10
(RNA-dependent RNA polymerase [RdRp] and zinc-binding domain [ZBD]) encoding
regions in the viruses present in the nasal secretions.
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Figure 2.6. Sliding window analyses showing evidence for positive evolutionary
selections in the sequential viruses during acute infection. Selection was estimated by
calculating the ratio of nonsynonymous and synonymous nucleotide diversity (∏n/∏s). A
value of >1 was indicative of positive selection, value of 1 = neutrality and value < 1 was
indicative of purifying selection; results were plotted against genomic position (x-axis) in
2000 bp intervals. (A) Viruses from nasal swab, a positive selection was identified in
genomic position corresponding to nsp9 and nsp10; (B) viruses from buffy coat, no
region was found under positive selection pressure; (C) and (D) semen viruses at 5 and 9
dpi respectively, semen virus at 5 dpi showed strong positive selection at multiple
locations, whereas at 9 dpi, the selection pressure decreased except in the nsp9 region.
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To investigate whether this is due to positive selection, the sliding window
analysis (∏n/∏s) was performed via spanning the entire genome of nasal swab viruses.
The results showed that the presence of strong positive selection (∏n/∏s >1) at the
genomic regions spanning nucleotides (nts) 6729 to 6816 (within nsp9 peptide) and nts
8469 to 8565 (within nsp10 peptide) (see previous page)

(Figure 2.6.A.). Similar

analysis was conducted with viruses present in the BC samples at 6 dpi. Interestingly in
the case of these samples, a decline in quasispecies diversity was observed as measured
by the decreased nucleotide diversity (1.6 x 10-4) and total population size (Figure 2.7.A.).
In addition, a minor shift in the population structure was identified in two stallions (L140
and L138) that resulted in fixation of synonymous nucleotide substitutions at genomic
positions 422 [G->A], 2567 [C->T] and 7417 [T->C] (Figure 2.5.C.). However, contrary
to what was observed in the case of nasal swab viruses, the sliding window analysis of
∏n/∏s in the buffy coat viruses has shown no supporting evidence for localized positive
selection (Figure 2.6.B.). In summary, despite a high level of consensus agreement and
same date of isolation (6 dpi), the analyses have identified differences in viral
quasispecies diversity, population size and evolutionary selection pattern between viruses
from nasal swab and buffy coat samples.
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Figure 2.7. Quasispecies diversity and population size of sequential viruses in nasal
secretions, buffy coat and semen during acute and persistent infections. (A)
Comparison of synonymous nucleotide diversity in the sequential viruses. The diversity
in the two long-term carrier stallions (L-136 and L-140) at later dpi (380 and 726) were
significantly higher (p< 0.0001; one-way ANOVA) than diversity detected in all other
samples in this study. (B) Nonsynonymous diversity at 5 dpi in the semen viruses had a
significantly higher substitution rate (p< 0.0001; one-way ANOVA) than any other
sequential virus isolate in this study. (C) The quasispecies population size in sequential
viruses has shown a trend of decline in the initial semen samples (at 5 and 9 dpi), where
at 9 dpi it attains its lowest point in the experimental period. NS (nasal swab), BC (buffy
coat) and S (semen).
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Quasispecies diversity and evolutionary selection in the initial semen viruses
Virus first appeared in semen at 5 dpi; the analysis of the viral quasispecies
population in these samples revealed marked differences in overall evolutionary
dynamics compared to viruses in the initial inoculum, nasal secretions and buffy coat
samples. One major observation is semen viruses at 5 dpi have a high rate of
nonsynonymous nucleotide diversity occurring at a rate (∏n = 4.2 x10-3) (Figure 2.7.B.).
This was the highest nonsynonymous substitution rate recorded for the entire
experimental period (p <0.0001). Interestingly, the viral quasispecies population size at 5
dpi demonstrated a slight decline compared to what it was in buffy coat viruses and a 3fold reduction when compared to viruses in the nasal swab (Figure 2.7.C.). This showed
that virus populations were bottlenecked during the initial infection of the stallion
reproductive tract. In addition, the presence of a high level of nonsynonymous nucleotide
diversity within the population (∏n=4.2 x 10-3) and the shifts of the minor and majority
variant population characterizes the type of bottleneck as a selective one (Figure 2.5.C.).
The sliding window analyses for ∏n/ ∏s also support the finding with additional
evidence of strong selective sweeps in multiple genomic positions of the semen viruses
(Figure 2. 6.C.). More interestingly, there were 29 new SNV fixed in the consensus
genome that contributed 8 nonsynonymous substitutions in the structural protein
encoding genes and in ORFs 1a and 1b. Given the nonstructural region is three-fourths of
the entire EAV genome, the rate of nonsynonymous substitutions was higher in the
structural protein encoding ORFs, which occupy one-fourth of the EAV genome. The
regions of nsp2 peptide and ORF5 each acquired three amino acid substitutions. The
changes in the nsp2 peptide region were at nucleotide positions 1,018 [P->L], 1633 [K-
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>R] and 1713 [A->T], whereas they were at genomic position 11,133[R->H], 11,162 [V>A] and 11,663[L->P] in ORF5 (Figure 2.5.C.).
At 9 dpi, in contrast to what was observed in 5 dpi semen viruses, the ∏n values
dropped significantly (p<0.0001), suggesting the selective sweeps observed in the initial
semen viruses. Very interestingly, examining the population structure and sliding window
analysis of ∏n/∏s showed only a very limited positive selection localized to the nsp9
encoding region of ORF1b (Figure 2.5.E. and Figure 2.6.D.).
Overall, the analysis of the viral population dynamics during the acute infection
period (0 to 9 dpi) has identified a selective genetic bottleneck event during establishment
of infection in the stallion reproductive tract (around 5 to 9 dpi). This is evidenced by the
initial number of limited variant population in the parental virus that gave rise to a higher
number of the variant population in nasal and buffy coat viruses with a dominant
purifying type of selection. That was followed by a decline in the viral quasispecies
population in the initial semen viruses. The presence of a strong positive selection across
multiple genomic regions and, at the same time, a shift of the quasispecies population
structure was clear indication of a selective bottleneck scenario that promotes variants
with an adaptive fitness to establishing infection in the stallion reproductive tract.
Additionally, the phylogenetic tree constructed from the nasal swab and buffy
coat viruses showed star-like features that identify a responsible major founder virus
population for establishment of the infection process. In contrast, the semen viruses (5
and 9 dpi) were shown to diverge from the founder virus population indicating the
emergence of a new dominant variant in the stallion reproductive tract (Figure 2.4.).
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Intra-host evolution of EAV KY84 strain in the stallion reproductive tract during
persistent infection
Of the 34 sequential EAV semen isolates from seven experimentally infected
stallions, 20 were isolated during the persistent infection period. Sequences from these
viruses were systematically analyzed to gain a detailed insight into the characteristic feature
of the EAV KY84 evolution in the stallion reproductive tract during long-term persistent
infection.
During the course of this experiment, five stallions had stopped shedding virus by
different dpi (stallions L137 and L138 at 170 dpi and L139, L141 and L142 at 345 dpi).
In contrast, stallions L136 and L140 became long-term carriers and continued shedding
virus throughout the experimental period (726 dpi). The data showed a general increase
in the viral quasispecies population size and diversity in the reproductive tract of these
two stallions (Figure 2.8.A.). However, it is interesting to note that quasispecies diversity
at later time points (380-726 dpi, where only L136 and L140 were shedding) was
significantly higher compared to any other time point in this study (p<0.007 to 0.0001)
(Figure 2.7.A.). This indicates the presence of a higher degree of heterogeneity in the
virus population of the two long-term carrier stallions at later dpi (380-726), compared to
those stallions that had stopped shedding. Overall, sequential viruses in this study were
more under strong purifying types of evolutionary pressure (p< 0.0057) than positive
(diversifying) selection (Figure 2.8.A.).
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Figure 2.8. Heat map showing the evolution of 49 sequential viruses from seven
experimentally infected stallions. At the full genome level, a strong purifying pressure
played a significant role in long-term evolution of the sequential viruses (**p< 0.0057).
(A) Nucleotide diversity (∏), nonsynonymous nucleotide diversity (∏n) and synonymous
nucleotide diversity (∏s) in the 49 sequential viruses. (B) Illustrates the temporal changes
in the SNV population detected in the inoculum over the two years of the experimental
period. This founder virus population was detected consistently in the nasal swab (NS)
and buffy coat (BC) samples, and detection and frequency shown to be variable in the
subsequent semen (S) viruses.
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According to the Figure 2.9., the initial population structures (in the inoculum, nasal
swab and buffy coat viruses) were becoming genetically divergent with the appearance of
high frequencies of minor variants. This indicates that the presence of a persistent selective
pressure that continually morphs the population structure. The second important observation
is the aggregation and fixation of a nonsynonymous variant population in the region of
genome that encodes for the minor and major structural proteins (between nucleotide
numbers 10,000 to 12,000) (Figure 2.9.). This indicates that mutations that occurred in this
region have a greater role in maintaining persistent infections in the stallion reproductive
tract. In order to investigate this observation further, the pooled semen viruses were
computed in the analyses to find out whether the evolutionary selection was at a particular
gene level. This revealed that ORF3 was under positive selection with a ∏n/∏s value of
1.19. Additionally, the sliding window analyses on pooled semen viruses identified multiple
regions within nonstructural and structural genes that are under strong positive selection
(Figure 2.10.).
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Figure 2.9. Quasispecies population structure during persistent infection (107 to 726
dpi). Each dot in the figures represents a major and minor SNV population identified
from the semen viruses of experimentally infected stallions (L136-142) collected during
persistently infected period; on y-axis population frequencies and x-axis genomic
position are drawn in 2000 bp intervals. Blue dot (a synonymous SNV), red dot
(nonsynonymous SNV). SNV population in the semen viruses at (A) 107 dpi, (B) 170 dpi,
(C) 380 dpi and (D) 726 dpi.
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Figure 2.10. Quasispecies populations and positive selection in semen viruses. (A)
SNV identified in semen viruses in the experimental period, each dot in the figures
represents a major and minor SNV population; on y-axis population frequencies and xaxis genomic position are drawn in 2000 bp intervals. Blue dot (a synonymous SNV), red
dot (nonsynonymous SNV). (B) Sliding window analyses for evidence of positive
evolutionary selections of the sequential viruses from semen, the results were plotted
against genomic position (x-axis) in 2000 bp intervals.
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Non-stochastic intra-host evolution of consensus viruses during persistent infection
in the stallion reproductive tract
In addition to characterizing the quasispecies population in experimental infection,
the role of the major variant population was investigated by constructing a consensus
sequence for each of the 48 viruses examined in this study. Comparative analyses of these
sequential virus genomes have shown a total of 298 SNV fixed in the consensus genomes,
and of these changes 68 were nonsynonymous substitutions. Using this information, the
maximum likelihood and Bayesian phylogenetic trees were generated that show the extent
of genetic divergence in the sequential viruses (Figure 2.11.A.). These viruses were evolving
at a rate of 2.5 x 10 -4 nucleotide substitutions /site/year.
A major observation from Bayesian inference analysis was the clustering of viruses
in the phylogenetic tree in a non-stochastic manner. At the full genome level, the analyses
have shown that EAV KY84 sequential viruses follow a linearly progressive type of
evolution; as a result viruses from later dpi had larger branch lengths than their predecessors
(Figure 2.11.). This was particularly emphasized in those viruses isolated from >107 dpi
(shaded light brown in the phylogenetic tree), where viruses clustered by their date of
isolation and the respective stallion. As a result, none of the viruses from two different
stallions at different dpi clustered together. This observation was further confirmed with root
to tip divergence analysis that demonstrated the clock-likeness of the sequential viruses by
fitting the nucleotide substitution rate and date of isolation into a regression model. This
showed a 0.90 correlation coefficient and R2= 0.81 (Figure 2.11.B.).
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Figure 2.11. Genetic divergence and evolution of EAV KY84 sequential viruses in
experimental stallions. (A) Full-genome Bayesian phylogenetic tree constructed from all
sequential viruses in the experimental period (726 dpi) and the numbers in each branch
showing posterior probabilities calculated from 1000 replicates. Bar under the graph
indicates the average pairwise distance of the sequential isolates from the original EAV
KY84 strain described as the nucleotide substitution rate /site. The light brown shaded areas
showing strict non-stochastic clustering of viral sequence; light blue shaded area shows
clustering of sequences mostly from the period of acute infection. (B) Root to tip divergence
analysis justified the use of molecular clock analysis on the sequential isolates in this study.
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Intra-host evolution and genetic divergence in the structural region of consensus
viruses during persistent infection
In order to get a deeper insight on the important genomic region that signifies the
evolutionary process, the data were systematically analyzed and these changes weighted by
ORFs. The diversity estimation used to measure evolution was pairwise distance matrix to
see how these sequential viruses diverged from the inoculum virus (original EAV KY84).
This analysis at the level of the full genome assumes equal rate of substitution in various
genomic segments over a period of time and hence was not satisfactory to identify the role
of a particular region in the evolutionary process. Therefore, the analyses were further
divided into by different ORFs and calculated a pairwise distance; this showed ORFs 5 and
3 are the two most evolving regions at rate of 3 x 10-3 nucleotide substitutions/site resulting
in sequence divergence of 1 to 1.4% respectively. ORF1ab and ORF7 were shown to be the
two most conserved regions with only 0.3 and 0.5 % of divergence from the parental EAV
KY84 over the two years of the experimental period.
These changes accumulating in the genomes of sequential isolates have either a
purifying or a selective role in the evolution of viral populations in the reproductive tract. To
characterize the changes in such a way, the ORF1ab region was broken down into
nonstructural protein coding regions (nsp1 to 12) and included the tally of synonymous and
nonsynonymous substitutions (Figure 2.12.). The analysis showed that despite a higher
number of synonymous changes occurring in the ORF1ab region, most nonsynonymous
changes were concentrated in the nsp2 encoding region of ORF1a. The 1.7 kb-long nsp2
had undergone 29 synonymous and 14 nonsynonymous substitutions over a period of 726
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days; this constitutes 42 % of the total nonsynonymous substitutions for the whole of
nonstructural region.

Figure 2.12. Rate of synonymous and nonsynonymous substitutions across genomic
regions and ORFs of the sequential viruses. (A) Tally of all nonsynonymous and
synonymous substitutions in the ORFs and peptide regions of the sequential viruses. (B)
Graph showing the rate of variation by which nucleotide substitution occurred in the region
of EAV KY84 sequential genomes, 13 nucleotide substitution/kb in the structural region and
only 3 substitutions/kb in nonstructural region.

In the structural protein encoding region (ORFs 2-7) of EAV, the sequential isolates
had a higher rate of nonsynonymous substitution compared to nonstructural region (Figure
2.12.B.). The data shows that for every kb in the nonstructural region, there were 3.3
nonsynonymous substitutions over the two year period of the study; whereas there were 12
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nonsynonymous substitutions /kb in the structural regions, clearly suggestive of a higher rate
of fitness-associated substitution in the structural region. This observation is also strongly
supported by ∏s and ∏n analysis, which indicated a strong positive selection in ORF3 and
also in ORF5 (Figure 2.13.). The result also demonstrated that the nsp2 peptide had
undergone a positive selection (∏n / ∏s >1) indicating an important role for this region in
the adaptive evolutionary process.

Figure 2.13. Comparison of nonsynonymous to synonymous nucleotide diversity in the
experimental horses. (A) Nucleotide diversity estimate by regions of the genome ∏n
(nonsynonymous diversity) ∏s (synonymous diversity). (B) Showing the presence of
positive selection in ORFs that have ∏n/∏s value > 1.
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To further investigate which specific codons were under selection pressure, the
sequences from ORF3 and ORF5 were used for a codon level estimate of positive selection.
A maximum likelihood reconstruction of ancestral states using a Muse-Gaut model
employed under MEGA7 was used to test the statistic dN - dS for detecting codons that
have undergone positive selection, where dS is the number of synonymous substitutions per
site (s/S) and dN is the number of nonsynonymous substitutions per site (n/N). A positive
value for the test statistic indicates an overabundance of nonsynonymous substitutions.
Analysis of ORF3 using this model demonstrated most codon positions in this gene were
found to be overabundant with nonsynonymous substitutions (Table 2.1.) indicating a
positive selection pressure in the codons highlighted yellow. However unlike ORF3, ORF5
contained a higher number of negative dN – dS values per codon site, indicating an
overabundant synonymous codon site. The values for ORF5 are given in Table 2.2. and the
overabundant nonsynonymous sites are highlighted in yellow.
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Table 2.1. Nonsynonymous and synonymous substitution site estimate for ORF3, values shaded in yellow are codon positions that
have more nonsynonymous substitutions than synonymous substitutions
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Table 2.2. Nonsynonymous and synonymous substitution site estimate for ORF5, values shaded in yellow are codon positions that
have more nonsynonymous substitutions than synonymous substitutions
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Intra-host evolution and genetic diversity of EAV KY84 strain in naturally infected
stallions over a span of 10 years
In addition to the experimentally infected horses, there was the opportunity to
analyze virus sequences from two naturally infected stallions. The two Thoroughbred
stallions (E and D) were on the farm where the first major EVA outbreak in
Thoroughbred horses in Kentucky occurred. These two stallions were initially infected
with EAV KY84 (inoculum virus) that was used for experimental inoculation of the
seven stallions. However, the two horses subsequently developed the natural carrier state
and continued to shed the virus in the semen for a period 7 to 10 years (stallion E, 1984 to
1991 and stallion D, 1984 to 1994, respectively). In this study, the complete genome of
four viruses that were isolated from the semen of stallion E in 1984, 1991 and stallion
D1984, 1994 (these viruses will be referred as E or D followed by year of isolation) were
sequenced and analyzed.
Comparative nucleotide and amino acid analyses showed that E84 and D84
viruses from naturally infected stallions are very similar to the inoculum virus that was
used for experimental infection of the other stallions. The only differences identified
were 9 substitutions in the D84 and E84 viruses compared to the EAV KY84 strain used
to inoculate the stallions. These changes resulted in three nonsynonymous substitutions in
D84 virus at position (583 T>I (nsp1), 5376 D>A (nsp9) and 10,886 F>L (GP4) and only
one nonsynonymous substitution in E84 virus at 5376 D>A (nsp9) (Figure 2.14.A.).
The quasispecies population structures in E84 and D84 viruses have some
collinearity with what was observed with viruses from the semen of the experimental
stallions, by having a number of minor variants (Figure 2.15.A and B.). However, the
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E91 and D94 viruses showed a clearing of the high frequencies of minor variants with a
new distinct population structure of new minor and new major variants (Figure 2.15.C
and D.).
Similar to the observation made in the experimental samples, a higher level of
nonsynonymous fixation was shown to aggregate in the structural regions of the genome.
For a detailed characterization of these changes, the consensus sequence was calculated
as genome-wide pairwise distance for stallion D and E viruses. The results showed
sequence divergence by 1.6 and 2% over the span of seven year for E91 and ten years for
D94 (Figure 2.14.B.).
Previous analyses of viruses from the experimentally infected stallions showed
that evolution of ORFs occurred at a variable rate. Hence, the extent of evolution was
investigated between the various ORFs in these four sequential viruses. In agreement
with earlier observation, different ORFs evolved independently with some accumulating
more numerous changes than others. In the 10 year period, ORF3 was shown to have a
4.5% sequence divergence from the original isolates, diverging at a rate of 2 .6 x 10-2
nucleotide substitutions / site (Figure 2.14.B.). By contrast, ORF7 was demonstrated to
have the lowest evolutionary rate with 2 x 10-3 nucleotide substitutions / site, which
resulted in a 1.2% pairwise sequence divergence from the original EAV KY84 genome
(Figure 2.14.B.).
These changes in various ORFs have brought 461 substitutions, which included
361 synonymous and 96 non-synonymous substitutions (Figure 2.15.C and D.). A higher
proportion of the nonsynonymous substitutions was shown in the structural protein
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coding region where 19.3 nonsynonymous substitutions / kb, whereas 4.1 amino acid
substitutions / kb were seen in the nonstructural region of the EAV genome.

B

Pairwise similarity to EAV KY84

A

Figure 2.14. Sequence alignments and comparison of sequential viruses in naturally
infected stallions D and E. (A) Multiple genome alignment of four sequential viruses
with the parental EAV KY84. The genome arrangement with arrowed boxes indicating
the location of peptides and important genes. A vertical line indicates disagreement
between the four viruses from the two naturally infected stallions with the parental EAV
KY84 strain. (B) Bar graph showing the pairwise similarity of these sequential genomes
from naturally infected stallions. Genome wide means comparing pairwise distance of
consensus sequences from stallion D and E viruses.
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Figure 2.15. Quasispecies population structure in naturally infected stallions D and
E. The stallions D and E were infected with EAV KY84 strain are very similar to the
inoculum virus used for experimental infection of the seven stallions. Each dot in the
figures represents a major and minor SNV population; on y-axis population frequencies
and x-axis genomic position are drawn in 2000 bp intervals. Blue dot (a synonymous
SNV), red dot (nonsynonymous SNV) and light green (reference variant). (A) SNV
population frequencies of E84, (B) SNV population frequencies of D84, (C) SNV
population frequencies of E91 and (D) SNV population frequencies of D94.
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To examine these changes and their role in the adaptive evolutionary process, the
computed ∏n/∏s analysis showed the presence of selection pressure in ORF3 and ORF5
(Figure 2.16.). However, contrary to what is observed in the experimentally infected the
stallions, those changes in the nsp2 region were found to be purifying rather than
associated with evolutionary fitness. Based on these results, further investigation was
focused on the codon level selection estimate on ORF3 where multiple nonsynonymous
overabundant codon sites were identified isolates (n=53) of both experimentally and
naturally infected horses that are highlighted yellow in Table 2.3.

Figure 2.16. Comparison of nonsynonymous to synonymous nucleotide diversity of
viruses from naturally infected stallions. (A) Nucleotide diversity estimate by regions
and ORFs in the EAV KY84 genome, ∏n (nonsynonymous nucleotide diversity) ∏s
(synonymous nucleotide diversity). (B) Showing the presence of positive selection in
ORFs that have ∏n/∏s value >1.
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Table 2.3. Nonsynonymous and synonymous substitution site estimate for ORF3 was identified in virus isolates from both
experimentally and naturally infected horses, values shaded in yellow are codon positions that have more nonsynonymous
substitutions than synonymous substitutions
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Mirroring the trend in the comparative evolution between experimentally and
naturally infected stallions
As described in the earlier section, one advantage of the sequences from naturally
infected isolates extended analyses to a ten-year window and enabled us to understand the
EAV evolutionary process over a longer time period. Hence, the evolutionary rate of EAV
KY84 was calculated from the combined sequences from the experimental infection with
isolates from stallion D and E. A full genome multiple alignment of 53 sequential viruses
was used to perform a Bayesian phylogenetic tree (Figure 2.17.). The result showed that
EAV KY84 isolates were evolving at rate of 4 x 10-4 nucleotide substitutions / site / year.
This is slightly higher nucleotide substitution rate than that individually estimated for the
experimental stallions (Figure 2.17.).
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Figure 2.17. Estimation of evolutionary rate of the sequential viruses. (A) Ancestral
reconstruction using a Bayesian phylogenetic. (B) Root to tip divergence analysis justifying
the use of a molecular clock analysis on the sequential isolates in this study.
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Figure 2.18. Comparative trend in nucleotide diversity and selection between viruses
from the natural and experimental infections. (A) Collinearity in trends of nucleotide
diversity in EXPT (sequential viruses from experimental infection), NAT (sequential viruses
from natural infection). (B) Collinearity in trends of positive and negative selection in EXPT
(sequential viruses from experimental infection), NAT (sequential viruses from natural
infection) various genomic region sequential viruses. Horizontal line showing where the
ratio ∏n/∏s is 1, which indicates equal rate of nonsynonymous and synonymous diversity.
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In addition, these combined sequences were used to compare and contrast virus
evolution and selection pressure between experimentally and naturally infected stallions.
This analysis has showed that the rate of nucleotide substitution / site described as an
average pairwise distance in Figure 2.18.A. and the diversity estimate ratio of ∏n/∏s
obtained across all ORFs followed a mirroring trend across genomic regions of viruses from
experimentally and naturally infected stallions (Figure 2.17.). These comparisons also
confirmed the previous observation that ORF3 and 5 have a prominent role in the
evolutionary process of viruses in experimental as well as natural infections.
In order to visually identify codons or regions of such importance in ORF3 and 5,
the FUBAR (fast-unconstrained Bayesian approximation for inference of selection) was
implemented in datamonkey server and fitted the data with a codon substitution model. This
method uses an empirical Bayes procedure in the phylogenetic likelihood framework to
identify codon regions with statistically significant evidence for diversifying and purifying
selection. The analysis has identified seven sites with diversifying (positive selection) in
ORF3 with a posterior probability > 0.9 at codon positions 3, 19, 27, 28, 30, 119 and 120
(Figure 2.19.). It also identified four sites with evidence of purifying (negative selection) at
posterior probability > 0.9, codon positions 93, 134, 137 and 145 (Figure 2.19.).
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Figure 2.19. Fast-unconstrained Bayesian approximations for inferring selection
(FUBAR) analysis of ORF3. (A) A rate class weight analysis of positive and negatively
selected codon positions with heat map calculated from posterior mean analysis of
nonsynonymous (beta) over synonymous sites (alpha) by the FUBAR algorithm. (B) Codon
positions with * (black) are the seven sites with statistically significant evidence for
diversifying selection at posterior probability of > 0.9 and * (red) the four sites identified
with statistically significantly purifying selection at posterior probability of > 0.9.
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Figure 2.20. Fast-unconstrained Bayesian approximations for inferring selection
(FUBAR) analysis of ORF5. (A) A rate class weight analysis of positive and negatively
selected codon positions with heat map calculated from posterior mean analysis of
nonsynonymous (beta) over synonymous (alpha) sites by FUBAR algorithm. (B) The four
codon positions with * (black) are identified with evidence for diversifying selection at
posterior probability of > 0.9 and * (red) showing the seven sites identified with purifying
selection at posterior probability of > 0.9.
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Similarly in ORF5, FUBAR has identified four statistically significant codon sites
with diversifying (positive selection) at codon positions 11, 72, 82 and 84 and eight sites (at
codon positions 2, 109, 110, 111, 117, 121, 138 and 154) with purifying (negative selection)
at posterior probability of > 0.9 (Figure 2.20.). The analysis by FUBAR was based on
pooled signals of all the phylogenetic tree branches; however, some studies have suggested
using the mixed effect model of evolution (MEME) that is more sensitive than FUBAR for
detection of selection on subsets of viral linages425–427. For this reason, ORFs 3 and 5 were
subjected to MEME analysis as implemented in the adaptive evolution server of
datamonkey. By doing so, additional sites of statistically significant value have been
identified (Table 2.4.). More interestingly, four out of the seven codon sites in ORF3 were in
concordance for evidence of diversifying positive selection in both FUBAR and MEME
algorithms (Table 2.4.).

Table 2.4. Analysis of positively selected codon sites in ORF3 and ORF5 of sequential
viruses
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By combining the information in Table 2.4. that identifies the sites under
diversifying selection and localization of the codons in Figure 2.19. and Figure 2.20., it is
possible to see the pattern of selection in ORF3 and 5. In this regard, the region that contains
the first 30 codons of ORF3 (an overlapping region with ORF2) is shown to preferentially
undergo a positive selection pressure, and this may indicate a fitness-associated role in this
region during persistent infection; whereas in ORF 5, the region between codon positions
100 to 154 as under significant influence of purifying type of selection, which showed that
genetic drift is the major driver of evolution in this region.

2.5. Discussion
Experimental evolutionary models constitute the most powerful means of
recapitulating natural evolution of viruses, and they have been used to test basic
theories/hypotheses and elucidate the mechanisms of viral survival and spread in shortterm and long-term viral infections428–430. In this study, seven sexually mature stallions
were used for experimental inoculation of the moderately virulent strain of EAV KY84
and then these stallions were followed for up to 726 dpi. This appears to be the first study
to experimentally characterize the intra-host evolutionary process of the prototype
arterivirus in its natural host. Similar studies for other RNA viruses have been shown to
elucidate viral evolution across a single transmission event and over the course of the
infection period416,431–433. However, a major strength of this study was the ability to
follow and sample experimentally and naturally EAV infected horses for relatively long
periods of time (~up to 2 and 10 years, respectively). The only other study that has
looked at the evolution of EAV in longitudinal samples was that of Hedges et al.
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(1999)142, where sequential viruses from two naturally infected stallions (D and E) during
the 1984 EAV outbreak in Kentucky were characterized. However, that study used
traditional RT-PCR amplification, cloning and Sanger sequencing methods to
characterize EAV ORFs 2 to 7 in sequential EAV KY84 viruses present in semen. With
significant improvement on this study, four sequential viruses were included from horses
(D and E) that were naturally infected during the 1984 EAV outbreak and employed NGS
technology to evaluate the intra-host evolution and compare it to the analysis from the
experimental stallions. In total, this study was based on data from 53 sequential viruses
that have been deep sequenced using an Illumina Miseq technology and used to
reconstruct the quasispecies population dynamics and overall genetic divergence of EAV
in the acute and persistent stages of the infection.
Recent advances in sequencing technology allow viral evolution to be studied
with deep insight into viral quasispecies populations429,434. As a result, investigating intrahost viral evolutions in longitudinal samples has become a part and parcel of
pathogenesis studies285,397,435. These types of studies have demonstrated that rapidly
evolving RNA viruses exist as genetically related but highly diverse and complex viral
populations436,437. These observations followed by identification of the viral evolution in
dynamic population structure indicate that variants undergo temporo-spatial change and
regulate quasispecies composition that can result in the emergence of new
phenotypes438,439.
The first reports on identification of EAV quasispecies populations were those
based on T1 oligonucleotide fingerprinting of viruses isolated from naturally infected
stallion semen142. Subsequently, others characterized the genetic divergence of this virus
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mainly by targeted sequencing of structural proteins encoding ORFs, mainly ORF5. In
this study, the EAV KY84 quasispecies populations in the inoculum and in nasal, buffy
coat and sequential semen samples were reconstructed. In agreement with observations
for other RNA viruses, the major and minor variant populations were defined in the
inoculum virus. These variants were traced in nasal swabs and buffy coat samples that
comprised successful establishment of experimental infection from the viral inoculum
populations. In the initial samples from the experimentally infected stallion, the founder
effect had been shown to result in loss of certain populations from the inoculum during
viral transmission. This might be associated with the efficiency of the nasopharyngeal
inoculation technique used to infect horses in this study. In larger animal models such as
horses, the presence of a more extensive surface area in the nasal cavities coupled with a
high viral challenge dose in the inoculum could facilitate efficient transmission of viral
populations.

A similar finding has also been reported in the case of intra-host

evolutionary studies of influenza virus where transmission bottleneck events occurring in
experimental infections of ferrets and mice were determined by the route of
inoculation434,440.
The presence of a high rate of mutation in RNA viruses is beneficial for rapid
adaptation to their microenvironment; at the same time, it has the disadvantage of random
generation of non-viable viruses285,439. However, contemporary thought on RNA virus
evolution suggests that a cloud of potentially beneficial mutations occur at the population
level285,428,439 . An interesting observation from this study was that viruses from nasal
swabs and buffy coats have distinct quasispecies population sizes and selection patterns.
This was examined as to how this cell population becomes infected. EAV initially
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invades the upper respiratory tract and multiplies in the nasopharyngeal epithelium and
tonsillar tissue as well as in bronchial epithelium and alveolar macrophages. Then, the
virus infects cells of the monocyte linages and CD3 T+ lymphocytes transport the virus to
the regional lymph nodes, where it undergoes a further cycle of replication before it
enters into the blood stream86,87,155,205. Based on the initial phase of the pathogenesis of
EAV, the viral quasispecies in nasal swab samples represent the initial population that
established infection in the experimental stallions. Analysis of these viruses showed an
expanded population size as a result of a high rate of de novo mutations. Very
interestingly, despite an overall purifying type of selection, there was a strong
diversifying pressure on the nsp9 encoding region of ORF1b (nt 6729 to 6816). This
suggests that the low frequency mutation on nsp9 may have a regulatory effect on virus
replication and may be associated with the higher population size in nasal swab viruses.
Consistent with this observation, shrinkage in population size was detected in the buffy
coat samples where there was no selection pressure on the indicated site (nt 6729 to 6816)
of the nsp9 peptide.
It is also important to note that the virus population being shed by individual
animals under the same sampling conditions, but from different cell types are distinct in
their quasispecies composition, selection pattern and population size. The reduction in
variant population size observed in buffy coat viruses may reflect a transmission
bottleneck scenario that confers fitness to variants with the right type of mutations to
infect cells of the monocyte lineages and CD3 T+ lymphocytes.
Similarly, viruses in semen at 5 dpi show a divergent population structure with the
appearance of several new fixations, reduced population size and multiple sites under
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positive selection. Given that the neutralizing antibodies first appeared in blood of
experimental stallions at 8 dpi, the driving force behind the selective sweep in the initial
semen samples is most likely associated with the fitness cost of adapting to the cells in
the stallion reproductive tract. EAV has been demonstrated in a variety of cells in the
ampullae and other accessory sex glands of stallions165. Although these sites of virus
persistence are not immunologically privileged, there is strong inflammatory cell
infiltration along with plasma cells producing EAV specific antibodies441. These
observations suggest that infections of various cells in the reproductive tract, as well as
adaptation to evade local inflammatory and immune responses may be the driving force
for the selection and reduction of the initial viral variant population in the reproductive
tract.
It has been shown that persistent infection with EAV is testosterone dependent
and castration of stallions leads to clearance of viral persistence11,209,212.

How this

hormone regulates EAV evolution in the reproductive tract, and whether the quasispecies
population is any different in the presence of variable concentrations of this hormone, is a
subject for future investigation. However, some studies have suggested testosterone is
associated with variable effects on reproductive tissue such as maintenance of susceptible
host cell population and immune suppression11,13,209,209
The study has also demonstrated the presence of continual positive selection in
specific regions of the genome that drives evolution of viruses isolated from semen. The
non-stochastic nature of EAV evolution in persistent infection and the swarm of
quasispecies populations that shows an atypical high frequency of a minor variant
population imply ongoing interaction between viral quasispecies populations and the host
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immune system. Persistent infection with EAV develops in 10 to 70 % of sexually mature
stallions11,140,156. This occurs in the presence of a high level of virus neutralizing
antibodies in serum that effectively eliminates systemic infection in body tissues with the
exception of the stallion reproductive tract. Previous studies have showed that natural
transmission of EAV can occur by aerosol or infective semen, however the quasispecies
diversity during persistent infection contrasts with the relative genetic stability observed
in horizontally transmitted disease outbreaks21,154,267. There is some evidence from
natural infection of lactate dehydrogenase-elevating virus and simian hemorrhagic fever
virus to suggest variants with lower virulence and immunogenicity are selected during
persistent infection, whereas more virulent variants seem to be favored during
outbreaks86,87,205,442.
In this study, ORF3 of viruses present in semen have been shown to be under
selective pressure during persistent infection. The ORF3 may have some of the T cell
epitopes of the virus but unfortunately, the T cell epitopes of this virus have not yet been
characterized. The result is also true for viruses from cases of natural infection suggesting
an important role for this particular gene in persistent EAV infection. Similar
observations have been made in previous works that have characterized natural EAV
infections. However, the observation showed a minimal role for ORF3 in the initial
stages of infection when viruses first appear in the reproductive tract. The pattern of
nonsynonymous substitutions at 5 and 9 dpi revealed that selection localizes in the ORF5
(GP5) and nsp2 peptide regions of ORF1a, suggesting a crucial role for these proteins in
the initial adaptation process of variant populations in the stallion reproductive tract. The

128

selection of ORF3 variants comes later in the persistent infection period when
maintenance of persistent infection is needed.
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CHAPTER THREE
Genomic, Phylogenetic and Antigenic Characterization of a Novel Field Strain of
Equine Arteritis Virus Isolated from a Feral Donkey in Chile

3.1. Summary
Here we describe the isolation and characterization of a new strain of equine
arteritis virus (EAV donkey VD7634 strain) from the vas deferens of a wild male donkey
from northern Chile in 2013. The full-length genome sequence of donkey VD7634 was
obtained using next-generation sequencing (NSG) with Illumina MiSeq technology.
Comparative nucleotide sequence analysis indicated that the donkey VD7634 virus had
only 77% and 76.8% nucleotide identity with North American and European strains of
EAV, respectively. The complete genome of the EAV donkey VD7634 strain was 12,703
bp in length and consists of ten open reading frames (ORFs) encoding 13 nonstructural
proteins and eight structural proteins. Comparative nucleotide and amino acid analyses,
as well as phylogenetic analysis demonstrated that this donkey strain is distinct from
reference EAV strains due to multiple insertions and deletions. However, the virus
appears antigenically very similar to the other EAV strains and could be neutralized with
polyclonal and monoclonal antibodies against EAV.

3.2. Introduction
Equine arteritis virus (EAV) is the causative agent of equine viral arteritis (EVA),
a respiratory and reproductive disease affecting members of the family Equidae, which
include horses, donkeys, mules and zebras. EAV was first isolated from the lung of an
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aborted fetus following extensive outbreak of respiratory disease and abortion on a
Standardbred breeding farm near Bucyrus, OH, USA, in 1953. Equine arteritis virus
(EAV) is a small, enveloped, positive-sense, single-stranded RNA virus that belongs to
the family Arteriviridae (genus: Equartevirus, order: Nidovirales). The EAV genome is
approximately 12.7 kb; it contains 10 open reading frames (ORFs) that are flanked by a 5′
leader sequence and a 3′ untranslated regions (UTR)3,17,19,21,64,199. ORF1a and 1b encode
two polyproteins (pp1a and pp1ab) that are processed post-translationally by three
ORF1a-encoded proteinases (nsp1, -2 and -4)21,55,112. These polyproteins are cleaved into
13 nonstructural proteins (nsp1-12, including nsp7α and 7β)21,36,37,55. The other eight
ORFs (2a, 2b and 3, 4, 5a, 5, 6 and 7) encode the envelope proteins E, GP2, GP3, GP4,
GP5, ORF5a protein and M and nucleocapsid protein, N, respectively5,21. The GP5
protein has been shown to carry the major neutralization determinants of the
virus16,20,21,82,443. Based on ORF5 phylogenetic analysis, EAV field strains can be broadly
divided into two distinct clades: North American (NA) and European (EU)
groups1,40,410,444. Phylogenetic analysis based on partial ORF5 sequences segregated EAV
isolates from around the world to North American (NA) and the European (EU) lineages
and each lineage as further such divided into two North American (NA-1 and NA-2) and
European (EU-1 and EU-2) clades (Table 3.3.); these sequences segregate into
independent branch when subjected to phylogenetic analysis10.
In 2013, Servicio Agricola y Ganadero (SAG) identified a large herd of wild
donkeys naturally infected with EAV in northern Chile. Serum samples from these wild
donkeys tested positive for anti-EAV antibodies by ELISA and virus neutralization test
(VNT) assays at SAG. Subsequently, 18 necropsy specimens from two male donkeys
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(animal ID: Donkeys 7634 and 7635) were collected and these included epididymis,
prostate, vas deferens, seminal vesicles and conjunctival swabs. Viral nucleic acid was
extracted from the vas deferens of Donkey 7634 and the partial sequence spanning ORFs
6 and 7 were obtained by sequencing the RT-PCR products. BLASTn analysis of ORFS 6
and 7 partial sequences showed 86 % and 90% nucleotide identity with EAV VBS
(GenBank accession number: DQ846750), respectively. This confirmed that the donkey
was infected with an EAV strain circulating in the wild donkey population. Samples
from donkeys 7634 and 7635 were submitted to the EVA OIE reference laboratory at the
Maxwell H. Gluck Equine Research Center, University of Kentucky, Lexington, KY,
USA. Here we describe the virus isolation, genetic, phylogenetic and antigenic
characterization of a novel donkey strain of EAV (EAV donkey VD7634) from a wild
donkey in northern Chile.

3.3. Materials and methods
Necropsy specimens
Eighteen frozen necropsy specimens (epididymis [2], prostate [2], vas deferens
[2], seminal vesicles [2], conjunctival swab [1] from two donkeys (7634 and 7635) were
received at the EVA OIE reference laboratory, Maxwell H. Gluck Equine Research
Center, University of Kentucky, Lexington, KY, USA for EAV testing.

Cells and viruses
High passage (HP) rabbit kidney 13 cells RK-13 (KY), passage level 399–409
derived from ATCC® CCL-37™, American Type Culture Collection, Manassas, VA,
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USA were maintained in Eagle’s minimum essential medium (EMEM, Cellgro ®,
Mediatech Inc., Herndon, VA, USA) with 10% ferritin-supplemented calf serum
(HyClone Laboratories, Inc., Logan, UT, USA), penicillin and streptomycin (100 U/mL
and 100 μg/mL) and 0.25 μg/mL of amphotericin B (Gibco®, Carlsbad, CA, USA). The
prototype Bucyrus strain of EAV (EAV VBS; ATCC VR-796, Manassas, VA, USA) was
used as a control virus in the neutralization assay.

Virus isolation
HP RK-13 (KY) cells were used for isolation of EAV from reproductive tract
tissues and the conjuctival swabs, as previously described. Briefly, 10% tissue
homogenates of necropsy specimens were prepared, centrifuged at 2,500 x g for 15 min,
and the supernatant serially ten-fold diluted (10-1 to 10-3). The conjunctival swab was
immersed in 5 mL of EMEM and the medium filtered through a 0.45 µm filter. One mL
of each tissue homogenate and conjunctival filtrate was inoculated in duplicate 25-cm2
flasks containing confluent monolayers of HP RK-13 (KY) cells. Additionally, 1 mL of
each undiluted tissue homogenate was inoculated in duplicate 25-cm2 flasks. After 1 hour
(h) adsorption at 37°C, monolayers were overlaid with EMEM supplemented with 0.75%
carboxymethylcellulose, incubated for 4 days at 37°C and checked for the appearance of
cytopathic effect (CPE). If there was no detectable CPE, a second blind passage was
performed. After decanting the medium, monolayers were stained with a 1% crystal
violet solution, and viral titers were expressed as plaque-forming units per gram of tissue
(PFU/g). The tissue culture fluids (TCFs) were subjected to a one-way serum
neutralization assay using polyclonal anti-EAV equine serum against the prototype VBS
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strain of EAV to confirm the identity of the isolates as previously described223. The
isolates were further confirmed by EAV specific TaqMan® real-time RT-PCR assay as
previously described232.

Microneutralization test
The neutralization phenotypes of the EAV donkey isolate was determined by a
microneutralization assay using a panel of neutralizing monoclonal antibodies (mAbs;
5G11, 6D10, 7E5, 10F11, 1H7, 1H9, 5E8, 6A2, 7D4 and 10B4)15–17,78 and polyclonal
equine antisera against EAV VBS, commercial live-attenuated vaccine strain of EAV
(MLV, ARVAC®; Zoetis, Kalamazoo, MI, USA), EAV KY84 strain and EAV CW01
strain were performed as previously described15,78. The non-neutralizing mAbs 12A4
(specific for EAV non-structural protein-1 [nsp-1]) and 3E2 (specific for N protein) and
normal equine serum were used as negative controls. Briefly, duplicate serial two-fold
dilutions of each equine antiserum sample from 1:4 to 1:8192 were made in
supplemented EMEM containing 10% guinea pig complement (25 µl per well; Rockland
Immunochemicals, Gilbertsville, PA, USA) and tested in 96-well plates. Ascitic fluid
containing each mAb was diluted from 1:16 to 1:32,384 in unsupplemented EMEM
without 10% guinea pig complement as previously described15–17,78. An equal volume
containing 200 TCID50 of the EAV donkey VD7634 strain was added to each well.
Plates were incubated at 37°C in 5% CO2 for 1 h. After incubation, a suspension of HP
RK-13 (KY) cells (125 µl per well) was added to each well, and the plates were
incubated for 72 hours at 37°C until CPE had fully developed in the virus control wells.
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The titer of a sample was recorded as the reciprocal of the highest serum dilution that
provided at least 50% protection of the monolayer.

Real-time RT-qPCR
The nucleic acids extracted from the reproductive tract tissue samples (10% tissue
suspensions), TCFs and conjunctival swabs were tested by an EAV specific TaqMan®
real-time RT-PCR assay as previously described
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. Briefly, viral RNA was directly

isolated from 50 µl of 10% tissue suspension or TCF using a commercial RNA isolation
kit (MagMAXTM -96 Viral RNA Isolation Kit, Thermo Fisher, Waltham, MA, USA)
according to the manufacturer’s instructions. Viral RNA was eluted in 50 l of nucleasefree water and stored at -80°C. RNA extracted from TCF derived from HP RK-13 (KY)
cells inoculated with semen samples that were negative for EAV, as well as from
nuclease-free water were included as negative controls. Viral RNA extracted from TCF
containing the EAV VBS was used as a positive control. A one-tube TaqMan® real-time
RT-PCR assay was performed as described in Miszczak et al. (2011)223.

Sanger sequencing
Viral RNA was extracted from the TCF containing EAV donkey D7634 strain
using MagMaxTM-96 viral RNA Isolation Kit (Thermo Fisher, Waltham, MA, USA). The
sequences of the PCR products were determined by the Sanger method. The extracted
viral RNA was first reverse-transcribed into cDNA using SuperScriptTM III Reverse
Transcriptase (Thermo Fisher, Waltham, MA, USA) with gene specific primer
(BN12707N) following the manufacturer’s instruction, and amplified by Qiagen
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HotStarTaq® DNA polymerase using forward and reverse primers described in
Supplementary Table 3.1. Fourteen new primers were designed based on published EAV
donkey sequences from South Africa405. In addition, fifteen EAV specific primers were
used for primer walking. ORFs 2-7 sequences including the flanking 5' ORF1b and 3'UTR (2912 bp) were determined. A similar approach was used to amplify the partial
ORF1ab regions (1-1087 [1087 bp], 1592-2093 [502 bp], 4152-4721 [570 bp] and 64366923 [488 bp] encoding the nsp1, partial nsp2, partial nsp5, nsp6, partial nsp7 and partial
nsp9, respectively. The PCR products were gel-purified using a high pure PCR product
purification kit (Roche). Both sense and antisense strands were sequenced. About 5559
base pairs (43.75%) of the entire genome were sequenced by Sanger methods. Then,
Illumina MiSeq next-generation sequencing technology was used to obtain the complete
genome sequence of EAV donkey D7634 strain.

Next-generation sequencing
Total RNA was isolated from HP RK-13 (KY) cells infected with the EAV
donkey VD7634 strain using a total RNA isolation kit (Norgen Biotek Corp., Niagara-onthe-Lake, Ontario, Canada). The RNA was quantified with a Qubit 2.0 spectrophotometer
(Life Technologies, Carlsbad, CA, USA) and purified RNA was stored at -80°C. The
complete genome sequence of EAV donkey VD7634 strain was determined by using
next-generation sequencing (NGS) technology on an Illumina MiSeq platform according
to previously established procedures445. Briefly, the cDNA libraries were constructed
from 100 ng of total RNA using a TruSeq Stranded total RNA sample preparation kit
(Illumina, San Diego, CA, USA) according to the manufacturer’s instructions and

136

previously described protocol . Multiplex libraries were prepared using barcoded primers
and a median insert size of 340 base pairs (bp). Libraries were analyzed for size
distribution using a Bioanalyzer and quantified by quantitative RT-PCR using a Kapa
library quantification kit (Kapa Biosystems, Boston, MA, USA); relative volumes were
pooled accordingly. The pooled libraries were sequenced on an Illumina MiSeq platform
with 150 bp end-reads following standard Illumina protocols. Sequences were mapped to
all known EAV strains and mapped read-sets were used for de novo assembly using
ABySS, v.1.3.7 (BC Cancer Agency, Vancouver, Canada) and Geneious 7.0.6 software
(Biomatters Ltd., Auckland, New Zealand). Sequences obtained by NGS technique were
mapped to all available published genome sequences of the family Arteriviridae
(currently 550 genomes are available at http://www.ncbi.nlm.nih.gov/) using BWAMWM (v0.7.5a). Sequence ID of mapped reads were extracted using SAMtools (v0.1.19).

Sequence analysis
The new paired-end read sets were extracted from the original paired-end fastq
files using seqtk with the list of mapped ID to insure both reads of one pair were selected.
The raw reads in FASTA formats were imported into IGV_2.3.79 for mapping and paired
using the default parameter for Illumina short read. Comparative nucleotide (nt) and
amino acid (aa) sequence alignment, maximum likelihood (ML) phylogenetic
reconstruction were performed using Geneious v.7.0.6 (Biomatters Ltd., Auckland, New
Zealand) and MEGA v.7.0.26 (http://www.megasoftware.net).
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Phylogenetic analysis
Phylogenetic trees were constructed by using the maximum likelihood method
based on the Tamura-Nei model446, applying Neighbor-Join and BioNJ algorithms to a
matrix of pairwise distances estimated using the Maximum Composite Likelihood (MCL)
distance with Gamma-distributed rates, pairwise gap deletion and boopstrap resampling
(1,000 replications)447.

3.4. Results
Virus isolation and RT-qPCR testing of the reproductive tissues from donkeys
EAV was isolated from the epididymis, prostate, vas deferens and seminal
vesicles of donkey number 7634, but not from the tissues of the donkey number 7635
(Supplementary Table 3.2.). The viral isolates were further confirmed by TaqMan® realtime RT-qPCR specific for EAV ORF7. These data unequivocally confirmed that virus
isolates from epididymis, prostate, vas deferens and seminal vesicles of VD7634 as EAV.
Viral RNA extracted from 10% tissue homogenates were also tested directly by EAVspecific RT-qPCR. Of the nine samples tested from donkey 7634 (Supplementary Table
3.2.), only three samples gave positive results with EAV RT-qPCR (epididymis, vas
deferens and seminal vesicles). All the necropsy samples from donkey 7635 were
negative for EAV nucleic acid by RT-qPCR. This further confirmed that the donkey
7635 was not persistently infected with EAV.
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Analysis of genomic sequence of EAV donkey VD7634 strain
The full-length genome sequence of the EAV donkey VD7634 strain isolated
from the vas deferens of donkey 7634 was determined by NGS. The complete genome of
EAV donkey VD7634 strain was 12,703 bp in length with ten ORFs which encode 13
nonstructural proteins (nsp) and eight structural proteins (sp) common to all known EAV
strains. The annotation of EAV donkey VD7634 strain was predicted based on NCBIreferenced EAV sequence (EAV Utr; accession numbers: NC002532), then compared to
both NCBI-referenced EAV sequence and our prototype virulent Bucyrus virus strain
(EAV VBS; accession numbers: DQ846750) to determine its general genome features1.
The sequence of EAV donkey VD7634 strain was deposited in GenBank under the
accession number MF598091.
The complete genome sequence of EAV donkey VD7634 strain was 1nt shorter in
length and had 75.6 % nucleotide identity to both EAV VBS and EAV Utr (GenBank
Accession numbers DQ846750 and NC002532, respectively). The nucleotide and amino
acid differences in ORF1a and ORF1b are shown in Table 3.1. The nsp2, nsp3 and nsp12
of donkey VD7634 had 1-3 amino acid deletions as compared to the EAV VBS and EAV
Utr. The leader sequence of EAV donkey VD7634 strain is 211 nucleotides, and its 5´
UTR is 6 nt longer than the other two EAV strains. The ORF1a and ORF1ab start codon
of EAV donkey VD7634 strain is located at nucleotide position 231.
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Table 3.1. Comparative nucleotide and amino acid sequence analysis of donkey VD7634
strain of EAV and published EAV sequences (EAV Utr [NC002532] and EAV VBS
[DQ846750]

ORF

Protein

5' TTR
Leader sequence
ORF1a
1a polyprotein
ORF1b
-

EAV donkey VD7634 strain
(MF598091) nucleotide sequence
(Start…End)

EAV donkey
EAV donkey
VD7634 strain
VD7634
(MF598091)
strain protein
nucleotide
length (aa)
position (nt)

EAV Utr (NC002532) nucleotide
sequence (Start...End)

EAV Utr
EAV Utr
(NC002532) (NC002532)
nucleotide protein length
position (nt)
(aa)

EAV VBS (DQ846750) nucleotide
sequence (Start...End)

EAV VBS
EAV VBS
(DQ846750) (DQ846750)
nucleotide protein length
position (nt)
(aa)

ATGGCAACCT…GTTAAACTGA
CTGAGAGCGC…ACCCGTGTGA

1-230
1-211
231-5405
5402-9748

1724
1448

ATGGCAACCT…GTTAAACTGA
CTGAGAGCGC…GCCCGTGTGA

1-224
1-211
225-5408
5405-9751

1727
1448

ATGGCAACCT…AGTGAATCAG
CTGAGAGCGC…GCCCGTGTGA

225-5399
5405-9751

1725
1448

ORF1ab

1ab polyprotein
nsp1
nsp2
nsp3
nsp4
nsp5
nsp6
nsp7
nsp8
nsp9
nsp10
nsp11
nsp12
Slippary sequence

ATGGCAACCT…ACCCGTGTGA
ATGGCAACCT…GAACTACGGT
GGGTACAACC…GTTGATTGGA
GGGTGGACCT…TGGTGTTTGA
GGGCTTGTTC…CAACAGAGAG
AGTAGCCTTT…CTTCCTTGAG
GGAGGTGTGA…CACTCAAGAA
AGTTTGACCG…CAGTTATGAA
GGGTTAGACA…CCAGTTAAAC
GGGTTAGACA…GCAGTACGAG
GCGGCTGTAT…GGAAAAACAG
TCAAACAAAG…TGTCCAGGAG
GGGATTGATG…AATTGGACCC
GTTAAAC

231-9748
231-1010
1011-2714
2715-3412
3413-4025
4026-4511
4512-4577
4578-5252
5253-5402
5253-7330
7331-8731
8732-9388
9389-9742
5398-5404

3172
260
568
232
204
162
22
225
50
693
467
219
118
-

ATGGCAACCT…GCCCGTGTGA
ATGGCAACCT…CAACTACGGC
GGCTACAATC…GCTGATAGGT
GGATGGATTT…GGTGTTTGAA
GGGCTATTCA…CAATAGAGAG
AGCAGCCTTT…CTTCCTGGAG
GGAGGAGTGA…TACCCAGGAG
AGTCTCACTG…GAGCTATGAA
GGCCTAGATC…TCAGTTAAAC
GGCCTAGATC…GCAGTATGAG
AGTGCCGTGT…GGAAAAGCAA
TCCAACAAAA…TGTCCAAGAG
GGTGTTGATG…CATTGGGCCC
GTTAAAC

225-9751
225-1004
1005-2717
2718-3416
3417-4028
4029-4514
4515-4580
4581-5255
5256-5405
5256-7333
7334-8734
8735-9391
9392-9745
5399-5405

3175
260
571
233
204
162
22
225
50
693
467
219
118
-

ATGGCAACCT…GCCCGTGTGA
ATGGCAACCT…CAACTACGGC
GGCTACAATC…GCTGATAGGT
GGATGGATTT…GGTGTTTGAA
GGGCTATTCA…CAATAGAGAG
AGCAGCCTTT…CTTCCTGGAG
GGAGGAGTGA…TACCCAGGAG
AGTCTCACTG…GAGCTATGAA
GGCCTAGATC…TCAGTTAAAC
GGCCTAGATC…GCAGTATGAG
AGTGCCGTGT…GGAAAAGCAA
TCCAACAAAA…TGTCCAAGAG
GGTGTTGATG…TGGGCCCGTG
GTTAAAC

225-9751
225-1004
1005-2717
2718-3416
3417-4028
4029-4514
4515-4580
4581-5255
5256-5405
5256-7333
7334-8734
9835-9391
9392-9748
5399-5405

3175
260
571
233
204
162
22
225
50
693
467
219
119
-

ORF2a
ORF2b
ORF3
ORF4
ORF5a
ORF5
ORF6
ORF7
3' TTR

E
GP2
GP3
GP4
ORF5a
GP5
M
N

ATGGGCTTAG…ACCTCTTTAA
ATGCTGTGCT…GATTTTGTAG
ATGGATTATG…AAGCTCGTAA
ATGAAGAACT…TTATCTATGA
ATGTTCTTCT…TGCGCTATGA
ATGTTATCTA…GGAGCCATAG
ATGGGAGCCA…GTTACAATGA
ATGGCGTCAA…AGGGCCGTAA
GACGTGGATA…AAGTATCCAG

9748-9951
9821-10504
10303-10794
10697-11155
11109-11288
11143-11910
11898-12386
12310-12642
12643-12703

67
277
163
152
59
255
162
110
-

ATGGGCTTAG…ACCTGTTTAA
ATGCAGCGCT…GATTTTGTAG
ATGGGTCGTG…AGGCTCGTAA
ATGAAGATCT…TTATCTATGA
ATGTTCTTTT…TGCGATATGA
ATGTTATCTA…GGAGCCATAG
ATGGGAGCCA…GCTACAATGA
ATGGCGTCAA…AGGGCCGTAA
GACGTGGATA…CCCAGGAACC

9751-9954
9824-10507
10306-10797
10700-11158
11112-11291
11146-11913
11901-12389
12313-12645
12646-12704

67
227
163
152
59
255
162
110
-

ATGGGCTTAG…ACCTGTTTAA
ATGCAGCGCT…GATTTTGTAG
ATGGGTCGTG…AGGCTCGTAA
ATGAAGATCT…TTATCTATGA
ATGTTCTTTT…TGCGATATGA
ATGTTATCTA…GGAGCCATAG
ATGGGAGCCA…GCTACAATGA
ATGGCGTCAA…AGGGCCGTAA
GACGTGGATA…CCCAGGAACC

9751-9954
9824-10507
10306-10797
10700-11158
11112-11291
11146-11913
11901-12389
12313-12645
12646-12704

67
227
163
152
59
255
162
110
-

-

Characterization of nucleotide hallmarks of EAV donkey VD7634 strain as
compared with other EAV strains
Comparative nucleotide sequence analysis of the full-length genome of VD7634
sequence and twenty-nine EAV strains in GenBank determined unique insertions and
deletions (Table 3.2.). These included four North American strains and twenty-five
European strains (EU-1 [CW and S numbered strains] and EU-2 [French strains]) that
were selected by BLASTn analysis. The nucleotide identity with North American and
European strains varied from 77% and 76.8%, respectively. Analysis identified a number
of unique insertions and deletions that were present in 5´ UTR, 3´ UTR, ORF1a (nsp2
coding region) and ORF3 of EAV donkey VD7634 strain (Table 3.2.).
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Table 3.2. Insertion and deletion positions in full-length genome alignments of EAV
isolates from North America and Europe

EAV donkey
VD7634 strain
nucleotide position

Nucleotide
substitution
length (bp)

Nucleotide substitution

Description

5' UTR

6
26
88-89
123
124
127
164
224

1
1
2
1
-1
-1
1
1

C
G
GT
T
T
G
C
T

Insertion
Insertion
Consecutive nucleotide insertions
Insertion, similar to F27, F60, F61, F62, F63 strains
Deletion, except F27, F60, F61, F62, F63 strains
Deletion
Insertion, similar to CW01, CW96, F27, F60, F61, F62, F63 strains
Insertion

nsp2

1399-1401
1460-1462
1478-1480
1515-1517
1565-1579

-3
3
3
3
- 15

AAC*
AAC
AGA
TTG

1621-1635

- 15

10,653-10,664
10658-106659
10,684-10,695

- 12
2
- 12

10,669 -10,670

-2

GG

12685
12703

1
1

G
C

ORF

GP3

3' UTR

Deletion
Insertion, similar to CW01, CW96, F60, F61, F62, F63, F27 strains
Insertion
Insertion
Insertion except EAV donkey VD7634 strain, CW01, CW96, F60,
CGTCCACAGTGGTCT*
F61, F62, F63, F27, HK25, HK116, VBS, ARVAC strains
GGCGTGTGGCCAAAA* Deletion
TGCGAAACCACT
AG
AGTGCATTTGGA*

Insertion in F61, F62, F63 strains
Insertion
Insertion except EAV donkey VD7634 strain, CW01, CW96, F60,
F61, F62, F63, F27, HK25, HK116, VBS, ARVAC strains
Deletion
Insertion
Insertion

*Most common deletion sequence is shown out of three different deletion sequences in
the nucleotide comparison among EAV referenced sequences.

The 5´-leader sequence of the EAV donkey VD7634 strain had three single
nucleotide insertions (C-6, G-26 and T-224), one single nucleotide deletion (G-127 based
on the EAV VBS sequence) and two consecutive nucleotide insertions (G-88 and T-89).
In addition, there was a single nucleotide insertion at T-123 of the EAV donkey VD7634
strain sequence that is similar to some of the French strains (F27, F60-F63). There was
one insertion followed by one consecutive single nucleotide deletion compared to the
earlier described French strains. Finally, there was a single nucleotide insertion in the 5´
leader sequence at position C-164, which is similar to some of the European strains
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(CW96, CW01; F27, F60-F63). The donkey EAV strain had two single nucleotide
insertions in the 3´ UTR (G-12,685 and C-12,703).
Interestingly, there was a consecutive 3-nucleotide deletion in the nsp2 of EAV
donkey VD7634 strain at nucleotide positions 1399-1401 based on the EAV VBS
sequence position numbering (AGC [CW96, CW96, HK25, HK116, Bucyrus and
ARVAC] or CGC [F27 and F60-F63] or AAC [S-3685, S-3685, S-3699, S-3711, S-3712,
S-3817, S-3854, S-3861, S-3886, S-3943, S-3961, S-4007, S-4216, S-4417, S-4421, S4227, S-4333 and S-4445]). Then, there were three consecutive nucleotide insertions
encoding region of ORF1a at three positions (A-1460, A1461 and C-1462; A-1478, G1479 and A-1480; and T-1515, T-1516 and G-1517). Seven other EAV strains also had
three consecutive nucleotide insertions at nucleotide positions 1460-1462 (CGT [CW96
and CW01] GGG [F27, F60-F63]). The consecutive 15-nucleotide insertion in nsp2
encoding region of ORF1a was presented by S-numbered EAV strains in nucleotide
positions at 1565-1579; CGTCCACAGTGGTCT [S-3685, S-3699, S-3711, S-3712, S3854, S-3861, S-3886, S-3943, S-3961, S-4007, S-4227, S-4333, S-4421 and S-4445] or
CGTCCACAGTGGTCC [S-3685, S-3817 and S-4216] or CATCCACAGTGGTCT [S4417]. Based on the EAV VBS sequence position numbering, EAV donkey VD7634
strain had a consecutive 15-nucleotide deletion at 1621-1635; GGCGCGTGACTAAAA
[CW01

and

CW96]

or

GGCGCGTGACAAAGA

[F27

and

F60-63]

or

GGCGTGTAGCCAAAA [S-4417] or GGCGTGTGGCCAAAA [HK25, HK116,
Bucyrus, ARVAC, S-3685, S-3685, S-3699, S-3711, S-3712, S-3817, S-3854, S-3861, S3886, S-3943, S-3961, S-4007, S-4216, S-4421, S-4227, S-4333 and S-4445].
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Two consecutive 12-nucletide insertions (10,653-10,664; TGCGAAACCACT
[F61] or TGCGAAACCAYT [F62] or TGCRAAACCAYW [F63]; and 10,684-10,695;
AGTGCATTTGGA [S-3583, S-3817, S-3685, S-3699, S-3711, S-3712, S-3854, S-3869,
S-3943, S-40007, S-4417, S-4445, S-3961 and S-4216] or TAGTGTATTTGGA [S-3886,
S-4333 and S-4421] or AGTGCACTTGGA [S-4227]) in some of the European strains
were not present in the ORF3 of EAV donkey VD7634 strain and the rest of the EAV
sequences available in GenBank. ORF3 of EAV donkey VD7634 strain had two unique
nucleotide insertions (A-10,658 and G-10,659) and two unique nucleotide deletions (G10,669 and G-10,670; according to EAV VBS sequence position numbering).
Additionally, the percentage identity (%) of nucleotide and amino acid sequence
alignment among EAV donkey VD7634 strain and other EAV sequences from GenBank
(n=29) were calculated and used to create bar graphs (Figure 3.1. and supplementary
table 3.5.). The average nucleotide and amino acid identity are 65.55% and 70.72% in
ORF1a (nsp2 coding region) and nsp2, respectively (Figure 3.1.A.). Similarly, the
average nucleotide identity and amino acid identity were 78.18% and 74.21% in ORF3
and GP3, respectively (Figure 3.1.B.). In nucleotide similarity, ARVAC, HK116, HK25
and Bucyrus NA strains showed 80.8% to 81.4% highest nucleotide identity in ORF3, as
well as 77% to 78.2% of amino acid identity in GP3. EAV isolates CW01, CW96, F27
and F60 strains showed second highest nucleotide identity from 78.1% to 79.6% in ORF3
and 72.7% to 73.9% amino acid identity in GP3.
EAV donkey VD7634 strain showed 81.3% to 81.5% and 93% nucleotide identity
and amino acid identity to partial ORF5 and GP5 gene from donkey isolates from
Republic of South Africa (RSA), respectively (Figure 3.1.C.). Even though two of the
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EAV donkey referenced sequences isolated from Italy presented low nucleotide identity
from 74.3% to 74.7%, respectively, these two sequences showed 86.6% amino acid
identity, which is the second highest similarity in partial GP5. The other EAV sequences
had 75.54% nucleotide identity and 86.34% amino acid identity in partial GP5 compared
to the EAV donkey VD7634 strain. There were no insertions or deletions in partial ORF5
sequences analyzed from donkeys.
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Figure 3. 1. Based on percentage homology among EAV 29 EAV strains; nucleotide
sequence identity (%) and amino acid sequence identity (%) analyses were used to
create bar graphs. (A) nsp2, (B) GP3 and (C) partial GP5. Blue bar indicates nucleotide
identity (%) and red bar indicates amino acid identity (%).

145

Comparison of partial ORF5 sequence of EAV donkey VD7634 strain and other
EAV donkey strains
Nine partial donkey EAV ORF5 sequences (nt 11,295-11,812 [518 bp in length]10
available in GenBank were compared to the EAV donkey VD7634 strain (Supplementary
Table 3.3.). The data showed that the EAV donkey VD7634 strain shared variable
nucleotide and amino acid identity with other EAV donkey strains: 74.3% to 81.5%
nucleotide identity and 86.7% to 93.4% amino acid identity. Phylogenetic analysis was
carried out on partial ORF5 sequences (Figure 3.2.). The maximum likelihood
phylogenetic tree was clearly divided into two lineage groups: Republic of South Africa
(RSA) and Italy.
J1-931125 RSA |AY956596.1|
J2-931125 RSA |AY956597.1|
50

66

J3-931209 RSA |AY956598.1|
J7-931125 |AY956602.1|

EVA donkey Republic of South Africa (RSA)

J5-940309 RSA |AY956600.1|
100

J6-940309 RSA |AY956601.1|
J4-931209 RSA |AY956599.1|
EAV donkey VD7634
1489V96 Italy |AF099829.1|
100

3308V96 Italy |AF099830.1|

EAV donkey Italy

0.05

Figure 3.2. Phylogenetic tree based on the partial ORF5 of EAV donkey VD7634
strain and nine EAV donkey reference strains. Phylogenetic trees constructed based
on nucleotide sequences of partial ORF5 (nt 11,295-11,812 [518 bp]) of EAV donkey
VD7634 strain using the maximum likelihood method implemented in MEGA7.0.
Bootstrap values for 1,000 replicates are shown at the nodes. The bar indicates genetic
distance.
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Both sequence identity and phylogenetic tree indicate that EAV donkey VD7634
strain was more closely related to Republic of South African (RSA) strains than the
Italian strains. According to Stadejek et al. (2006), the RSA EAV donkey strains
sequenced from the semen of naturally infected donkeys were different from reference
sequences obtained from viruses in horses in North American and European groups10. In
contrast, ORF5 sequences of Italian EAV donkey strains were clustered in European
groups, indicating that these donkeys had probably become infected from horses227,412.

Phylogenetic analysis of EAV donkey VD7634 strain
Twenty-nine EAV full-length genome sequences from GenBank were
downloaded and used in phylogenetic analysis (Figure 3.3.). These sequences included
EAV strains from both North American (NA) and European (EU) lineages. In addition,
partial ORF5 sequences from EAV and donkey isolates from South Africa and Italy were
included in the analysis. Phylogenetic analysis was conducted using maximum likelihood
based on the Tamura-Nej model and neighbor-joining methods446. As the result, EAV
donkey VD7634 strain was presented as more diverged than other referenced EAV
strains.
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Figure 3.3. Phylogenetic analyses of EAV were inferred based on primary
nucleotide alignment. (A) Whole genome of 29 referenced strains and EAV donkey
VD7634 strain and amino acid alignment of (B) ORF1a, nsp2 encoding region, (C) ORF3
and (D) Partial GP5 includes nine additional strains of EAV donkey reference strains.
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Phylogeny based on full-length genome
Based on BLASTn analysis of GenBank database, twenty-nine EAV whole
genome sequences were selected to perform sequence alignment and phylogenetic
analysis (Figure 3.3.A.). The EAV donkey VD7634 strain is 12,703 nucleotides in length,
slightly shorter than EAV CW strains (12,708 nucleotides; EU-1), EAV French strains
(12,710 to 12722 nucleotides; EU-2), EAV North American strains (12704 nucleotides;
NA) and EAV S numbered strains (12,731 nucleotides; EU-1). The EAV donkey
VD7634 strain shares average homology of 75.37% at the nucleotide level among 29 full
genomes of EAV referenced sequences (Supplementary table 3.4.). Analyzing homology
at the amino acid level for specific ORFs, least similarity was noted across ORF1a and
ORF3 which encode nsp2 and GP3 at 70.72% and 74.21%, respectively. These proteins
were previously described with nucleotide hallmarks of unique insertions and deletions.
The greatest similarity at the amino acid level was ORF7, which encode nucleocapsid (N)
protein at 95.67% among 29 full genomes of EAV referenced sequences (Supplementary
table 3.4.). Phylogenetic analysis did not cluster EAV donkey VD7634 with the other
EAV full-length genome sequences and segregated it into an independent lineage.

Phylogeny based on ORF1a nsp2 coding region and ORF3
EAV donkey VD7634 strain has unique genetic hallmarks in nsp2 and ORF3,
thus these protein sequences at the amino acid level were analyzed phylogenetically to
compare among each genome of 29 EAV referenced sequences (n=29) (Figure 3.3. B and
C). In these analyses, EAV donkey VD7634 strain segregated into an independent lineage
similar to the full-length genome sequences. (Figure 3.3.A.)
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Phylogeny based on ORF5 partial sequences including other EAV donkey strains
Phylogenetic analysis of the EAV partial ORF5 sequences including other EAV
donkey sequences from Italy (n=2) and Republic of South Africa (n=7) was carried out
(Figure 3.3.D.). Interestingly, EAV donkey VD7634 strain was clustered with EAV
donkey strains from the Republic of South Africa, and this clustering was supported by a
bootstrap value of 99%. It suggests that EAV donkey VD7634 strain was most closely
related to EAV donkey strains that originated in the Republic of South Africa. Not
surprisingly, partial ORF5 sequences of Italian EAV donkey strains were clustered in the
European group (EU-1), but were distantly related to other EU-1 virus isolates in this
phylogenetic subgroup.

Neutralization phenotype of EAV donkey VD7634 strain
A panel of 12 monoclonal antibodies (mAbs) and a panel of 6 of polyclonal
equine antisera were used to characterize the neutralization phenotypes of EAV donkey
VD7634 strain (Table 3.3.). EAV donkey VD7634 strain was neutralized by mAbs 5G11,
6D10, 7E5, 10F11 and 6A2. Especially, mAbs 6D10, 7E5 and 6A2 neutralized the
donkey virus to a higher titer. In contrast, mAbs 1H7, 1H9, 5E8, 7D4 and 10B4 did not
neutralize EAV donkey VD7634 strain. Only anti-KY84 and anti-CW96 polyclonal
equine antisera were able to neutralize the EAV donkey VD7634 strain to a higher titer.
Interestingly, anti-ARVAC and anti-VBS polyclonal equine sera did not neutralize
donkey VD7634 to a high titer. Furthermore, anti-EAV NVSL sera failed to neutralize
the donkey strain.
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Table 3.3. Serum neutralization test titers of mAbs and polyclonal equine antisera against
EAV donkey VD7634 strain and other EAV isolates

Antibody

Virus
Protein specificity/epitope location
Virus of SNT result from Balasuriya et al. (2004)a
(amino acid no. and site)
EAV donkey VD7634 strain CW96a
CW01a EAV 030a ATCCa

Virus SNT result from Zhang et al. (2010)b
ARVAC

b

S3583

b

S4216

b

S3685b

S3861b

S3854b

S4333b

S3943b

S4445b

mAbs
5G11
6D10
7E5
10F11
1H7
1H9
5E8
6A2
7D4
10B4
Control mAbs
3E2*
12A4*
Polyclonal equine sera
anti-ARVAC
anti-VBS
anti-KY84
anti-CW96
Control polyclonal
equine sera
anti-EAV NVSL positive
anti-EAV NVSL negative

GP5/102 and 104 [D]
GP5/99 [D]
GP5/102 [D]
GP5/ND [D]
GP5/49 [A]
GP5/69 [C]
GP5/61 [B]
GP5/69 [C]
GP5/69 [C]
GP5/62-101 deleted [C and D]

512
4096
512
4096
16
<16
<16
2048
<16
32

512
4096
32
4096
<32
<32
<32
128
<32
<32

4096
>4096
256
>4096
<32
<32
<32
<32
<32
<32

4096
>4096
256
>4096
<32
<32
<32
<32
<32
<32

>4096
>4096
256
>4096
<32
<32
<32
<32
<32
<32

<32
512
32
2048
<32
<32
<32
<32
<32
<32

1024
4096
128
2048
<32
<32
<32
256
<32
<32

512
2048
128
1024
<32
<32
<32
64
<32
<32

2048
2048
512
4096
<32
<32
<32
1024
<32
<32

2048
4096
128
4096
<32
<32
<32
256
<32
<32

1024
4096
512
4096
<32
<32
<32
2048
<32
<32

2048
>4096
128
4096
<32
<32
<32
512
<32
<32

1024
4096
256
4096
<32
<32
<32
1024
<32
<32

1024
4096
256
4096
<32
<32
<32
32
<32
<32

N
nsp1

16
<16

<32
<32

<32
<32

<32
<32

<32
<32

<32
<32

<32
<32

<32
<32

<32
<32

<32
<32

<32
<32

<32
<32

<32
<32

<32
<32

NA
NA
NA
NA

16
64
1024
1024

<8
64
512
ND

8
16
32
ND

128
512
>1024
ND

8
512
>1024
ND

256
256
64
ND

16
128
256
ND

64
128
64
ND

32
128
128
ND

32
128
512
ND

32
128
128
ND

16
64
64
ND

8
128
512
ND

16
128
128
ND

NA
NA

16
<8

32
<8

16
<8

128
<8

64
<8

128
<8

64
<8

16
<8

32
<8

32
<8

32
<8

32
<8

32
<8

16
<8

Neutralization titers are expressed as the inverse of the antibody dilution providing 50%
protection of RK-13 cell monolayers against 200 TCID50 of virus. Significant differences
in neutralization titers (four-fold or greater) are indicated by bold numbers. ND, not
determined. NA, not applicable. EAV donkey VD7434 strain SNT result was compared
to previously published data.
*

mAb to the nucleocapsid (N) protein and nonstructural protein 1 (nsp1) of EAV was

used as negative control
a

Viruses of neutralization test result titers were from Balasuriya et al. (2004)17

b

Viruses of neutralization test result titers were from Zhang et al. (2010)21
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Previously published data described neutralization phenotypes of the same panel
of mAbs and polyclonal equine antisera (exception of anti-CW96 polyclonal equine sera)
against different EAV strains: CW96, CW01, EAV030, ATCC, ARVAC, S3583, S4216,
S3685, S3861, S3854, S4333 and S394317,21. Interestingly, 6A2 showed significant
variability in its ability to neutralize different EAV isolates, but the same mAb
neutralized the EAV donkey VD7634 strain to a higher neutralization titers17,21. In
summary, these neutralization data suggest that EAV donkey VD7634 strain has a
distinct neutralization phenotype. Comparative amino acid sequence analysis of the
critical neutralization regions of the GP5 protein of this isolate are shown in Figure 3.4.

Figure 3.4. Comparative amino acid substitution of ORF5 of EAV donkey VD7634
to 29 full-length EAV strains according to the serum neutralization test (SNT) result
by mAb.
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Interestingly, the GP5 protein of the EAV donkey VD7634 strain had an amino
acid substitution in neutralization site B (aa 61), 13 amino acid substitutions in site C (aa
67, 69-73, 79, 81-82, 84-85, 89 and 90) and 4 amino acid substitutions in site D (aa 100101, 104 and 106) compared to 29 EAV referenced sequences. These amino acid
substitutions in GP5 may contribute to its distinctive neutralization phenotype
(Supplementary table 3.6.).

3.5. Discussion
We have successfully determined the complete genome sequence of the novel
EAV donkey strain isolated from a naturally infected wild donkey in northern Chile. In
this study, we demonstrated the full genomic, phylogenetic and antigenic characterization
of the EAV donkey VD7634 strain. The complete genome of EAV donkey VD7634
strain was 12,703 bp in length, which was 1nt shorter in length and had 75.6% nucleotide
identity to both NCBI reference EAV sequence and our prototype virus EAV VBS.
Comparisons of the EAV donkey VD7634 strain to both NCBI referenced EAV sequence
and our prototype EAV VBS defined its genomic annotation. Further sequence alignment
among 29 EAV referenced full-genome sequences determined nucleotide and amino acid
percentage homology (%) and revealed a unique number of insertions and deletions in
both 5′ and 3′ UTRs, nsp2 and GP3.
Six insertions and two deletions were found in the 5′ UTR and two insertions
were found in 3′ UTR in EAV donkey VD7634 strain by comparison with 29 EAV
referenced sequences. It is known that the 5′ and 3′ UTRs of PRRSV play important roles
in viral replication, subgenomic RNA transcription and infectivity448–450. Even though 5′
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and 3′ UTR sequences are highly conserved, the unique presence of insertions and
deletions have been frequently identified in both North American and European
genotypes of PRRSV450,451. A previous study demonstrated that a deletion of either one or
two consecutive nucleotides had occurred in both 5′ and 3′ UTRs in highly pathogenic
PRRSV isolates from China452. In contrast, a single-nucleotide deletion observed in an in
vitro serial cell culture passaged PRRSV strain that was overattenuated from a highly
pathogenic PRRSV strain453. These studies indicate that both 5′ and 3′ UTR sequences of
Arteriviruses are involved in viral virulence and these may also affect EAV donkey
VD7634 strain.
In this study, we determined that the EAV donkey VD7634 strain has a number of
insertions and deletions in ORF1a (particularly in the encoding region of nsp2 replicase
subunit) and ORF3. Very interestingly, EAV donkey VD7634 strain has similar unique
patterns of insertions and deletions to EAV CW strains and French strains17,19. For
instance, the consecutive 15-nucleotide insertion in ORF1a nsp2 encoding region
(nucleotide position at 1565-1579) was present in S-numbered EAV isolates, but EAV
donkey VD7634 strain and EAV CW and French strains did not have this particular
insertion.
According to previous studies, the ten ORFs of EAV evolve at different rates
during persistent infection. Most variations occur among the ORFs encoding viral
structural proteins ORF3 and ORF5, which encode GP3 and GP5 enveloped
glycoproteins of the virus, respectively17,19,21. For instance, EAV F61-63 strains have
been shown to have a consecutive 12-nucleotide insertion in ORF3; this was not present
in the EAV donkey VD7634 strain at nt location 10,653-10,66419. Molecular
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characterization of the EAV S-numbered isolates revealed a unique consecutive 12nucleotide insertion feature at nt position 10,684-10,695 that had not been observed in
GP3 of EAV donkey VD7634 strain as well as CW, French and NA strains of EAV.
Interestingly, EAV donkey VD7634 strain had two additional unique nucleotide deletions
(G-10,669 and G-10,670) following this consecutive 12-nucleotide insertion in Snumbered isolates of EAV.
The GP5 protein, encoded by ORF5, consists of the known neutralization
determinants of EAV15,16,78. Previous studies determined that the individual amino acid
substitutions within the GP5 ectodomain occur during persistent infection of stallions.
This results in the emergence of viruses with different neutralization phenotypes142,164,166.
Neutralization testing with a large panel of well-characterized mAbs and polyclonal
equine sera confirmed different phenotypes and demonstrated the nucleotide variations of
ORF5 in EAV donkey VD7634 strain compared to other strains of EAV (CW96, CW01,
EAV030, ATCC, ARVAC, S3583, S4216, S3685, S3861, S3854, S4333 and S394321,82.
EAV donkey VD7634 strain was found to have a distinct neutralization phenotype. This
virus was highly neutralized by any of the mAbs that neutralized other isolates (mAbs:
6D10, 7E5, 10F11 and 6A2) as well as neutralized to a significantly high titers by
polyclonal equine sera (anti-KY84) compared with other isolates. Interestingly, the
comparative amino acid sequence analysis of GP5 protein determined that EAV donkey
VD7634 strain had an amino acid substitution in neutralization site B (aa 61), 13 amino
acid substitutions in site C (aa 67, 69-73, 79, 81-82, 84-85, 89 and 90) and 4 amino acid
substitutions in site D (aa 100-101, 104 and 106) compared to 29 EAV referenced
sequences. These amino acid substitutions in GP5 may correlate to this unique
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neutralization phenotype of EAV donkey VD7634 strain associated with EAV
persistency, however this needs to be investigated further.
In conclusion, there are approximately 3,000 wild donkeys living in small herds in
the Huasco province, Atacama Region, Chile454. In the 16th century, Spanish settlers
introduced donkeys in Chile for transportation454. In order to evaluate the health status of
infectious diseases in these animals, SAG collected 312 serologic specimens from
randomly selected wild donkeys and subjected them to serum neutralization testing454. As
result of a serological survey for animal health monitoring, neutralizing EAV antibodies
were found in 53% of the obtained samples giving a statistically significant p-value of
0.001. This finding indicates that the virus circulates in the wild donkey population454.
Yet, EAV has not been detected in domestic horses in Chile455. EAV strains have been
spread globally through the international movement of equids or shipment of semen and
on occasion, have been responsible for epidemics of major economic consequences266.
Also, EAV outbreaks appear only periodically, hence it is hard to trace the historic origin
so we assume that EAV has been in circulation long before it’s first isolation48.
Phylogenies may be used for epidemiologically tracing the virus origin. For instance,
EAV Gb_Glos_2012 strain from Great Britain was reported as presumably transferred
from an imported Spanish stallion48.
By reviewing the historical background of wild donkeys in Chile and the
relationship of EAV donkey VD7634 strain to other EAV donkey strains and horse
strains based on the phylogeny of ORF5, the origin of EAV donkey VD7634 strain may
be closely related to EAV donkey strains from Republic of South Africa. The history of
donkey movement by Spanish settlers would suggest that EAV donkey VD7634 strain
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and EAV donkey strains from Republic of South Africa might have originated from each
other or another source centuries ago.
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CHAPTER FOUR
Complete Genome Sequence of a Noncytopathic Strain of Bovine Viral Diarrhea
Virus 1 (BVDV-1), a Contaminant of the High Passage RK-13 Cell Line
Published in ASM Genome Announc. 3(5): e01115-15.
Modified with permission

4.1. Summary
It has been previously reported that the rabbit kidney continuous cell line (RK-13;
ATCC CCL-37 cell line, ATCC, Manassas, VA, USA) and its derivative high passage
RK-13 cell line (HP-RK-13[KY]) is contaminated with a noncytopathic bovine viral
diarrhea virus (ncpBVDV). Our laboratory has been using the HP-RK-13 (KY) cell line
for isolation of equine arteritis virus from clinical specimens for many years. In this study,
we report the complete genome sequence of the noncytopathic bovine viral diarrhea virus
1 (ncpBVDV-1) contaminating the HP-RK-13 (KY) cell line. The complete genome of
this ncpBVDV strain (ncpBVDV HP-RK-13) is 12,271 nucleotides (nts) in length; it
contains a single open reading frame (ORF) made up of 11,697 nts [387-12,083])
encoding 3898 amino acid polyproteins. Phylogenetic analysis indicated that this strain
belongs to BVDV group 1b.
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4.2. Introduction
Bovine viral diarrhea virus (BVDV) is a non-enveloped, positive-sense, singlestranded RNA virus whose genome size is approximately 12.3-12.5 kb. The virus is a
member of the genus Pestivirus in the family Flaviviridae which also includes Border
disease virus and classical swine fever virus456,457. Two major genotypes of BVDV are
recognized (type 1 [BVDV-1] and 2 [BVDV-2]). BVDV-1 strains are genetically
subdivided into at least 17 subtypes (a to q) and BVDV-2 strains into four subtypes (a to
d)458–461. In addition, two distinct biotypes within each genotype have been identified:
cytopathic viruses (cpBVDV) that cause cytopathic effects in cultured cells and
noncytopathic viruses (ncpBVDV) that do not cause cytopathic effects in cultured cells
(7-10). It has previously been reported that a number of cell lines (e.g. of cattle, sheep,
goat, deer, bison, rabbit and domestic cat origin) including the RK-13 cell line (CCL-37;
American Type Culture Collection [ATCC], Manassas, VA, USA) are persistently
infected with ncpBVDV resulting from the use of BVDV contaminated fetal bovine
serum in cell culture media462–466. Many laboratories use the RK-13 cell line from the
ATCC or it derivatives for research and laboratory confirmation of various viral agents.
Our laboratory has been using high passage RK-13 cells (P399-409; HP-RK-13 [KY]) for
routine laboratory diagnostic investigation for over 50 years467. In this study, we
determined the complete genome sequence of ncpBVDV virus present in the HP-RK-13
(KY) cells (P404) using next-generation sequencing (NGS) technology on an Illumina
MiSeq platform according to previously established procedures445.
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4.3. Materials and methods
Cells and viruses
High passage rabbit kidney 13 (HP399-409; HP-KY-RK-13 [KY]; derived from
ATCC® CCL-37™, American Type Culture Collection) cells were maintained in Eagle’s
minimum essential medium (EMEM, Cellgro®, Mediatech Inc., Herndon, VA, USA)
with 10% ferritin-supplemented calf serum (HyClone Laboratories, Inc., Logan, UT,
USA), penicillin and streptomycin (100 U/mL and 100 μg/mL) and 0.25 μg/mL of
amphotericin B (Gibco®, Carlsbad, CA, USA).

Next-generation sequencing
Total viral RNA was extracted from the tissue culture fluid following freeze thaw
of HP-RK-13 (KY) cell monolayers (P404) in 25-cm2 flasks using a total RNA
purification kit (Catalog no. 17200, Norgen Biotek Corp., Ontario, Canada). The RNA
was quantified with a Qubit 2.0 spectrophotometer (Life Technologies, Carlsbad, CA,
USA) and purified RNA was stored at -80°C. The complete genome sequence of
ncpBVDV HP-KY-RK13 strain was obtained by next-generation sequencing (NGS)
technology on an Illumina MiSeq platform following a previously established protocol445.
Briefly, cDNA libraries were constructed from 100 ng of total RNA using a TruSeq
Stranded total RNA sample preparation kit (Illumina, San Diego, CA, USA) according to
the manufacturer’s instructions and previously described protocol. Multiplex libraries
were prepared using barcoded primers and a median insert size of 340 base pairs (bp).
Libraries were analyzed for size distribution using a Bioanalyzer and quantified by
quantitative RT-PCR using a Kapa library quantification kit (Kapa Biosystems, Boston,
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MA, USA); relative volumes were pooled accordingly. The pooled libraries were
sequenced on an Illumina MiSeq platform with 150 bp end reads following standard
Illumina protocols.

Sequence analysis
Sequences were mapped to all known BVDVs and mapped read sets were used
for de novo assembly using ABySS, v.1.3.7 (BC Cander Agency, Vancouver, Canada)
and Geneious 7.0.6 software (Biomatters Ltd., Auckland, New Zealand). The new pairedend read sets were extracted from the original paired-end fastq files using seqtk with the
list of mapped ID to insure both reads of one pair were selected. The raw reads in FASTA
formats were imported into IGV_2.3.79 for mapping and paired using the default
parameter for illumine short read. Comparative alignment analysis of nucleotide (nt) and
amino acid (aa) sequences was performed through Geneious 7.0.6 software (Biomatters
Ltd., Auckland, New Zealand).

Phylogenetic analysis
Phylogenetic trees were constructed by using the Maximum Likelihood method
based on the Tamura-Nei model446, applying Neighbor-Join and BioNJ algorithms to a
matrix of pairwise distances estimated using the Maximum Composite Likelihood (MCL)
distance with Gamma-distributed rates, pairwise gap deletion and boopstrap resampling
(1,000 replications)447.
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4.4. Results and discussion
The complete genome of ncpBVDV contaminating the HP-RK-13 (KY) cell line
(ncpBVDV HP-KY-RK13 strain) is comprised of 12,271 nucleotides (nt) and contains a
5′ untranslated region (UTR; 386 nts), a single open reading frame (ORF; 11,697 nt [38712,083]) and a 3′ UTR (188 nt). The single ORF encodes a 3,898 amino acid polyprotein
which is predicted to be cleaved into 12 proteins (Table 4.1.468). The polyprotein is
cleaved into 12 proteins that are respectively enumerated from amino acids to carboxyl
terminus as follow: NH2-Npro-C-Erns-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5BCOOH. Specifically, the polyprotein is cleaved by the viral protease into four structural
proteins (C, Erns, E1 and E2) and eight nonstructural proteins (Npro, P7, NS2, NS3, NS4A,
NS4B, NS5A and NS5B). Based on the putative cleavage sites of structural and
nonstructural proteins of other BVDVs (Table 4.1.), the ncpBVDV HP-KY-RK13 strain
UTRs and genes were annotated to the following nucleotide positions in the genome: 5′
UTR, 1-386 (386 nt); Npro, 387-887 (501 nt); C, 888-1,196 (309 nt); Erns, 1,197-1,877
(681 nt); E1, 1,878-2,462 (585 nt); E2, 2,463-3,584 (1,122 nt); P7, 3,585-3,794 (210 nt);
NS2, 3,795-5,153 (1,359 nt); NS3, 5,154-7,202 (2,049 nt); NS4A, 7,203-7,394 (192 nt);
NS4B, 7,395-8,435 (1,041 nt); NS5A, 8,436-9,923 (1,488 nt); NS5B, 9,924-12,083
(2,160 nt); 3′ UTR, 12,084-12,271 (188 nt) (Table 4.2.). The complete genomic sequence
of ncpBVDV HP-KY-RK13 strain has been submitted to GenBank under accession
number: KT355592.
Comparative nucleotide sequence analysis showed that the ncpBVDV HP-KYRK-13 strain had 85.2% to 99.7% identity with 11 strains of BVDV-1b and 68.6% to
70.9% identity with eight strains of BVDV-2. This further demonstrated that the
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ncpBVDV HP-KY-RK13 strain is very closely related to the previously described
ncpBVDV present in the RK-13 cells from Japan (RK13/E- strain [GenBank accession
number: JX419397.1; 12064 nt, 99.7% identity])469. The ncpBVDV HP-KY-RK13 strain
was compared with eleven other BVDV-1b subtypes available in GenBank; P7 and
NS5A proteins are the most variable (78.1% to 99.0% and 79.1% to 99.6%, respectively),
whereas the Erns, NS3, NS4A and NS4B proteins are the most conserved. The ncpBVDV
HP-KY-RK13 strain had several nucleotide insertions and deletions compared to several
of the other BVDV-1b strains (Table 4.3.). However, the specific insertion(s) and/or
deletion(s) that are predictable for pathogenesis and establishment of persistent infection
in the HP-RK-13 (KY) cell line have not been determined.
A phylogenetic tree was constructed using the complete genome sequence of
ncpBVDV HP-KY-RK13 strain along with 34 BVDV strains available in GenBank
(Figure 4.1.). The phylogenetic analysis determined that ncpBVDV HP-KY-RK13 strain
belongs to BVDV-1b genotype.
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Table 4.1. Cleavage sites between structural and nonstructural proteins of reference BVDV strains and HP-KY-RK13 strain
Table 1. Cleavage sites between structural and nonstructural proteins of reference BVDV strains and HP-KY-RK13 strain
ORF
SH-28
XJ-04
890
NADL
ZM-95
SD0803
CC13B
HP-KY-RK13

Npro
-LWVTS
-LWVTS
-LWVTS
-LWVTT
MELIS-LWVTS
MELIS-WVASC
MELIT-LWVSS
MELIT-LWISS

C
Erns
E1
E2
P7
NS2
CSDEG-QLVTG
ENIT-FGAYA ASPYC-TGAQG FPECK-QIAMG ARVNT-GVVKA
SKTNTCSDEG-QLVEG
ENIT-FGAYA ASPYC-TGAQS FPECK-QIAMG
ARVNT-GLVKA
REINTCSDEG-QLVTG ENITQ-FGAHA ASPYC-TGVQG FPECK-QMAMG AGVNT-GAVKA
IPPEECSDTK-QVTMG ENIT-FGAYA
ASPYC-TGVQG KKLFD-QKALG IQYGS-DVVKA
DSGGQCSDTK-QVTAG ENIT-FGAYA ASPYC-TGAQG YPDCK-QRASG TQCGA-GAVKA ESGTQ-HLGWI
SDPKN-QVTMG ENIT-FGAYA
ASPYC-TGVQG IPECR-QKASG AQCGA-GAVKA DSETQ-GWILR
CSDTK-QVTMG ENTI-FGAYA ASPYC-TGAQG YPDCK-QMALG AQYGS-GMVKA EPGTK-GWILR
CSDTK-QVTVG ENIT-FGAYA ASPYC-TGVQG YPDCK-QMASG AQYGA-GMARA EPGAQ-GWILR

NS3
QVTGL
-QVTGL
-QVTGL
-QVTGL
LRGPA-QVAGL
GPAVC-QVVGL
GPAVC-QVVGL
GPAVC-QVVGL

NS4A
STAEN-ELKEL
STAEN-ELKEL
STAEN-ELKEL
SSAEN-ELKEL
SSAEN-ELKEL
SSAEN-ELKEL
SSAEN-ELKEL
SSAEN-ELKEL

NS4B
QKIKE-KIRNL
AVGDL-KIRNL
AVGDL-KIRNL
ASGDV-KIRNL
ALGDV-KIRNL
ALGDT-KIRNL
AVGDL-KIRNL
AVGDL-KIRNL

NS5A
SSNYL-YTMKL
SSNYL-YTMKL
SGNYI-YTMKL
SGNYI-YAMKL
SGNYI-YTMKL
SGNYI-YTMKL
SGNYV-YTMKL
SGNYV-YTMKL

NS5B
SSWSTSSWSTSSWSTSSWFLSSWFM-VGASS
SSWFL-VNASS
SSWFL-VGASS
SSWFL-VGASS

Cleavage sites of sites
SH-28, XJ-04,
NADL, ZM-95
Strains of890,
BVDV from
Tao et al. Virus
Genes (2013)
46:81–87of BVDV from Tao et al. (2013)468.
Cleavage
of 890,
SH-28,
XJ-04,
NADL,
ZM-95
strains

Table
4.2. Nonstructural and structural proteins of BVDV strains
Table 2. Nonstructural and structural proteins of BVDV strains
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BVDV strain
(GenBank
accession
number)
Full-length
genome (nt)
1 ORF amino
acid sequence
length (aa)
ORF
5′ UTR
Npro
C
Erns
E1
E2
P7
NS2
NS3
NS4A
NS4B
NS5A
NS5B
3′ UTR

BVDV HP-KY-RK13 (KT355592.1)

BVDV SD0803 (JN400273.1)

BVDV CC13B (KF772785.1)

BVDV 1 Japan (JX419397.1)

BVDV ZM-96 (AF526381.3)

122271 nt

12271 nt

12265 nt

12064 nt

12220 nt

3898 aa

3898 aa

3898 aa

3898 aa

3901 aa

Nucleotide length
(nt)
1-386 (386)
387-887 (501)
888-1196 (309)
1197-1877 (681)
1878-2462 (585)
2463-3584 (1122)
3585-3794 (210)
3795-5153 (1359)
5154-7202 (2049)
7203-7394 (192)
7395-8435 (1041)
8436-9923 (1488)
9924-12083 (2160)
12084-12271 (188)

Amino acid
Nucleotide length
length (aa)
(nt)
- (128)
1-388 (388)
1-167 (167)
389-892 (504)
168-270 (103)
893-1198 (306)
271-497 (227)
1199-1879 (681)
498-692 (195)
1880-2464 (585)
693-1066 (374) 2465-3586 (1122)
1067-1136 (70)
3587-3796 (210)
1137-1589 (453) 3797-5155 (1359)
1590-2272 (683) 5156-7204 (2049)
2273-2336 (64)
7205-7396 (192)
2337-2683 (347) 7397-8437 (1041)
2684-3179 (496) 8438-9925 (1488)
3180-3898 (719) 9926-12085 (2160)
- (62)
12086-12271 (186)

Amino acid
length (aa)
- (129)
1-168 (168)
169-270 (102)
271-497 (227)
498-692 (195)
693-1066 (374)
1067-1136 (70)
1137-1589 (453)
1590-2272 (683)
2773-2336 (64)
2337-2683 (347)
2684-3179 (496)
3180-3898 (719)
- (62)

Nucleotide length
(nt)
1- 380 (380)
381-881 (501)
882-1190 (309)
1191-1871 (681)
1872-2456 (585)
2457-3578 (1122)
3579-3788 (210)
3789-5147 (1359)
5148-7196 (2049)
7197-7388 (192)
7389-8429 (1041)
8430-9917 (1488)
9918-12077 (2160)
12078-12265 (188)

Amino acid
length (aa)
- (126)
1-167 (167)
168-270 (103)
271-497 (227)
498-692 (195)
693-1066 (374)
1067-1136 (70)
1137-1589 (453)
1590-2272 (683)
2273-2336 (64)
2337-2683 (347)
2684-3179 (496)
3180-3898 (719)
- (62)

Nucleotide length
(nt)
1-388 (388)
389-892 (504)
893-1198 (306)
1199-1879 (681)
1880-2464 (585)
2465-3586 (1122)
3587-3796 (210)
3797-5155 (1359)
5156-7204 (2049)
7205-7396 (192)
7397-8437 (1041)
8438-9925 (1488)
9926-12085 (2160)
12086-12271 (186)

Amino acid length
(aa)
- (129)
1-168 (168)
169-270 (102)
271-497 (227)
498-692 (195)
693-1066 (374)
1067-1136 (70)
1137-1589 (453)
1590-2272 (683)
2773-2336 (64)
2337-2683 (347)
2684-3179 (496)
3180-3898 (719)
- (62)

Nucleotide length
(nt)
1-329 (329)
330-833 (504)
834-1145 (312)
1146-1826 (681)
1827-2411 (585)
2412-3536 (1125)
3537-3746 (210)
3747-5099 (1353)
5100-7154 (2055)
7155-7346 (192)
7347-8387 (1041)
8388-9875 (1488)
9876-12035 (2160)
12036-1220(185)

Amino acid length
(aa)
- (109)
1-168 (168)
169-272 (104)
273-499 (227)
500-694 (195)
695-1069 (375)
1070-1139 (70)
1140-1590 (451)
1591-2275 (685)
2276-2339 (64)
2340-2686 (347)
2687-3182 (496)
3183-3901 (719)
- (61)

Table 4.3. Insertion and deletion positions in full-length genome alignments of BVDV1b strains
Table 3. Insertion and deletion positions in full length genome alignments of BVDV-1b strains
Compared strain
(GenBank accession number)
JL-1
|KF501393.1|

CP7 strain
|U63479.1|

3156
|JN704144.1|

Germini
|JX297516.1|

Nucleotide
position
11
17
45-48
75-76

A
T
AAAA
AA

E2

2719-2721

GAA

insertion

NS2

5010-5021

AATATCCTTCAG

deletion

5′ UTR

45-47

AAA

deletion

NS2

4358-4384

5′ UTR

45-47
75-76

NS5A

9406
9411
9800-9803
9812-9815

NS5B

11960
11976

3′ UTR

12090-12092
12116-12120
12125-12129
12168-12176
12185-12206
12210-12215

E2

2469-2471
2720-2725

3′ UTR

12033

ORF
5′ UTR
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Nucleotide substitution

HP-KY-RK13
Insertion/Deletion
deletion
deletion
insertion
insertion

GGGTGTTCCTTATCCGGACCCTCAAAC deletion
AAA
AA

insertion
insertion

A
A
GGGC
AAGT

insertion
deletion
insertion
deletion

A
A

deletion
insertion

AAT
GAATT
TGTAT
CCTCAAAAG
CTCAACATACACAGCTAAACAG
TTGAGA

insertion
deletion
insertion
deletion
deletion
deletion

GAC
AAGAAA

insertion
insertion

C

insertion

100 50 BVDV 1b |KF835698.1| 50 strain
70 50a BVDV 1b |KF835699.1| 50a
87

AU526 BVDV 1b |KF835697.1|

100

526 BVDV 1b |HQ174294.1|

83

6151 BVDV 1b |JN380083.1|

90

RK13/E- BVDV1b |JX419397.1|

BVDV HP-KY-RK13 |KT355592|
100

BVDV 1b

RK13/E+ BVDV 1b |JX419398.1|
64

Gemini BVDV 1b |JX297516.1|
CP7 BVDV1b |U63479.1|

100
100
93

CC13B BVDV 1 |KF772785.1|
12F004 BVDV 1 |KC963967.1|

100

890 BVDV 1 |U86599.1|

100

JL-1 BVDV 1b |KF501393.1|

78

BVDV 1

KE9 BVDV 1 |EF101530.1|
GX4 BVDV 1 |KJ689448.1|

100

100 Av69 VEDEVAC BVDV 1 |KC695814.1|
56

3156 BVDV 1b |JN704144.1|
NADL BVDV 1 |AJ133739.1|

85

Oregon C24V BVDV 1 |AF091605.1|

100
100

61

GS5 BVDV 1 |KJ541471.1|
10JJ-SKR BVDV 1 |KC757383.1|
ZM-95 BVDV 1 |AF526381.3|
SD0803 BVDV 1 |JN400273.1|

100
100

camel-6 BVDV 1 |KC695810.1|

uwaCp BVDV 1 |KC853441.1|
100 SuwaNcp BVDV 1 |KC853440.1|
SD1301 BVDV 2 |KJ000672.1|

100

Hokudai-Lab/09 BVDV 2 |AB567658.1|
HLJ-10 BVDV 2 |JF714967.1|

100

SH-28 BVDV 2 |HQ258810.1|
100

XJ-04 BVDV 2 |FJ527854.1|

70
97

BVDV 2

KZ-91-CP BVDV 2 |LC006970.1|

51

C413 BVDV 2 |NC 002032.1|
100

11F011 BVDV 2 |KC963968.1|

0.1

Figure 4. 1. Phylogenetic analyses of whole genome of 34 reference BVDV strains
obtained from GenBank and the ncpBVDV HP-KY-RK13 strain identified with a
black dot.
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CHAPTER FIVE
Summary of Research Findings
Chapter one provides a review of the current literature on equine arteritis virus
(EAV) and equine viral arteritis (EVA) which includes viral classification, genome
organization, replication cycle and neutralization determinants and the disease caused by
the virus including epidemiology, modes of transmission, immune response, clinical
signs, pathogenesis, persistent infection in the stallion, diagnosis, treatment, prevention
and control. Also, a brief overview of RNA virus quasispecies theory and viral
evolutionary mechanisms is provided. Viruses are infectious particles that cannot selfreplicate without susceptible and permissive host cells. Like other RNA viruses, the EAV
RNA-dependent RNA polymerase enzyme lacks proofreading capability (error-prone),
which results in the generation of a large number of viral genomes with mutations. The
viral population size, number of mutations and quasispecies effect drive RNA virus
evolution. RNA viruses evolve close to their error threshold at a high mutation rate
during a short period of viral replication and produce a large viral population and enough
mutants to enhance viral survival. Viral populations exist as a dynamic mutant
distribution (mutant swarms) that is called quasispecies. The viral quasispecies
population constantly evolves in the face of selection pressures to adapt to a given
environment. When the virus fitness decreases, the viral population loses the ability to
adapt to its environment and it experiences a bottleneck event, which is a sharp reduction
in the size of a population due to environmental events such as selective pressure and
viral fitness.
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In chapter two, EAV evolution was studied during long-term persistent infection
established following experimental infection of seven stallions with the KY84 strain of
EAV. In addition, two stallions naturally infected with the EAV KY84 strain for a period
of 7 to 10 years were also included in the study. This was the first study where the
evolution of the full-length EAV genome was studied during long-term persistent
infection using next-generation sequencing. The sequencing data were analyzed using
contemporary sequence and phylogenetic analysis software. The statistical analyses were
performed to measure the intra-host evolutionary dynamics, quasispecies diversity, rate
of evolution and selection pressure among viral populations from the ancestral strain (the
initial inoculum) through the evolutionary time scale (acute and persistent infection
periods). Analysis of viral sequences in nasal secretions and buffy coat cells revealed a
lack of extensive positive selection; however, characteristics of the mutant spectra were
different in the two sample types. By contrast, virus populations in semen during the
acute infection phase were under selective pressure and subjected to bottleneck events,
which was reflected in a reduction in population size and the positive selection of viral
genomes. During long-term persistent infection, virus evolved in the reproductive tract of
the stallions; as a result, a non-stochastic evolutionary process with many atypical highfrequency minor variants was identified. This indicates that an active selection pressure
continually morphs EAV quasispecies population structures and dynamics during
persistent infection. Comparative analysis of the evolution in experimentally infected
stallions with that of naturally infected stallions showed a higher degree of correlation in
the rate of sequence divergence through time and mirrored the patterns of selection
between experimental and naturally infected stallions.
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In summary, this study

demonstrated the genetic bottleneck event and selection during the acute infection period
and intra-host quasispecies diversification during persistent infection in the stallion
reproductive tract.
A total of 53 sequential isolates made during acute and persistent infection were
analyzed and compared to the of EAV KY84 strain present in the inoculum. Major and
minor viral populations were identified in the inoculum used for experimental infection
of the seven stallions. The more homogenous virus populations with major and minor
variants were demonstrated in the inoculum virus and viruses isolated during the acute
infection period. A distinct quasispecies population size and selection pattern were
observed during the initial establishment of the viral population in nasal swab and buffy
coat samples. For instance, the reduction in variant population size observed in buffy coat
virus isolates may reflect a transmission bottleneck scenario. The results indicate that the
selective bottleneck event happens during virus migration from the upper respiratory tract
to the regional lymph nodes via the blood stream until EAV reaches its final destination
in the male reproductive tract. In the virus population during acute infection period,
strong negative evolutionary selection was observed at nucleotide positions of nsp9
located at aa 6729-6816, which play a role in RdRp function and in assembly of the viral
replication complex. This suggested that the conserved nsp9 region with low frequency
mutation might have a regulatory effect on viral replication.
In contrast, the presence of continual positive selection resulting in quasispecies
diversity was observed in specific regions of the genome that drives the evolution of
semen virus isolates made during persistent infection. For instance, an atypical high
frequency minor variant population implies an ongoing interaction between the viral
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qausispecies population and the host immune system. Even though 10 to 70% of stallions
become persistently infected carriers, the presence of high levels of serum virus
neutralizing antibodies effectively eliminates systemic infection in body tissues except
for the reproductive tract of the stallion. The strong diversifying selection was observed
especially in ORF3 and ORF5. The results suggest that quasispecies diversity may play a
significant role in establishment of persistent infection and the pathogenesis of EAV.
In conclusion, this study identified virus evolution with the dynamic population
in sequential samples from both experimentally and naturally infected stallions during
acute and persistent infection. Questions to emerge from the research findings are as
follows: What leads to persistent infection of EAV in the stallion reproductive tract?
Supplementary tables 2.2. and 2.3. may provide a key to understanding the major amino
acid changes in structural proteins, particularly GP5, which contains the major
neutralization sites of EAV. What will happen to pathogenesis of the virus as it evolves
over time? Does the phenomenon of the virus quasispecies population occur similarly in
mares? Due to the lack of resources, this in vivo study could not be extended to include
breeding trials with experimental mares to define the pathogenesis of the infection.
However, supplementary tables 2.4. and 2.5. suggest the presence of distinctive
neutralizing phenotypes; further investigation of the latter may well help in understanding
in pathogenesis of the virus as well as persistent infection of EAV in the stallion
reproductive tract.
Chapter three was devoted to a study of the isolation and characterization of a
novel field strain of EAV from a persistently infected donkey in northern Chile, described
as EAV donkey VD7634 strain. This is the first full-length genome sequence of EAV
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obtained from a wild male donkey. The annotation of EAV donkey VD7634 strain was
predicted based on the NCBI referenced EAV sequence (accession numbers: NC002532).
There are only partial ORF5 sequences (nucleotide location: 11,295-11,812 [518 bp in
length]) of donkey EAV isolates available from GenBank. Both sequence identity and
phylogenetic analyses indicated that the partial ORF5 sequence of EAV donkey VD7634
strain was closely related to that of a donkey isolate from the Republic of South Africa
(RSA). However, further phylogenetic analysis using 29 full-length EAV strains from
horses grouped the EAV donkey VD7634 strain with French and CW strains (EU-2
subgroup). Although EAV donkey VD7634 strain diverged from both NA and EU
subgroups of 29 referenced EAV sequences of horses, phylogenetic analysis including
other arteriviruses indicated that EAV donkey VD7634 strain belongs to the genus
Equartevirus (Family: Arteriviridae and Order: Nidovirales). Neutralization testing with
a large panel of well-characterized mAbs and polyclonal equine sera confirmed antigenic
cross reactivity of this strain. The newly identified EAV donkey VD7634 strain had a
unique neutralization phenotype compared to other EAV strains.
Even though EAV has not yet been detected from domestic horses in Chile, this
is the first isolate of EAV from a carrier male donkey originating from a wild herd for an
unknown period of time. It is very difficult to imagine how these feral donkeys survive,
some persistently infected with EAV, in Huasco province, Atacama region in Chile, that
is geographically surrounded by arid desert, salt lakes and felsic lava that flows towards
the Andes mountains470. There are very large deposits of sodium nitrate in the region,
which could serve as fertilizer and may enable plants to grow as a food source for the
feral donkeys. Although the geographical location limits the possibility of contact of
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EAV positive feral donkeys with domestic equids including donkeys and horses, this
study might suggest that there could be the potential for an outbreak of EVA.
Accordingly, implementation of prevention and control measures against EVA are highly
recommended to protect the domestic equine population in Chile from the risk of such an
event.
Chapter four, the full-length genome sequence of a noncytopathic bovine diarrhea
virus 1 (ncpBVDV-1) contaminating the high passage rabbit kidney continuous cell line
(HP-RK-13 [KY]). It has been repeatedly reported that the RK-13 cell line is
contaminated with noncytopathic bovine viral diarrhea virus (ncpBVDV) as a result of
the use of BVDV contaminated fetal bovine serum in cell culture media. This laboratory
has been using the HP-RK-13 (KY) cell line for isolation of EAV from clinical
specimens for many years.
In this study, the complete genome of ncpBVDV-1 (ncpBVDV HP-KY-RK13
strain) was determined and the genome organization predicted by comparing cleavage
sites to other published BVDV sequences. Several nucleotide insertions and deletions
were observed in the ncpBVDV HP-KY-RK13 strain by comparing it to several other
BVDV-1b strains; however, its role in the pathogenesis and establishment of persistent
virus infection has to be determined. Phylogenetic analysis determined that the
ncpBVDV HP-KY-RK13 strain belongs to the BVDV-1b genotype.
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APPENDIX 1
List of Abbreviations
°

C
3CLSP
TCID50
R2
COOH
Vero or MA-104
APRAV-1
AAEP
ATCC
AVMA
aa
BHK-21
bp
NH2
BVDV
BC
HS or HT-7
CO2
CMC
CD
CF
cDNA
Cys
CP
cp
cpBVDV
CPE
dpi
DNA
DIVA
DMV
EMEM
ER
E
ELISA
EAV
C-X-C motif
EqCXCL16
ECA11

Celsius
3C-like serine proteases
50% tissue culture infective dose
Accuracy of the linear regression analysis
Acidic carboxylic group
African green monkey kidney
African pouched rat arterivirus
American Association for Equine Practitioners
American Type Culture Collection
American Veterinary Medical Association
Amino acid
Baby hamster kidney-21
Base pair
Basic amino group
Bovine viral diarrhea virus
Buffy coat
Canine hepatitis virus-transformed hamster tumor
Carbon dioxide
Carboxymethylcellulose
Cluster of differentiation
Complement-fixing
Complementary DNA
Cysteine
Cysteine protease
Cytopathic
Cytopathic BVDV
Cytopathic effect
Days post-infection
Deoxyribonucleic acid
Differentiate vaccinated from infected animals
Double-membrane vesicle
Eagle's minimum essential medium
Endoplasmic reticulum
Enveloped protein
Enzyme-linked immunosorbert assay
Equine arteritis virus
Equine chemokine
Equine chemokine ligand 16
Equine chromosome 11
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EEC
EO
EVA
ERGIC
EU
FUBAR
FMDV
GP
GnRH
h
H
HmLu
HS
HAV
HBV
HCV
HP-RK-13 (KY)
hpi
huCXCL16
HIV
HyPhy
ARTERVAC®
pEAVrMLVB
IACUC
iiRT-PCR
IFN
IL
ICTV
KY
KY84
kb
kDa
L
LDV
LTH
MCL
ML
M
mRNA
μg/mL
µL
MIA

Equine endothelial cell
Equine ovary cell
Equine viral arteritis
ER-Golgi intermediate compartment
European
Fast unconstrained Bayesian analysis for inferring
selection
Foot-and-mouth disease virus
Glycoprotein
Gonadotropin releasing hormone
Hour
Hemagglutinin
Hamster lung
Heparin sulfate
Hepatitis A virus
Hepatitis B virus
Hepatitis C virus
High passage RK-13 (KY)
Hours post-infection
Human chemokine ligand 16
Human immunodeficiency virus
Hypothesis testing using phylogenies
Inactivated EAV vaccination
Infectious cDNA clone of the MLV strain of EAV
Institutional Animal Care and Use Committee
Insulated isothermal RT-PCR
Interferon
Interleukin
International Committee for Taxonomy of Viruses
Kentucky
Kentucky 84 strain
Kilobase
Kilodalton
Liter
Lactate dehydrogenase-elevating virus
Leader TRS hairpin
Maximum composite likelihood
Maximum likelihood
Membrane protein
Messenger RNA
Microgram per milliliter
Microliter
Microsphere immunoassay
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MEME
ARVAC®
MLV
mAbs
NS
NAHMS
NCBI
N
NGS
NendoU
ncp
ncpBVDV
nsp
NS3
n
∏n
n/N
NA
N protein
NTPase
nt
∏
dN
dS
ORF
p
PCP
P1
P-PMO
PMO
PFU/mL
PCR
pp
PRRSV
RK-13
qRT-PCR
rRT-PCR
RTC
RSA
RVN
RT-PCR
RNA
RdRp

Mixed effect model of evolution
Modified live attenuated EAV vaccination
Modified live attenuated vaccination
Monoclonal antibodies
Nasal swab or nasal secretion
National Animal Health Monitoring System
National Center for Biotechnology Information
Neuraminidase
Next-generation sequencing
Nidoviral-endonuclease specific for U
Noncytopathic
noncytopathic BVDV
Nonstructural protein
Nonstructural protein 3
Nonsynonymous
Nonsynonymous nucleotide diversity
Nonsynonymous substitutions per site
North American
Nucleocapsid protein
Nucleoside-triphosphatase
Nucleotide
Nucleotide diversity
Number of n/N
Number of s/S
Open reading frame
P-value
Papain-like cysteine protease
Passage 1
Peptide-conjugation to the PMO
Phosphorodiamidate morpholino oligomer
Plaque-forming units per milliliter
Polymerase chain reaction
Polyprotein
Porcine reproductive respiratory syndrome virus
Rabbit kidney-13
Real-time RT-PCR
Real-time RT-PCR
Replication/transcription complex
Republic of South Africa
Reticulovesicular network
Reverse transcription-polymerase chain reaction
Ribonucleic acid
RNA-dependent RNA polymerase
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RT-nPCR
S
SP
SAG
SHFV
SNV
ss
SH2
sp
sg mRNA
s
∏s
s/S
TCF
TRS
TNF
USDA-APHIS
USA
U/mL
UTR
VS
VN
VBS
VI
VNT
VRP
VLP
WPDV
OIE
ZF
ZBD

RT-nested PCR
Semen
Serine protease
Servicio Agricola y Ganadro
Simian hemorrhagic fever virus
Single nucleotide variant
Single stranded
Src homology 2
Structural protein
Subgenomic viral messanger RNA
Synonymous
Synonymous nucleotide diveresity
Synonymous substitutions per site
Tissue culture fluid
Transcription regulating sequence
Tumor necrosis factor
United States Department of Agriculture Animal and
Plant Health Inspection Service
United States of America
Units per milliliter
Untranslated region
Vas deferens
Viral neutralizing
Virulent Bucyrus strain
Virus isolation
Virus neutralization test
Virus replicon particle
Virus-like particle
Wobbly possum disease virus
World Organisation for Animal Health
Zinc finger
Zinc-binding domain
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APPENDIX 2
Glossary Relevant to the Virus Evolution
Adaptation

Antigenic drift

Bottleneck event

The constant steady replication of large viral populations results in a
consequence of high fitness
One of the main mechanisms that is a result of point mutations in
influenza virus genes, encoding HA and NA that cause alternations
in the structure of the main viral surface antigens. This is a slow
process that is on-going and which causes antigenic differences in
strains of influenza virus
Modification of viral population sizes resulting in the heterogeneous
and dynamic nature of viral populations that are suitable in the
environment by fitness gain

Defectors

Types of defective mutants that are associated with virus extinction
caused by lethal mutagenesis

Drug resistance

A general phenomenon and the selection of a drug-resistant mutant
against a specific antiviral drug is evidence of the phenomenon

Error-threshold

The value that is determined by the replication accuracy and the
virus fitness of the dominant or master sequence corresponding to
the mean fitness value of the error copies

Exonuclease
activities

The DNA-dependent DNA polymerases have proofreading ability
that are enable them to modify or correct any such mistakes

Lethal
mutagenesis

A process of suppression in the replication of a high fitness variants

Molecular clock

Mutant spectra

Mutation
frequency

Mutation rate

The neutral theory of molecular evolution that means the rates of
evolution reflect mutation rates
The ensemble of genomes that forms a viral quasispecies and its
complexity and formation are closely related to its biological
environment.
The proportion of mutant viruses in a population, and is affected by
many biochemical and environmental selective factors
The frequency of occurrence of a mutation during genome
replication that can be calculated by mutations per site per
replication. It is a value that is an independent of the fitness of the
parental and mutated genomes
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Negative
selection

The process of removing a genotype in an evolving population that
causes the negative evolution of phenotypic traits expressed by
individuals

Next-generation
sequencing

The application of modern technologies to study the virus evolution
and viral quasispecies population

Non-equilibrium

A mutant spectrum in variable fitness landscapes, a theoretical
construction of the evolutionary process

Nonsynonymous
mutation

A nucleotide mutation that changes the amino acid sequence of a
protein

Population
equilibrium

An important role in maintaining a constant consensus sequence in
viral populations

Positive selection

Quasispecies

Quasispecies
dynamics
Quasispecies
memory
Rate of evolution

Reassortant

The process of a dominant genotype resulting in the positive
evolution of phenotypic traits expressed by the individuals of the
evolving population
Also known as mutant swarms or mutant clouds; a continuous
process of genetic variations in RNA viruses is responsible for
heterogeneous mutant distributions in virus population
RNA viruses evolve as a consequence of disequilibria of mutant
distributions instead of linear accumulation of mutations
The presence of maintaining virus subpopulations in the mutant
spectrum at high frequencies than mutation rates
Viral quasispecies parameter which is the number of accumulated
mutations in viral genomes through a time point
When a susceptible host cell is coinfected by two strains of a virus,
the progeny virus may have a mixture of genome segments from the
two parental strains of a virus

Recombination

Viruses evolve by rearranging their genomes or functional parts
among different viruses

RNA-dependent
RNA polymerase

Most RNA viruses encode for a low fidelity polymerase enzyme that
encoded by most RNA viruses that can result in a mutation rate of
103 to 105 errors per nucleotide per replication cycle.

Selective
constraints

Antiviral drugs, immune components of the innate or the adaptive
immune response including those induced by vaccination and
interfering RNAs
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Synonymous
mutations

Viral fitness

Viral quasispecies

Virus extinction

A nucleotide mutation that does not change the amino acid sequence
of a protein
A major parameter which results in a viral population adapting to a
specific environment and producing infectious progeny under the
formulation of quasispecies theory and the error threshold
relationship
It allows RNA viruses to adapt to a given environment with the
advantages of dynamics of infection, virus spread, attenuation and
virulence, complexity and self-organization
Mutant spectrum complexity occurs by an increase in the mutation
rate above an extinction threshold.
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APPENDIX 3
Supplementary Tables
Supplementary table 2.1. GenBank submission information of 53 sequential isolates of
EAV KY84 strain from this study
Sample
Number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

Sample ID
EAV KY84 strain
L136 (A) NS D6
L137 (B) NS D6
L138 (C) NS D6
L139 (D) NS D6
L140 (E) NS D6
L141 (F) NS D6
L142 (G) NS D6
L136 (A) BC D6
L137 (B) BC D6
L138 (C) BC D6
L139 (D) BC D6
L140 (E) BC D6
L141 (F) BC D6
L142 (G) BC D6
L136 (A) S D5
L137 (B) S D5
L138 (C) S D5
L139 (D) S D5
L140 (E) S D5
L141 (F) S D5
L142 (G) S D5
L136 (A) S D9
L137 (B) S D9
L138 (C) S D9
L139 (D) S D9
L140 (E) S D9
L141 (F) S D9
L142 (G) S D9
L136 (A) S D107
L137 (B) S D107
L138 (C) S D107
L139 (D) S D107
L140 (E) S D107
L141 (F) S D107
L142 (G) S D107
L136 (A) S D170
L139 (D) S D170
L140 (E) S D170
L141 (F) S D170
L142 (G) S D170
L139 (D) S D345
L141 (F) S D345
L136 (A) S D380
L140 (E) S D380
L136 (A) S D548
L140 (E) S D548
L136 (A) S D726
L140 (E) S D726
Stallion D84
Stallion D94
Stallion E84
Stallion E91

GenBank Submission
Name
KY84
KY84-L136A-NS6
KY84-L137B-NS6
KY84-L138C-NS6
KY84-L139D-NS6
KY84-L140E-NS6
KY84-L141F-NS6
KY84-L142G-NS6
KY84-L136A-BC6
KY84-L137B-BC6
KY84-L138C-BC6
KY84-L139D-BC6
KY84-L140E-BC6
KY84-L141F-BC6
KY84-L142G-BC6
KY84-L136A-S5
KY84-L137B-S5
KY84-L138C-S5
KY84-L139D-S5
KY84-L140E-S5
KY84-L141F-S5
KY84-L142G-S5
KY84-L136A-S9
KY84-L137B-S9
KY84-L138C-S9
KY84-L139D-S9
KY84-L140E-S9
KY84-L141F-S9
KY84-L142G-S9
KY84-L136A-S107
KY84-L137B-S107
KY84-L138C-S107
KY84-L107D-S107
KY84-L140E-S107
KY84-L141F-S107
KY84-L142G-S107
KY84-L136A-S170
KY84-L139D-S170
KY84-L140E-S170
KY84-L141F-S170
KY84-L142G-S170
KY84-L139D-S345
KY84-L141F-S345
KY84-L136A-S380
KY84-L140E-S380
KY84-L136A-S548
KY84-L140E-S548
KY84-L136A-S726
KY84-L140E-S726
KY84 Stallion D84
KY84 Stallion D94
KY84 Stallion E84
KY84 Stallion E91

Collection
dpi
0
6
6
6
6
6
6
6
6
6
6
6
6
6
6
5
5
5
5
5
5
5
9
9
9
9
9
9
9
107
107
107
107
107
107
107
170
170
170
170
170
345
345
380
380
548
548
726
726
-
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Specimen Type

GenBank ID

Tissue culture fluid
Nasal swab
Nasal swab
Nasal swab
Nasal swab
Nasal swab
Nasal swab
Nasal swab
Buffy coat
Buffy coat
Buffy coat
Buffy coat
Buffy coat
Buffy coat
Buffy coat
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen

MG137429
MG137434
MG137443
MG137448
MG137453
MG137460
MG137469
MG137476
MG137435
MG137444
MG137449
MG137454
MG137461
MG137470
MG137477
MG137436
MG137445
MG137450
MG137455
MG137462
MG137471
MG137478
MG137437
MG137446
MG137451
MG137456
MG137463
MG137472
MG137479
MG137438
MG137447
MG137452
MG137457
MG137464
MG137473
MG137480
MG137439
MG137458
MG137465
MG137474
MG137481
MG137459
MG137475
MG137440
MG137466
MG137441
MG137467
MG137442
MG137468
MG137430
MG137431
MG137432
MG137433

Supplementary table 2.2. Comparative amino acid substitution analysis of both nonstructural and structural proteins between
inoculum and semen viruses of EAV KY84 strain from the experimentally infected carrier stallions during acute and persistent
infection periods
Amino Acid Substitutions
Open Reading
Frames (ORFs)
Amino Acid Substution:
ORF 1ab (255-9751)

Protein (aa length)

Amino acid
position

O-EAV
KY84

nsp1: Met1-Gly260 (260)
nsp2: Gly261-Gly831 (571)

265
411
447
458
462
489
509
549
1148
1439
226
582

Pro (P)
Asp (D)
Ala (A)
Thr (T)
Ser (S)
Ser (S)
Thr (T)
Ala (A)
His (H)
Ala (A)
Asp (D)
Ile (I)

842
863

Glu (E)
Ser (S)

-

-

-

-

-

-

-

-

-

-

E (67)

-

-

-

-

-

GP2 (227)

81

Ala (A)

Tyr (Y)

3
19
22
28
30
84
116
118
119

His (H)
Arg (R)
Phe (F)
Asp (D)
Ile (I)
Phe (F)
His (H)
His (H)
Leu (L)

GP4 (152)

14
116

Ala (A)
Lys (K)

ORF5a protein (59)

13

Ala (A)

GP5 (255)

71
73
82
84
104
173

Glu (E)
Ile (I)
Asp (D)
Tyr (Y)
Asp (D)
Leu (L)
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nsp3: Gly832-Glu1064 (233)
nsp4: Gly1065-Glu1268 (204)
nsp5: Ser1269-Glu1430 (162)
nsp6: Gly1431-Glu1452 (22)
nsp7: Ser1453-Glu1677 (225)
nsp8: Gly1678-Asn1727 (50)
nsp9: Gly1678-Arg2370 (693)
nsp10: Ser2371-Gln2837 (467)

nsp11: Ser2838-Glu3056 (219)
nsp12: Gly3057-Val3175 (119)
ORF2a (9751-9954)
ORF2b (9824-10507)
†

ORF3 (10306-10797)

ORF4 (10700-11158)

ORF5a (11112-11291)
ORF5 (11146-11913)

Amino Acid Substitutions

L136 (A) L136 (A) L136 (A) L136 (A) L136 (A) L136 (A)
S D5
S D107
S D170
S D380
S D548
S D726
1
1
2
5
11
21
-

L140 (E) L140 (E) L140 (E) L140 (E) L140 (E) L140 (E) L140 (E)
S D5
S D9
S D107
S D170
S D380
S D548
S D726
3
1
1
4
6
7
13
Leu (L)

Gly (G)
Thr (T)
Ile (I)
Leu (L)
Cys (C)
Ile (I)
Arg (R)
-

-

-

-

-

-

Thr (T)
-

-

-

-

-

-

-

-

-

-

-

Gly (G)

Gly (G)

Gly (G)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Tyr (Y)

Tyr (Y)

Tyr (Y)
Cys (C)

Tyr (Y)
Cys (C)

Tyr (Y)
Cys (C)
Ser (S)
Asn (N)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Thr (T)
-

Thr (T)
-

Val (V)

Val (V)

Cys (C)

Cys (C)

-

-

-

-

-

-

-

-

-

-

Tyr (Y)

Ala (A)

†

GP3 (163)

ORF6 (11901-12389)

M (162)

88
135

Ile (I)
Lys (K)

ORF7 (12313-12645)

N (110)

-

-

Cys (C)

Cys (C)

Tyr (Y)
Cys (C)

Asn (N)
Thr (T)

Thr (T)
Leu (L)

Arg (R)
Ser (S)

Arg (R)
Ser (S)

Gln (Q)
Ser (S)

Ser (S)

Arg (R)
Ser (S)

Pro (P)

Pro (P)

Pro (P)

Val (V)
Gln (Q)
Val (V)

Val (V)

Val (V)
His (H)

Val (V)
Asn (N)
His (H)

Asp (D)
Val (V)
Asn (N)
His (H)
Gly (G)

Val (V)

Val (V)

Val (V)

His (H)

His (H)

Val (V)
Asn (N)
His (H)

-

-

-

Pro (P)

-

-

-

-

Met (M)

Met (M)
Arg (R)

-

-

-

-

-

-

Supplementary table 2.3. Comparative amino acid substitution analysis of both nonstructural and structural proteins between
inoculum and semen viruses of EAV KY84 strain from the experimentally infected stallions that stopped shedding the virus
Amino Acid Substitutions
Open Reading
Frames (ORFs)
Amino Acid Substution:
ORF 1ab (255-9751)

Protein (aa length)

Amino acid
position

O-EAV
KY84

nsp1: Met1-Gly260 (260)
nsp2: Gly261-Gly831 (571)

nsp12: Gly3057-Val3175 (119)

145
404
411
470
495
497
511
705
844
873
1681
200
441
819
1039
1142
1168
1190
1234
1379

Val (V)
Ser (S)
Asp (D)
Lys (K)
Phe (F)
Ala (A)
Thr (T)
Thr (T)
Val (V)
Thr (T)
Gln (Q)
Val (V)
Ser (S)
Val (V)
Ser (S)
Leu (L)
Leu (L)
Thr (T)
His (H)
Ala (A)

E (67)

-

-

GP2 (227)

9
10
217

Tyr (Y)
Leu (L)
Ser (S)

1

nsp3: Gly832-Glu1064 (233)
nsp4: Gly1065-Glu1268 (204)
nsp5: Ser1269-Glu1430 (162)
nsp6: Gly1431-Glu1452 (22)
nsp7: Ser1453-Glu1677 (225)
nsp8/9: Gly1678-Asn1727 (50)
nsp9: Gly1678-Arg2370 (693)
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nsp10: Ser2371-Gln2837 (467)
nsp11: Ser2838-Glu3056 (219)

ORF2a (9751-9954)
ORF2b (9824-10507)

†

ORF3 (10306-10797)

ORF4 (10700-11158)

ORF5a (11112-11291)

ORF5 (11146-11913)

L137 (B) L137 (B) L137 (B)
S D5
S D9
S D107
1

3

L138 (C)
S D107
4

Amino Acid Substitutions
L139
L139
L139
(D) S
(D) S D5 (D) S D9
D170
1
1
6

3
19
27
28
118
119
120
121

His (H)
Arg (R)
Ser (S)
Asp (D)
His (H)
Leu (L)
Thr (T)
Thr (T)

GP4 (152)

3
145

Thr (T)
Arg (R)

ORF5a protein (59)

8
13

Val (V)
Ala (A)

6
70
73
82
84

Val (V)
Asp (D)
Ile (I)
Asp (D)
Tyr (Y)

GP5 (255)

ORF6 (11901-12389)

M (162)

66

Val (V)

ORF7 (12313-12645)

N (110)

-

-

L141 (F) L141 (F) L141 (F) L141 (F)
S D5
S D107 S D170 S D345
2

6

6

10
Met (M)

Amino Acid Substitutions
L142
L142
L142
(G) S
(G) S
(G) S D5
D107
D170
2
1
3

Arg (R)
Gly (G)
Arg (R)
Ser (S)
Thr (T)
Ile (I)
Ala (A)

Arg (R)

-

-

-

-

-

Ile (I)
-

Ile (I)
Ile (I)
-

Gly (G)

Gly (G)

-

-

-

-

-

-

-

-

-

-

Ala (A)
Phe (F)
Gly (G)
Phe (F)
Phe (F)
Tyr (Y)

Phe (F)
Ala (A)
Tyr (Y)

-

-

Cys (C)

Cys (C)
Ser (S)

Val (V)
-

-

-

-

-

-

-

-

-

-

Cys (C)

Phe (F)

†

GP3 (163)

Amino Acid Substitutions
L139
(D) S
D345
15

Tyr (Y)
Cys (C)

Cys (C)

Cys (C)

Cys (C)

Arg (R)
Ser (S)

Ser (S)

Ser (S)

Cys (C)
Tyr (Y)
Pro (P)
Ile (I)
Met (M)
Ile (I)
His (H)

His (H)

His (H)

His (H)

Ile (I)

Ile (I)

Ile (I)

Ile (I)

Val (V)

Val (V)
Asn (N)
His (H)

Val (V)
Ala (A)

His (H)

Asn (N)

Asn (N)

-

-

Phe (F)
-

-

-

-

-

-

-

-

-

-

-

-

-

Supplementary table 2.4. Serum neutralization test titers of mAbs against semen viruses of EAV KY84 strain from both
experimentally and naturally infected stallions during acute and persistent infection periods
EAV Strain

Neutralizing mAbs
1H7
1H9
<16
<16
<16
<16
<16
<16
<16
<16
<16
<16
<16
<16
16
<16
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L136 d5
L136 d9
L136 d107
L136 d170
L136 d380
L136 d548
L136 d726

5G11
16
16
16
<16
32
32
16

6D10
16
16
<16
<16
256
64
16

7E5
16
64
<16
<16
512
128
16

10F11
<16
16
<16
<!6
1024
512
256

L139 d5
L139 d9
L139 d107
L139 d170
L139 d345

<16
16
32
32
16

<16
<16
32
16
16

<16
16
32
32
32

<16
16
32
16
128

<16
<16
<16
<16
<16

L140 d5
L140 d9
L140 d107
L140 d170
L140 d380
L140 d548
L140 d726

16
32
<16
<16
<16
64
16

<16
32
<16
<16
64
128
512

<16
64
<16
<16
64
128
128

128
32
<16
16
16
256
2048

L141 d5
repeated
L141 d9
L141 d107
repeated
L141 d170
repeated
L141 d345

32

16
16
<16
64
<16
16
16
<16

32
16
16
2048
16
32
16
16

16
32
16
<16

Control mAbs
3E2
12A4
<16
<16
<16
<!6
<16
<16
<16
<16
<16
<16
<16
<16
<16
<16

5E8
<16
<16
<!6
<16
<16
<16
<16

6A2
32
64
16
32
512
256
<16

7D4
<16
<16
<16
<!6
<16
<16
<16

10B4
16
<16
<16
16
<16
<16
<16

<16
<16
<16
<16
<16

<16
<16
<16
<16
<16

<16
16
64
64
128

<16
16
<16
<16
<16

<16
16
<16
<16
16

<16
<16
<16
<16
16

<16
<16
<16
<16
16

64
16
<16
<16
<16
<16
16

<16
<16
<16
<16
16
16
<16

<16
<16
<16
<16
<16
<16
<16

128
32
16
16
16
128
1024

<16
<16
<16
<16
<16
<16
<16

32
<16
<16
<16
<16
<16
16

32
16
<16
<16
<16
<16
<16

<16
<16
<16
<16
<16
<16
<16

<16
<16
<16
16
<16
32
<16
16

16
<16
16
16
<!6
<16
<16
<16

Ab toxic
<16
16
16
<16
16
<16
<16

<16
<16
<16
<16
<16
<16
<16
<16

64
16
32
64
32
256
16
<16

Ab toxic
<16
<16
16
<16
<16
<16
<16

Ab toxic
<16
16
32
<16
Ab toxic
<16
<16

Ab toxic
<16
32
32
<!6
16
<16
<16

<16
<16
<16
<16
<!6
<16
<16
<16

L142 d5
repeated
L142 d9
L142 d107
L142 d170

32
16
32
16

16
<16
16
256
32

32
32
16
128
128

Wrong
<16
<16
32
128

<16
<16
<16
32
<16

32
<16
<16
<16
<16

<16
<16
<16
<16
<16

256
32
32
128
64

16
<16
16
<16
<16

16
<16
16
<16
16

16
<16
16
<16
16

<16
<16
16
<16
<16

EAV KY84
EAV VBS
EAV ARVAC

2048
1924
256

4096
8192
1024

2048
1024
128

2048
4096
1024

<16
64
<16

<16
<16
<16

<16
<16
<16

<16
256
<16

<16
<16
<16

<16
<16
<16

<16
<16
<16

<16
<16
<16

EAV KY84 D84
EAV KY84 D94
EAV KY84 E84
EAV KY84 E91

2048
64
32
1024

2048
512
<16
2048

256
64
<16
256

4096
64
32
4096

<16
<16
<16
16

<16
<16
<16
<16

<16
<16
<16
<16

128
<16
<16
64

<16
<16
<16
<16

<16
<16
<16
<16

<16
<16
<16
<16

<16
<16
<16
<16

Supplementary table 2.5. Serum neutralization test titers of polyclonal equine antisera against semen viruses of EAV KY84 strain
from both experimentally and naturally infected stallions during acute and persistent infection periods

L136 d170
L136 d380
L136 d548
L136 d726
EAV KY84
EAV VBS
EAV ARVAC

Isolate Equine Sera
d14
d726
1:64
1:32
1:32
1:16
1:8
1:16
1:16
1:16
1:16
1:32
1:128
1:128
1:128
1:64

L139 d5
L139 d345
EAV KY84
EAV VBS
EAV ARVAC

1:4
1:16
1:16
1:32
1:256

1:8
1:8
1:32
1:32
1:64

1:16
1:32
1:8
1:64
1:128

1:16
1:64
1:16
1:256
1:256

1:8
1:8
<1:4
<1:4
1:128

<1:4
<1:4
<1:4
1:4
1:16

<1:4
<1:4
<1:4
<1:4
<1:4

L140 d5
L140 d170
L140 d380
L140 d548
L140 d726
EAV KY84
EAV VBS
EAV ARVAC

1:4
1:4
1:4
1:8
1:16
1:8
1:128
1:16

1:16
1:8
1:16
1:8
1:16
1:32
1:16
1:32

1:8
1:8
1:8
1:8
1:64
1:16
1:32
1:64

1:8
1:8
1:16
1:16
1:64
1:64
1:256
1:64

1:4
<1:4
<1:4
1:4
1:4
<1:4
<1:4
1:256

<1:4
<1:4
<1:4
<1:4
<1:4
<1:4
1:32
1:8

<1:4
<1:4
<1:4
<1:4
<1:4
<1:4
<1:4
<1:4

L141 d170
L141 d345
EAV KY84
EAV VBS
EAV ARVAC

1:8
1:16
1:8
1:256
1:256

1:8
1:16
1:8
1:128
1:128

1:8
1:8
1:4
1:128
1:128

1:16
1:32
1:32
1:64
1:256

<1:4
<1:4
<1:4
<1:4
1:128

<1:4
<1:4
<1:4
<1:4
1:8

<1:4
<1:4
<1:4
<1:4
<1:4

L142 d107
L142 d170
EAV KY84
EAV VBS
EAV ARVAC

1:32
1:64
1:64
>1:512
1:128

<1:4
1:32
1:32
1:128
1:258

1:16
1:8
1:8
1:64
1:128

1:8
1:16
1:32
1:128
1:128

<1:4
<1:4
<1:4
<1:4
1:128

<1:4
<1:4
<1:4
1:4
1:16

<1:4
<1:4
<1:4
<1:4
<1:4

EAV Strain

Anti-KY53
1:128
1:32
1:16
1:32
1:16
1:64
1:128

Polyclonal Equine Antisera
Anti-KY84 Anti-ARVAC
Anti-EAVNVSL
1:128
1:8
<1:4
1:32
1:8
<1:4
1:16
<1:4
<1:4
1:32
1:16
<1:4
1:64
<1:4
<1:4
1:64
<1:4
1:4
1:128
<1:512
1:32

Control Serum
NVSLNEG
1:8
1:4
<1:4
<1:4
<1:4
<1:4
<1:4
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Supplementary table 3.1. Primers used for reverse transcription and PCR amplification
Numbers
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

Primer
BN1P
BD501P
JQ548N
BD800N
JQ1100N
JQ1524P
JQ2106N
JQ4002P
BD4546N
JQ4600N
JQ6077P
JQ6577N
JQ9745P
BD10330N
BD10449P
BD10507N
BD10621N
BD10764P
BD11148N
BN11220P
UB11255P
BD11284N
BD11361P
BD11619P
BD11800N
N11877P
BN12707N
UB12296P
BD12322N

Polarity
+
+
+
+
+
+
+
+
+
+
+
+
+
+
-

Position
1-21
501-520
548--568
800-781
1124-1103
1524-1542
2140-2121
4002--4021
4546-4527
4619-4600
6077-6096

Nuleotide sequence (5'-3')
GCTCGAAGTGTGTATGGTGCC
CTTGAGCTGTTGCAACACCC
CTTGCCTCTTCAATGGCTAAC
AGTTCGTTGTTCGCGGTAGT
AGCCAACTCATCATCACACCAC
CAGGCGCCCATCCCAGCACC
ACAGTGCAAGGAACATAAGC
CTGATTGATGGCTTATCCAA
GGCGGTGACACTCTCTTTCA
GTCATCATCAGTGAGGGCAG
GCTGACATCAGCTGTGACGC

9745-9767
10330-10311
10449-10468
10507-10488
10621-10602
10764-10783
11148-11125
11187-11207
11272-11293
11284-11264
11361-11380
11619-11638
11800-11781

CGTGTGATGGGCTTAGTGTGGTC
TTGGCCTAGCGTTGGCATAA
TAATGTCACCTTCCCGTCGC
CTACAAAATCTTGCGCCGCG
AGCATACACAGTGACAGGCC
TGCACTTTCTACCCATGCCA
GTTGAGCCCAACGTACCAGT
GCCATCACATGCTTACTTCTC
GCCAATTTGCTGCGATATGATG
GCAGCAAATTGGCAATAACGC
AGTCATCACCTTCGGCACAG
TGTACAGCGGGGCTTACTTG
GCAACTGGCAAACTGGGATC

12698-12679

TTGGATCCTGGGTGGCTAATAACTACTT

12305-12286

TTACCAACTGCGGTGTACCC
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Supplementary table 3.2. List of total clinical specimens from two male donkeys and
results of EAV confirmation test

Animal ID
Clinical specimens
Epididymis 1*
Epididymis 2*
Prostate 1*
Prostate 2*
Vas deferens 1*
Vas deferens 2*
Seminal vesicles 1*
Seminal vesicles 2*
Conjunctival swab 1

Donkey 7634
Virus isolation
-**
+ (1 pfu each in 3 of 4 flasks)
+ (1-4 pfu in all 4 flasks)
+ (1 pfu each in 3 of 4 flasks)
+ (1.35x10E4pfu/mL in all 4 flasks)
+ (2.15x10E4pfu/mL in all 4 flasks)
+ (1 pfu in 1 of 4 flasks)
+ (5.2x10E1pfu/mL in all 4 flasks)
-**

Donkey 7635
Virus isolation
qPCR
-

qPCR
+ (very weak)
+
+ (very weak)
-

*1 mL of 10% tissue suspension into 4 x 25-cm2 flasks of RK-13 (KY) cells. All virus
isolations detected on 1st passage in cell culture
**Negative for virus after 3 blind passages in RK-13 (KY) cells

Supplementary table 3.3. Partial GP5 sequence identities (%) of the novel EAV donkey
VD7634 strain to EAV donkey reference strains
Nucleotide position of partial GP5 located at 11,295-11,812 (518 bp in length)
Strain in GenBank with the
highest similarity
J1-931125
J2-931125
J3-931209
J4-931209
J7-931125
J5-940309
J6-940309
1489V/96
3308V/96

Nucleotide
identity (%)
81.5
81.5
81.5
81.5
81.5
81.3
81.3
74.7
74.3

Amino acid
identity (%)
93.0
93.0
93.0
93.0
93.0
93.0
93.0
86.6
86

*Republic of South Africa (RSA)
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Origin
RSA
RSA
RSA
RSA
RSA
RSA
RSA
Italy
Italy

GenBank accession
number
|AY956596.1|
|AY956597.1|
|AY956598.1|
|AY956599.1|
|AY956602.1|
|AY956600.1|
|AY956601.1|
|AF099829.1|
|AF099830.1|

Supplementary table 3.4. Nucleotide and amino acid sequences of average pairwise identity of EAV donkey VD7634 compared to
29 full-length EAV strains

EAV donkey
EAV donkey
Average pairwise
Average pairwise
Average pairwise identity Average pairwise identity
VD7634 strain VD7634 strain
identity of nucleotide identity of aimino acid
of nucleotide alignment of aimino acid alignment
nucleotide position protein length
alignment (%) n=2
alignment (%) n=2
(%) n=29
(%) n=29
(bp)
(aa)
EAV donkey and CW strains (EU-1)
75.37
75.15
-

Average pairwise
identity of nucleotide
alignment (%) n=5

Average pairwise
identity of aimino acid
alignment (%) n=5

Average pairwise
identity of nucleotide
alignment (%) n=4

Average pairwise
identity of aimino acid
alignment (%) n=4

Average pairwise
identity of nucleotide
alignment (%) n=18

Average pairwise
identity of aimino acid
alignment (%) n=18

ORF

Protein

Full length

-

5' TTR
Leader sequence

-

1-230
1-211

-

67.56
-

-

66
-

-

67.62
-

-

66.68
-

-

67.91
-

-

ORF1a

1a polyprotein

231-5405

1724

72.91

84.12

72.55

84.2

72.72

83.88

72.95

84.05

72.99

84.19

ORF1b

-

5402-9748

1448

75.29

88.4

75.35

88.6

75.2

88.34

74.98

88.68

75.37

88.34
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ORF1ab

ORF2a
ORF2b
ORF3
ORF4
ORF5a
ORF5
ORF6
ORF7
3' TTR

EAV donkey and French strains (EU-2)
75.36
-

EAV donkwy and NA strains (NA)
75.35
-

EAV donkey and S numbered strains (EU-1)
75.41
-

1ab
polyprotein
nsp1
nsp2
nsp3
nsp4
nsp5
nsp6
nsp7
nsp8
nsp9
nsp10
nsp11
nsp12
Slippary
sequence

231-9748

3172

74

-

73.8

-

73.86

-

73.85

-

74.09

-

231-1010
1011-2714
2715-3412
3413-4025
4026-4511
4512-4577
4578-5252
5253-5402
5253-7330
7331-8731
8732-9388
9389-9742

260
568
232
204
162
22
225
50
693
467
219
118

78.16
65.55
75.74
74.37
78.37
82.47
76.2
74.48
75.38
75.8
74.83
73.27

88.41
70.72
90.19
37.81
91.86
92.33
93.18
94.7
44.62
90.63
84.95
85.31

77.35
65.6
75.7
73.45
77.05
79.55
76.15
74.7
75.25
75.8
75.55
73.3

89.4
71
89.7
35.8
92
90.9
94.2
92
43.8
89.5
84.95
86.6

89.12
65.16
75.18
75.74
76.7
89.56
76.56
75.46
75.34
75.68
74.56
73.92

77.2
69.6
89.2
40.1
92.48
95.5
94.7
91.62
43.34
90.6
84.68
85.96

77.9
65.68
76.65
73.86
77.45
84.8
75.2
78.7
75.65
75.15
74.08
73.3

87.8
71.55
90.3
40.1
90.55
95.5
92.53
94
44.58
90.75
85.7
85.7

78.57
65.62
75.71
74.21
79.18
90.9
76.32
73.24
75.34
75.98
74.99
73.08

88.23
70.81
90.5
37.33
91.97
80.3
92.79
96
45.08
90.74
84.86
84.9

5398-5404

-

-

-

-

-

-

E
GP2
GP3
GP4
ORF5a
GP5
M
N
-

9748-9951
9821-10504
10303-10794
10697-11155
11109-11288
11143-11910
11898-12386
12310-12642
12643-12703

67
277
163
152
59
255
162
110
-

80.06
88.68
72.24
82.14
89.84
84.84
87.7
94.04
-

80.4
83.45
81.08
78.28
92.08
77.78
83.75
89.28
81.7

80.6
85.03
77.9
83.75
87.68
84.1
86.4
94.28
-

81.04
83.61
77.44
77.81
90.6
78.09
83.86
88.97
80

77.6
87.57
74.03
84.86
86.4
85.28
86.97
96.4
-

80.96
83.46
78.17
77.99
91.09
78.1
83.83
88.97
80.92

78.45
87.39
74.21
84.06
87.05
86.1
86.98
95.67
-

81.15
82.3
78.75
77.2
89.4
78.1
83.4
89.05
81.7

82.1
87.2
73.3
82.25
84.7
86.1
86.4
95.95
-

81.02
83.36
78.28
78.72
92.72
78.34
83.98
88.68
83.3

Supplementary table 3.5. Percent homology (%) of nucleotide and amino acid
sequences of EAV donkey VD7634 compare to 29 full-length EAV strains used for bar
graph
(A) nsp2

EAV
donkey
VD7634
CW01
CW96
F27
F62
F63
F61
F60
S3583
S3817
S4216
S3685
S3854
S3711
S3712
S3699
S3961
S4333
S4227
S3886
S4421
S3943
S4445
S3861
S4007
S4417
HK25
HK116
Bucyrus
ARVAC

nt (%)

aa (%)

65.4
70.8
65.8
70.8
65.4
70.8
65.1
70.8
65
70.8
65.3
70.8
65
70.8
65.7
70.8
65.7
70.8
65.7
70.8
65.6
71
65.6
71
65.5
71
65.5
71
65.7
70.6
65.7
70.6
65.6
70.6
65.5
70.8
65.6
71.7
65.6
71.7
65.7
71.5
65.7
71.3
65.6
70.1
65.5
69.5
65.7
69.3
65.7
68.8
65.6
70.3
65.7
71
65.7
71
1900.9 2050.8
65.5483 70.7172

(B) GP3
EAV
donkey
VD7634
CW01
CW96
F27
F62
F63
F61
F60
S3583
S3817
S4216
S3685
S3854
S3711
S3712
S3699
S3961
S4333
S4227
S3886
S4421
S3943
S4445
S3861
S4007
S4417
HK25
HK116
Bucyrus
ARVAC

(C) Partial GP5
nt (%)

aa (%)

79.4
73.9
78.1
72.7
79.4
73.7
77.3
70.5
77.3
71.1
77.8
72.1
79.6
73.8
77.7
74.3
77.7
74.3
77.7
74.3
77.5
74.3
77.5
74.3
77.1
73.7
77.3
73.7
77.3
74.3
77.3
74.3
77.7
74.3
77.6
73.7
77.5
74.3
77.5
73.7
77.5
74.3
77.5
74.3
76.9
73.1
77.3
73.1
77.3
74.3
81.2
78.2
80.9
78.2
81.4
78.2
80.8
77.0
2267.1
2152
78.17586 74.2069

188

EAV donkey
VD7634
RSA J7-931125
RSA J3-931209
RSA J2-931125
RSA J1-931125
RSA J6-940309
RSA J5-940309
RSA J4-931209
Italy 3308V/96
Italy 1489V/96
CW01
CW96
F27
F62
F63
F61
F60
S3583
S3817
S4216
S3685
S3854
S3711
S3712
S3699
S3961
S4333
S4227
S3886
S4421
S3943
S4445
S3861
S4007
S4417
HK25
HK116
Bucyrus
ARVAC

nt (%)

aa (%)

81.5
93.4
81.5
93.4
81.5
93.4
81.5
93.4
81.3
93.4
81.3
93.4
81.5
93.4
74.3
86.7
74.7
86.7
74.1
85.5
75.3
85.5
73
84.3
73.6
84.3
73.9
84.3
74.3
84.9
74.3
84.9
74.7
84.9
75.1
85.5
74.7
85.5
74.3
84.9
74.3
84.9
74.3
84.9
74.3
84.9
74.3
84.9
74.7
85.5
74.5
84.9
74.7
84.9
74.1
85.5
74.4
85.5
74.5
84.9
74.1
84.3
74.3
84.9
73.9
83.1
74.5
84.9
73.7
83.7
73.4
82.5
73.9
84.3
72.2
80.7
2870.5
3280.9
75.53947 86.33947

Supplementary table 3.6. Comparative amino acid substitutions of ORF5 of EAV
donkey VD7634 to 29 full-length EAV strains and SNT result mAb that explains Figure
3. 4.

Specific
Amino
Amino acid substitution
Amino acid
amino acid
acid
substitution
EAV other
substitution change
Donkey
position
strains/isolates
site in GP5 numbers

aa 49
(site A)

None

aa 61
(site B)

1

aa 67-90
(site C)

13

61

67

-

K

E

?
Q
R
F
V

E
E
E
E
E

V

T

E
?
T

T
T
T

All of EAV S numbered isolates and French strains are very different to EAV
donkey VD7634 strain
EAV S3817, S4227, S4216, S3961, S4417, S4445 and S4007 isolates
EAV F60 strain (? Is undetermined amino acid sequence from GenBank)
NA and CW strains 100% identity to EAV donkey VD7634 strain

All of EAV S numbered isolates and NA strains are very different to EAV
donkey VD7634 strain
EAV F61-63 straisn (? Is undetermined amino acid sequence from GenBank)
EAV F27 strain
EAV F60 strain
EAV CW01 isolate
EAV CW96 isolate

P

L

EAV ARVAC strain

70

N

D

EAV S4417 and S4007 isolates

71

D

E

EAV CW01 isolate

72

K

Q

EAV ARVAC strain

73

I

V

?
V

V
V

D

G

G

G

81

D

N

EAV HK116, HK25, and ARVAC (laboratory NA strains)

82

D

N

N

N

Rest of all strains are different to EAV donkey VD7634 strain
EAV S3817, S4216, S3961 and S4417 isolates and F60-61 strains are 100%
identity to EAV donkey VD7634 strain

84

D
I
F
Y

Y
Y
Y
Y

EAV S4007 isolate
EAV F27, F60-63 strains and CW01 isolate
EAV CW96 isolate
Rest of all EAV strains are 100% identity to EAV donkey VD7634 strain

85

T
A
S

S
S
S

EAV S4007 and S4445 isolates
EAV F27, 60-63 and NA strains
Rest of all EAV strains are 100% identity to EAV donkey VD7634 strain

89

A

S

S

S

T

V

E

V

?

V

L
V

V
V

all S numbered EAV isolates are different to EAV donkey VD7634 strain
All EAV NA strians (HK25, HK116, Bucyrus and ARVAC) are differnet to EAV
donkey VD7634 strain
EAV F62 and F63 strains (? Is undetermined amino acid sequence from
GenBank)
EAV F27 strain
EAV F60, F61, CW01, CW96 are 100% identity to EAV donkey VD7634 strain

G

S

EAV HK116 and ARVAC strains are differnet to EAV donkey VD7634 strain

S

S

Rest of all EAV strains are 100% identity to EAV donkey VD7634 strain

101

V
T

T
T

Rest of all strains are very different to EAV donkey VD7634 strain
CW96 and CW01 strains are 100% identity to EAV donkey VD7634 strain

104

G
D

D
D

EAV HK116 and ARVAC strains
Rest of all EAV strains are 100% identity to EAV donkey VD7634 strain

106

V
M

M
M

EAV ARVAC strain
Rest of all EAV strains are 100% identity to EAV donkey VD7634 strain

90

4

-

69

79

aa 98-106
(site D)

Variant sequences of EAV strains (Description)

100

S3699, S3861, S3712, S3711, S3854, S3685, S3583, S3886, S3817, S4216,
S4007, F60 and NA strains are very different to EAV donkey VD7634 strain
EAV F61 strain (? Is undetermined amino acid sequence from GenBank)
Rest of all EAV strains are 100% identity to EAV donkey VD7634 strain
Rest strains are very different to EAV donkey VD7634 strain
EAV S3886, S4421 and CW strains are 100% identity to EAV donkey VD7634
strain

All EAV NA strians (HK25, HK116, Bucyrus and ARVAC) are differnet to EAV
donkey VD7634 strain
Rest of all EAV strains are 100% identity to EAV donkey VD7634 strain
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APPENDIX 4
Experimental Methods
Our standard laboratory protocol for commonly used tissue culture media recipes
Rabbit kidney-13 high passage and low passage from Dr. William McCollum, UKY
Laboratory designated name: RK-13 HP #399-409 and RK-13 LP #194-204
Eagle’s minimum essential medium (EMEM;
500 mL
with Earle’s salts and L-glutamine; GIBCO# 11095-080)
Cosmic calf serum 10% (HYCLONE# SH30087.03)
50 mL
Penicillin and streptomycin (GIBCO# 15140-122)
5 mL
Rabbit kidney 13 (ATCC# CCL-37)
Laboratory designated name: CCL-37-RK13
Eagle’s minimum essential medium (EMEM;
with Earle’s salts and L-glutamine; GIBCO# 11095-080)
Fetal bovine serum 10% (FBS; HYCLONE# SH30396.03)
Penicillin and streptomycin (GIBCO# 15140-122)
1.0 mM Sodium pyruvate (100 mM [100X]; GIBCO# 11360-070)
0.1 mM Non-essential amino acids (10 mM [100X]; GIBCO# 11140-050)
Equine pulmonary artery endothelial cells (EPAEC)
Laboratory designated name: EPAEC, currently EEC
Dulbecco’s modified Eagle medium (DMEM;
With high glucose [4.5 g/L], without L-glutamine; CELLGRO# 15-013-CM)
Fetal bovine serum 10% (FBS; HYCLONE# SH30396.03)
Penicillin and streptomycin (10,000 U/mL and μg/mL; GIBCO# 11140-050)
0.1 mM Non-essential amino acids (10 mM [100x]; GIBCO# 11140-050)
2 mM L-glutamine (200 mM [100X]; GIBCO# 25030)
Equine derm cells (ATCC# CCL-57)
Laboratory designated name: ED (Equine derm)
Eagle’s minimum essential medium (EMEM;
with Earle’s salts and L-glutamine; GIBCO# 11095-080)
Fetal bovine serum 10% (FBS; HYCLONE# SH30396.03)
Penicillin and streptomycin (GIBCO# 15140-122)
1.0 mM Sodium pyruvate (100 mM [100X]; GIBCO# 11360-070)
0.1 mM Non-essential amino acids (10 mM [100X]; GIBCO# 11140-050)
Baby hamster kidney-21 (ATCC# CCL-10)
Laboratory designated name: BHK-21
Eagle’s minimum essential medium (EMEM;
with Earle’s salts and L-glutamine; GIBCO# 11095-080)
Fetal bovine serum 10% (FBS; HYCLONE# SH30396.03)
Tryptose phosphate broth (TPB)
Penicillin and streptomycin (GIBCO# 15140-122)
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500 mL
50 mL
5 mL
5 mL
5 mL

1L
110 mL
11 mL
11 mL
10 mL

500 mL
50 mL
5 mL
5 mL
5 mL

500 mL
50 mL
50 mL
5 mL

Cell lines grown with EMEM 10% FSCS in incubator without CO2
Rabbit kidney-13 high passage and low passage (RK-13 HP #399-409 and RK-13 LP
#194-204) from Dr. William McCollum, UKY, Equine derm cells (ATCC Cat# CCL-57)
and Baby hamster kidney-21 (ATCC Cat# CCL-10)
10 L stock cell culture media, EMEM 10% FSCS
Materials
Eagle’s minimum essential medium (EMEM;
10 L/bottle
NEAA, L-glutamine; MEDIATECH #50-011-PB; 10 L/bottle)
Ferritin supplemented calf serum (FSCS; HYCLONE# SH30072.03)
1,000 mL
Penicillin and streptomycin (10,000 U/mL and μg/mL; GIBCO# 11140-050)
100 mL
Fungizone (SIGMA A-9528; one vial)
10 mL
Fungizone (Amphotericin B; 1,000 μg/mL)
50 mg
Sterile distilled water
50 mL
Dissolve fungizone in dH2O and dispense in 10 mL aliquots. Store at -20°C
Unreconstituted vial should be stored at 4°C
Sodium bicarbonate (NaHCO3; SIGMA# S5761-500 g)
6.0 g
Glass fiber prefilter (MILLIPORE# AP2012450)
Durapore® membrane filters (0.45 μm; MILLIPORE# HVLP14250)
Materials in order
EMEM
NaHCO3
Penicillin and streptomycin
Fungizone (Amphotericin 1,000 μg/mL)
Ferritin supplemented calf serum (FSCS)
dH2O (tissue culture grade water)

96.1 g
6.0 g
100 mL
10 mL
1,000 mL
q.s. to 10,000 mL

Method
1. Autoclave and sterilize the containers, filter with membrane filters, hose, 12
bottles (1 L).
2. Add 8 L dH2O to 12 L bottle wit stir bar.
3. Place on stirrer/hotplate and turn stirrer to setting #3. Make sure stir bar is
standing middle in the bottom of 12 L bottle.
4. Add EMEM bottle quickly without losing powder. Rinse twice with dH2O. Let it
mix well until dissolved in about 15 min.
5. Add sodium bicarbonate (color should change from yellow to red), penicillin and
streptomycin, fungizone and serum (rinse each container twice with dH2O).
6. Final concentration of penicillin and streptomycin 100 U/mL and 100 μg/mL and
fungizone 1 μg/mL.
7. Instead of #4-5, anti-anti (1 bottle [100X GIBCO# 15240]) can be used.
8. Add dH2O to 10 L and mix 5 min.
9. In cell culture room, filter through sterile Millipore filter unit using a prefilter.
Dispense 1 L/sterile 1 L bottle.
10. Perform sterility check. Store at 4°C.
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Carboxymethylcellulose (CMC) overlay media (1.3X EMEM 10% FSCS)
Materials
Carboxymethylcellulose, medium viscosity (SIGMA# C4888)
Distilled water (dH2O)

6.0 g
140 mL

Method 1
1. Add 140 mL of dH2O to a 1 L bottle (12), swirl while adding 0.75%
carboxymethylcellulose (CMC) and then shake if necessary.
2. Let stand (12 bottles) overnight at room temperature (shake occasionally).
3. Autoclave for 20 min at 121°C (liquid setting).
4. When cooled to approx. 40°C, add filtered 1.3X EMEM 10% FSCS to the 800
mL mark.
10L stock CMC overlay media (1.3X EMEM 10% FSCS)
Materials
EMEM
NaHCO3
Penicillin and streptomycin
Fungizone (Amphotericin 1,000 μg/mL)
Ferritin supplemented calf serum (FSCS)
dH2O (tissue culture grade water)

96.1 g
6.0 g
100 mL
10 mL
1,000 mL
q.s. to 7,800 mL

Method 2
Prepare method 1 a day before making the CMC stock
Prepare EMEM 10% FSCS by following the protocol except start with 6 L dH2O and q.s.
to 7.8 L
5. Shake the bottle to dissolve cooled carboxymethylcellulose dilution.
6. Perform sterility check. Store at 4°C.
7. Before using, add 0.8 mL gentamicin/bottle (working concentrationg – 50 μg/mL).
Virus transport medium
Hanks’s balanced salt solution with phenol red 1X (INVITROGEN# 14170112) 500 mL
HEPES buffer (final concentration 25 mM; INVITROGEN# 15630080)
20 mL
Bovine serum albumin V (final concentration 0.5%; SIGMA# A9647)
2.5 g
Antibiotic-Antimycotic (100X, Penicillin, Steptomycin & Amphotericin B;
5 mL
INVITROGEN# 15240112)
Gentamicin sulfate (final concentration 250 mg/L; CELLGRO# 30-005-CR)
2.5 mL
Freezing media
Dimethylsulfoxide (DMSO; SIGMA# D-2650)
EMEM 10% FSCS
Method
5 mL of DMSO + 95 mL of complete medium (depending on which cell lines)
Generally, 1 x 106 cell/mL DMSO/1vial
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10%
90%

Or
RecoveryTM cell culture freezing medium (GIBCO# 12648-010)
Cells from T-75 = averages 8.4 x 106 cells/mL DMSO/1vial, makes 5 vials
Dublecco’s phosphate-buffered saline (PBS)
Materials
PBS (GIBCO# 21600-069)
Sterile distilled water (dH2O)

95.5 g (1 bottle)
q.s. to 10,000 mL

Method
1. Add 9 L dH2O to 12 L bottle with stir bar. Place on stirrer/hotplate and turn stirrer
to setting #3. Make sure stir bar is standing middle in the bottom of 12 L bottle.
2. Add PBS bottle quickly (rinse twice with water) and mix for 10 min.
3. Distribute evenly into each 1 L bottle 1 L for about 800ml. Autoclave the PBS
contained bottles for 20 min at 121°C (liquid setting).
4. Cool bottles down to room temperature before tightening caps and labeling.
Perform sterility check. Store at room temperature.
Trypsin EDTA solution (0.5%)
Materials
PBS (sterile 1X)
Trypsin EDTA (no phenol red [10X]; GIBCO# 15400-054)

180 mL (900 mL)
20 mL (100 mL)

Aliquot out 45 mL in 50 mL conical tube and store at -20°C (for long term) and store at
4°C (for current use).
Guinea pig complement
Material
100 mL/bottle (ROCKLAND# C300-0100).
Method
Thaw and dispense (on ice) into 1 or 2 mL volumes and store at -70°C.
Antibiotics for cell culture
Gentamicin MEDIATECH# 30-005-CR
Gentamicin sulfate, 50 mg/mL, 10 mL/vial and store at 4°C
Fungizon SIGMA A-9528
Amphotericin B (1,000 μg/mL)
Aliquot out 11 mL in 15 mL conical tubes and store at -20°C
Penicillin/Streptomycin GIBCO# 11140-050
10,000 μg/mL Pen and 10,000 μg/mL Strep
Aliquot out 11 mL in 15 mL conical tubes and store at -20°C
Antibiotic-Antimycotic (Anti-Anti 100X) GIBCO# 15240
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L-Glutamine 100X GIBCO 25030
Aliquot out 11 mL in 15 mL conical tubes and store at -20°C
MEM NEAA 100X GIBCO 11140 MEDIATECH #50-011-PB
Aliquot out 11 mL in 15 mL conical tubes and store at -20°C
Miscellaneous
70% Ethanol
95% Ethanol
147 mL
368 mL
2,944 mL

dH2O
53 mL
132 mL
1,056 mL

Total
200 mL
500 mL
4,000 mL

Roccal
Maintain at 1:1200 dilution (20 mL of Roccal : 4 L of dH2O)
Our standard laboratory protocol for commonly used bacterial media recipes
Liquid media
LB Medium (Luria-Bertani Medium; 500 mL)
Materials
Deionized water
500 mL
Bacto-trypto
5g
Bacto-yeast extract
2.5 g
NaCl
5g
Method
1. Stir until the solutes have dissolved. Adjust the pH to 7.0 with 5N NaOH.
2. Sterilize by autoclaving for 20 min on liquid cycle.
Psi Broth (500 mL)
Materials
Bacto-trypto
Bacto-yeast extract
NaCl
5 mM MgSO4
10 nM KCl
dH2O
Autoclave liquid cycle 30 min.

5g
2.5 g
5g

to 500 mL

Media containing agar
LB Agar plates
Materials
Deionized water
Bacto-trypto
Bacto-yeast extract
NaCl

500 mL
5g
2.5 g
5g
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Method
1. Prepare LB medium according to the above recipe. Just before autoclaving, add
7.5 g of Bacto agar. Sterilized by autoclaving for 20 min on liquid cycle.
2. When the medium is removed from the autoclave, swirl it gently to distribute the
melted agar throughout the solution (need to be very careful, the media may bio
over when swirled). Allow the medium to cool to 45-50°C before adding
antibiotic*.
3. To avoid air bubbles, mix the medium by swirling. Pour 20-25 mL of medium in
a petri dish (use the tissue culture hood and florescent light should be off).
4. When medium has hardened completely, invert the plates and wrap in aluminum
foil and store them at 4°C until needed. The plates should be removed from
storage 1-2 hours before they are used and allow them to dry.
*Antibiotics solutions
Antibiotic
Ampicillin
Streptomycin
Tetracycline
Kanamycin
Carbenicillin
Chloramphenicol

Working concentration
50 μg/mL
50 μg/mL
50 μg/mL
50 μg/mL
50 μg/mL
170 μg/mL

Stock solutions should be stored at -20°C. Avoid repeated freezing thawing and exposure
to light. Magnesium ions are antagonists of tetracycline. Use media without magnesium
salts for selection of bacteria resistant to tetracycline.
Our standard laboratory protocol for commonly used solutions and buffers for
molecular biology
0.5 M EDTA (pH 8.0)
Deionized water
115 mL
EDTA (di-sodium)
27.918 g
5N NaOH
15,825 μL
Bring the volume to 150 mL with deionized water
5.0 M Sodium chloride
NaCl
Distilled water
1M Tris HCl(pH 8.0)
Tris HCl
4.44 g/1 mL
88.8 g/1 mL
8.88 g/100 mL
17.76 g/200 mL

29.22 g
100 mL

Tris base
2.65 g/1 mL
53.0 g/1 mL
5.30 g/100 mL
10.6 g/200 mL
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Molarity
0.05 M
1.0 M
1.0 M
1.0 M

1M Tris HCl (per liter)
Tris base
Add deionized water to 800 mL
Desired pH
pH 7.4
pH 7.6
pH 8.0
Add deionized water to 1 L
TE buffer
pH 8.0
10 mM Tris HCl (pH 8.0)
1 mM EDTA (pH 8.0)

121.1 g
Volume of HCl
70 mL
60 mL
42 mL

pH 7.6
10 mM Tris HCl (pH 7.6)
1 mM EDTA (pH 8.0)

pH 7.4
10 mM Tris HCl (pH 7.4)
1 mM EDTA (pH 8.0)

TAE (Tris-acetate; 50X concentrated stock solution [per L])
Tris base
Glacial acetic acid
0.5 M EDTA (pH 8.0)
Deionized water
Working concentration 1X (dilute 10 mL in 490 mL of deionized water)

242 g
57.1 mL
100 mL
q.s.

TAE (50X to 1X)
50mL of 50X TAE buffer + 1960 mL dH2O = 2 L
TAE (10X to 1X)
200 mL of 50X TAE buffer + 1800 mL of dH2O = 2 L
100 mL of 50X TAE buffer + 900 mL of dH2O = 1 L
50 mL of 50X TAE buffer + 450 mL of dH2O = 500 mL
Ethidium bromide (EtBr; 10 mg/mL)
Method
1. EtBr in agarose: 5.0 μL of EtBr (10 μg/μL) solution per 100 mL of agarose.
2. EtBr staining solution (1XTAE with 0.5 μg/mL EtBr): 25 μL of EtBr stock
solution in TAE buffer.
25 bp ladder (INVITROGEN# 10597-011)
25 bp DNA ladder (1 μg/μL)
6X loading buffer
Nuclease free water

50 μL
100 μL
450 μL

100 bp ladder (INVITROGEN# 15628-019)
100 bp DNA ladder (1 μg/μL)
6X loading buffer
Nuclease-free water

50 μL
100 μL
450 μL

196

1 Kb ladder (INVITROGEN# 15615-024)
1 Kb plus DNA ladder (1 μg/μL)
6X loading buffer
Nuclease-free water

50 μL
100 μL
450 μL

PCR products
PCR products
6X loading buffer

10 μL
2 μL

PCR products to estimate concentration
PCR products
6X loading buffer
Nuclease-free water

2 μL
2 μL
8 μL

Our standard laboratory protocol for commonly used stains
Crystal violet stain (10X stock solution)
Crystal violet (MALLINCKRODT# 8839)
12 g
Methanol (FISHER# A412-20)
600 mL
Method
Large volume of crystal violet (10X stock)
1. Measure 1200 mL of methanol, add 24.0g of crystal violet
2. Stir well with a pipet. Aliquot equally 400 mL to 1 L bottles (3)
3. Store at room temperature
Crystal violet stain (working solution)
1 part of crystal violet (stock solution)
9 parts of 10% buffered formalin (FISHER 23-245-685)

100 mL
900 mL

Our standard laboratory protocol for commonly used antibodies
EAV specific antibodies
Monoclonal antibodies
Protein specificity/epitope location
5G11
GP5/102 and 104 [D]
6D10
GP5/99 [D]
7E5
GP5/102 [D]
10F11
GP5/ND [D]
1H7
GP5/49 [A]
1H9
GP5/69 [C]
5E8
GP5/61 [B]
6A2
GP5/69 [C]
7D4
GP5/69 [C]
10B4
GP5/62-101 deleted [C and D]
Control monoclonal antibodies
3E2
N
12A4
nsp1
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Polyclonal equine sera
Anti-ARVAC
Anti-VBS
Anti-KY84
Anti-CW96
Anti-EAV NVSL positive
Anti-EAV NVSL negative

NA
NA
NA
NA
NA
NA

Our standard laboratory protocol for commonly used for tissue culture techniques
Maintenance of continuous cell line
Materials
Trypsin EDTA (keep in the water bath for few min at 37°C)
Confluent T-75 flask of cells
Appropriate cell culture medium
Method
1. Check the cell under the microscope to verify cells are confluent and ready to be
passaged (3-7 days old).
2. Pour off media from the flask.
3. Rinse cells 2-3 times with PBS (pH 7.4).
4. Add 1 mL (25-cm2 flask; T-25), 2 (3) mL (75-cm2 flask; T-75), 4 (5) mL (150-cm2
flask; T-150) trypsin-EDTA, and rock gently for 30 sec, then let the flask(s) sit at
room temperature for 1 min.
5. Pour off trypsin-EDTA (optional) and incubate the flask(s) another 7-8 min at
37°C.
6. When cells are visualized on the bottom of flask, bang the flask hard to remove
cells.
7. (Option) Add media (T-25: 5 mL; T-75: 10 mL; T150: 20 mL) into flask and
aliquot out into conical tube. Centrifuge it at 800 rpm for 5 min to get the cell
pellet. Throw the media out in the conical tube and break the pellet cell by collide
with pipet tube. Add fresh EMEM media (T-25: 8 mL; T-75: 10 mL; T-150: 20
mL) and mix it well to evenly distribute 1:5 dilution of the cell into new flask. Fill
up the fresh EMEM media to appropriate amount of media up to 10 mL (T-25),
30 mL (T-75), 60 mL (T-150).
8. Add appropriate amount of media (EMEM 10% FSCS for 1:5 split) up to 10 mL
(T-25), 30 mL (T-75), 60 mL (T-150).
Once a week split cells: 150-cm2 flask with confluent RK-13 cells is made up to approx.
300 - 335 mL EMEM 10% FSCS.
10 mL (T-25), 30 mL (T-75), 60 mL (T-150)
Note: to get a confluent monolayer within 24-36 hours transfer 2 mL of cell suspension
into a T-75 flask and add 20 mL of complete medium to the flask (1:5 split).
Generally one T-75 flask is sufficient to seed five 96-well plates for neutralization or
microtitration assays.
For specific cell lines: One T-75 flask of RK-13 cells (confluent) is sufficient within 3-4
days for 96-well plates.
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Freezing cells
Materials
Freezing medium
Cells in log phase of growth
Trypsin EDTA (keep in the water bath for few min at 37°C)
NalgeneTM Cryo 1°C freezing container (NALGENE# 5100-0001)
Method
1. Pour off the media.
2. Add 3-4 mL of trypsin EDTA solution and rinse the cells (this is to remove the
fetal bovine serum).
3. Add 3-4 mL of fresh trypsin EDTA solution and leave it for 3-4 min (preferably
at 37°C) and bang on the flask to detach the cells from the surface.
4. Add 10-12 mL of complete medium (the medium contains 10% fetal bovine
serum and this will inhibit trypsin) and pour into a 50 mL conical tube.
5. Centrifuge at 1,100 or 1,300 rpm (200 x g) in a tabletop centrifuge for 5 min at
25°C.
6. Aspirate the supernatant and resuspend the cell pellet in freezing medium at
approx. 107 cells/mL.
7. Freeze cells first in NalgeneTM Cryo 1°C freezing container with isopropanol at 80°C for 1 day.
8. Transfer frozen cell vials to liquid nitrogen container.
Recovery of frozen cells
Materials
Frozen cells (-70°C) in aliquots
Growth medium
Method
1. Rapid thawing of the cells is necessary. Thaw the cells in the water bath at 37°C,
by swirling the tube (do not submerge the lid to avoid contamination of the cells).
2. Resuspend in 15 mL of growth medium and centrifuge at 1,200 or 1,300 rpm (200
x g) in a tabletop centrifuge for 5min at 25°C.
3. Aspirate the supernatant and resuspend the cells in 10 mL of growth medium.
Transfer the cell suspension into a T-75 flask and add 10 mL of medium. Incubate
at 37°C for 2-3 days.
Our standard laboratory protocol for commonly used classical virology techniques
Processing of nasal swabs for virus isolation
Materials
10 mL syringes
Autoclaved plastic forceps
0.45 μm syringe filter CORNING#431220 or MILLIPORE Millex#SLHA033SB
1.7 mL screw cap tubes SARDSTEDT# 72.694.996 (color) #72.694.006 (clear)
15 mL conical tubes
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Method
1. Thoroughly swab the nasopharyngeal area with a sterile rayon swabs (1/2” x 1”)
with plastic shafts (16”).
2. After collection, the rayon tip of each swab is cut off into 7 mL of virus transport
medium (Hank’s balanced salt solution with penicillin, streptomysin, gentamicin
sulfate and amphotericin B; LIFE TECH).
3. Squeeze the swab to recover maximum amount of media and centrifuge at 300 x g
for 10 min to remove debris.
4. Transfer individual nasal swabs in transport medium to the barrel of a 12 mL
disposable syringe and express through 0.45 μm syringe filter (Millipore).
5. Collect the filtrate into a 15 mL conical tube. Bring up the sample volume to 7
mL with plain MEM to normalize samples (e.g. after filtration usually approx. 6
mL is recovered). Leave approx. 2 mL for virus isolation and aliquot the
remaining filtrate (approx. 1 mL x 2) into tubes. Freeze at -70°C until tested.
6. Aspirate off media from confluent RK-13 cells in 6-well plates and inoculate 500
μL specimen/well in duplicate.
7. Incubate plates at 37°C in presence of 5% CO2 for 1-2 hours.
8. Add 10 mL CMC overlay to each flask and incubate at 37°C in the presence of 5%
CO2 for 5 days.
9. Do second passage on day 4 using the same cells. Stain cells on day 5 with crystal
violet. Archive the TCF at -80°C.
Processing of buffy coat for virus isolation (without gradient purification)
Method
1. Draw blood by venipuncture into vacutainer tubes containing sodium citrate or
EDTA and mix thoroughly.
2. Allow blood to stand for 1-2 hours or sediment at 600-700 rpm (100 x g) for 10
min at 4°C. Remove layer and sediment at 2,000 rpm for 10 min at 4°C. The few
red blood cells in pellet cause no apparent concern.
3. Aspirate off supernatant; resuspend pellet in 5 mL EMEM 10% FSCS and vortex
thoroughly. If desired, pellet can be washed with PBS before resuspending in
EMEM media. Freeze or inoculate.
4. Process as in steps 5-8 above.
For buffy coat from the EDTA tube
1. Centrifuge 700 rpm for 10 min at 4°C. You will see plasma, white blood cells
and red blood cells from top to bottom in the tube.
2. Centrifuge 2,000 rpm for 10 min at 4°C.
3. Remove yellow top plasma and save white blood cells at the bottom (pellet
cell).
4. Add 5 mL of media, mix it well.
5. Aliquot out 0.5 mL for DNA extraction and save rest.
6. 1 mL goes for RK-13 LP, RK-13 HP and EEC cells for virus isolation.
Collecting PBMC from buffy coat
Peripheral blood mononuclear cell (PBMC)
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1.
2.
3.
4.
5.
6.

Spin the sample at 700 rpm for 10 min (1st).
Remove plasma only.
Spin plasma for 1,900 rpm for 10 min (2nd).
Pour out the plasma. Break and mix PBMC (pellet cell) with MEM.
Aliquot out in 1.5 mL tube.
Freeze at -80°C.

Serum processing
Materials
Vacutainer needles
Vacutainer adapters (TERMUNO, VENOJECT II# P-1316R)
15 mL BD vacutainer tubes (KENDALL MONOJECT [no additive]# 8881 301819)
1.7 mL screw cap tubes (SARDSTEDT# 72.694.006)
Transfer disposable pipets for serology (SAMCO SCIENTIFIC# 202-1S)
Methods
1. Collect blood into vacutainer tubes via jugular venipuncture (about 15 mL blood).
2. Transport blood tubes to the lab. Spray tubes with diluted Roccal-D (1:200).
Rinse tubes and dry with paper towel. Let stand at room temperature for 4-5 hours
or for 1 hour at 37°C (water bath works faster).
3. Sediment blood cells at 2,000 rpm (300 x g) for 10 min.
4. Collect serum and aliquot into tubes (1.4 mL x 4). Freeze at -20°C until tested for
virus or antibody.
5. Process as in steps 5-8 above.
Virus isolation from semen
Protocol
1. Thaw 15 mL tube containing semen sample in warm tap water, then place on ice.
2. Label 8 flasks (T-25) [4 RK-13 (KY) ”high passage” and 4 RK-13 (ATCCCCL37)”low passage”]/semen, 2x10-1, 1x10-2, 1x10-3 for high passage and 2x10-1,
1x10-2, 1x10-3 for low passage.
3. Sonicate (output 20 #4.5 on dial) samples on ice 3 x 15 sec; let vials set on ice for
15 sec. 1 min between sonications (dilute small volumes to 5 mL). Clean
sonicator probe with 95% EtOH 2X between each sample. Spin 300 x g (1,900
rpm) for 10 min to remove sperm and debris, save and use supernatant (SSP).
4. Set up 3 tubes (10-1 to 10-3) for each sample, 4.5 mL EMEM 10% FSCS per tube.
5. Aspirate off media from T-25 (3-6 day old RK-13 monolayers). Do not rinse.
Make 10-1 (0.5 mL sample in 4.5 mL diluent), vortex; with new pipet add 0.5 mL
of 10-1 to tube #2 (10-2) and 1 mL to each of 4 flasks marked 10-1. Continue the
same way with dilutions 10-2 and 10-3 (2 flasks each).
10-1
(2.7) 4.5 mL EMEM
(0.3) 0.5 mL SSP

10-2
(2.7) 4.5 mL EMEM
(0.3) 0.5 mL SSP
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10-3
(2.7) 4.5 mL EMEM
(0.3) 0.5 mL SSP

6. Incubate all flasks at 37°C in air incubator (incubator without CO2) with caps
closed for 1 hour (2 hours maximum).
7. Add 10 mL of CMC overlay to each flask and incubate at 37°C in air incubator
(incubator without CO2) with caps closed.
8. Check for CPE on day 4. If bacterial contamination occurs, redo after
bacteriological examination and sensitivity testing to find out which antibiotics to
used in the tissue culture media. Repeat test as above and also note contamination.
Specimen may be filtered through a 0.45 μm filter using 5 or 10 cc syringe, if
necessary.
9. If negative, a second passage is performed on day 4 (2nd passage).
10. If sample is toxic, this material is passaged as is (2nd passage).
11. If positive, supernatant is usually harvested from a 10-2 flask showing viral
activity (store at -20°C) and a reverse SNT is performed against known positive
and negative sera (see reverse SNT).
12. After 5 days harvest supernatant from flasks and stain flasks with crystal violet
using 2 mL crystal violet (working stock). Stain 1-24 hours, remove stain, rinse
flasks with tap water and read.
13. All semen samples are placed in freezer zip lock storage bags and stored at -70°C.
14. Permanently store negative SSP at -20°C and positive SSP at -70°C.
Second passage
1. Aspirate media from 2 “high passage” and 2 “low passage” confluent 3-5 day old
RK-13 cells in T-25 flasks for each negative semen sample.
2. From 2 flasks of 10-1 passage #1 take up 0.5 mL from each with same pipet (1 mL)
and add 1 mL to the new flask for each high and low passage. Do the same for 102
passage #1, taking up 1 mL from each. Do 10-1 to 10-2 only. Close caps and
incubate at 37°C for 1-2 hours (minimum 1 hour) in air incubator.
3. Add 10 mL of CMC overlay to all flasks, close caps, and incubate at 37°C in air
incubator (without CO2).
4. Read after 3-4 days.
5. After 4 days, harvest media and stain flasks (see passage #1).
Preparation of working virus stock
Materials
EAV
Five confluent monolayers of RK-13 cells in T-150 flasks
EMEM
RK-13 medium
50 mL conical centrifuge tubes
Freezing vials
Method
1. Inoculate monolayers with EAV at an m.o.i. of 1. Resuspend the virus in
approximately 50 mL of serum-free MEM and add 10 mL per T-150 flask.
2. At the same time mock infect one T-75 flask of RK-13 cells.
3. Adsorb for 1 hour at 37°C.
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4. Add 40 mL of complete RK-13 medium / T-150 flask. Incubate at 37°C for 48
hours or until 95-100% CPE.
5. Centrifuge at 5,000 g (or 3,000 rpm in the tabletop centrifuge) at 4°C for 15 min.
6. Make 1.8 mL and 0.5 mL aliquots of supernatant and store at -70°C.
7. Use one 0.5 mL frozen vial to titrate the virus.
Preparation of high titer virus stock
Method
1. Seed cells into 3, triple-deck flasks and grow until confluent.
2. Remove the medium and leave approx. 50 mL of complete medium
contaminating 10% fetal bovine serum. Add 500 μL/mL of virus per flask. If the
titer of the virus is known use an m.o.i. of 1 (higher m.o.i. will may produce
deletion mutants).
3. Adsorb for 1 hour at room temperature on the orbital shaker.
4. Add 20-40 mL of complete medium containing 10% fetal bovine serum and
incubate at 37°C for 3-4 days. Check for signs of infection 2 days after the start of
infection.
5. Pellet down the cellular debris (3,000 rpm/4°C/15 min) and aliquot into freezing
vials and store at 4°C (stable for up to 6 months) or -70°C (for long term storage).
Virus should be stored away from the fluorescent lights since the virus titer
appears to decrease when exposed to fluorescent light for a prolonged period of
time.
6. Determine the virus titer using the plaque assay procedure.
Microtitration assay for estimation of virus titers
Materials
96-well microtitration plates (FALCON#3072)
Sterile snap cap tubes (FISHER or FALCON#2054)
Multi channel pipette (8 or 12 channels)
Antiserum or ascetic fluid (monoclonal antibodies)
Negative control serum or control ascetic fluid
EMEM (BIOWHITTAKER)
Complete RK-13 medium
Confluent RK-13 cells (one T-75 flask is sufficient for five 96-well plates)
Virus stock to be titrated
Crystal violet staining (working solution)
Method
1. Each test virus is done in triplicate. Label the 96 well plates with cell controls.
2. Dilute the test virus from 10-1 to 10-8 in EMEM (10-fold serial dilution). Use 200
μL of virus and 1800 μL of EMEM.
10-1
1800 μL EMEM
200 μL Virus

10-2 ...Continue... 10-8
1800 μL EMEM
1800 μL EMEM
200 μL Virus
200 μL Virus
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3. Add 50 μL of EMEM to all the wells except to control wells (column 10, 11 and
12) where 100 μL of EMEM should be added.
4. Trypsinize a confluent T-75 flask or RK-13 cells and resuspend the pellet in 10
mL of RK-13 cell medium. Take 2 mL of the cell suspension and resuspend in 10
mL (1:5) of RK-13 medium (or 4 mL in 20 mL would be better. This gives
enough volume to work).
5. Add 50 μL of diluted virus to test wells in triplicate. Start with the highest dilution
(10-8) and go to the lowest dilution (10-1; therefore, can use the same pipet tip).
6. Add 100 μL of resuspended RK-13 cells to each well. Incubate at 37°C for four
days.
7. Feed the plates with 50 μL of growth media on day 2 and day 3 (if necessary) to
maintain monolayers.
8. When CPE occurs (usually 4 days), dump out the media into infectious waste
container and stain with crystal violet (1X working solution) for 20-30 min and
then wash gently with tap water to remove excess crystal violet (three times). Air
dry plates and determine titer by Reed and Munch method.
9. 50% end point values, by Reed and Munch Method. Underlined numbers indicate
logarithmic characteristic of end point dilution. In triplicates.
3 – 2 – 0 – 0 = 0.25
3 – 1 – 2 – 0 = 0.5
3 – 2 – 1 – 0 = 0.5
3 – 1 – 3 – 0 = 0.2
3 – 2 – 2 – 0 = 0.0
3 – 0 – 0 – 0 = 0.5
3 – 2 – 3 – 0 = 0.3
3 – 0 – 1 – 0 = 0.7
3 – 1 – 0 – 0 = 0.75
3 – 0 – 2 – 0 = 0.8
3 – 1 – 1 – 0 = 0.0
3 – 0 – 3 – 0 = 0.0
10. Report virus titers as TCID50 per 50 μL.
Plaque assay
Materials
6-well plates
RK-13 cells
Carboxymethylcellulose (CMC) overlay media (1.3X EMEM 10% FSCS)
Virus for titration
Method
1. Prepare RK-13 cell in 6-well plates
2. Make virus dilution (10-1 to 10-8) in complete 10% EMEM growth media.
3. Aspirate the medium and add 200 μL of diluted virus to each well in duplicate
(start from 10-8 and go to 10-1). Mix gently by rocking the plate.
4. Incubate the plate at 37°C for 1 hour to allow virus particles to adsorb into cells.
5. Following 1 hour incubation period, overlay cells with 4 mL (per well) of CMC
overlay media adding to the side of the plate.
6. Allow plates to sit undisturbed on a leveled surface for 4 days until visible
plaques develop.
7. After 4 days, discard supernatant and stain with crystal violet staining solution.
8. Count >10 to <100 plaques per well.
9. PFU/mL – (number of plaques in each well [duplicate]/2) x (highest dilution that
gives number of plaques) x (dilution factor).
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10. E.g. [(25 + 30)/2] x 10-5 x 5 (200 μL) = 137.5 x 10-5 = 1.37 x 10-7 PFU/mL.
Our standard laboratory protocol for commonly used serology technique
Serum neutralization test (SNT)
Method
1. Inactivate sera at 56°C for 30 min.
2. Label plate, tube after calculate working dilution depends on result of 200 TCID50
titration. Ex) 50 μL x 96 well plate = 4800 μL = 5 mL / plate needed
Ex) Virus: 105.5 200 TCID50 / 50 μL
200/1E5.5 (log10) -3.19 (round up to -3.20) = 1E3.20 = 1584 = 1/1600
3. Dilute the virus to 1/1600 for total volume: 30 mL (4 plates)
1/100
(1/10) 1/100 (1/4) 1/400 (1/2) 1/800 (1/2) 1/1600
200 μL Virus 1 mL
5 mL
10 mL
15 mL
1800 μL MEM 9 mL
15 mL
10 mL
15 mL
4. Prepare back titration (virus working dilution [w])
10-1
10-2
10-3
100 μL Virus
900 μL
900 μL
900 μL MEM
100 μL
100 μL
5. Label 4 plates, depends on number of antibodies. Antibody dilution starts at 1:4.
Duplicate the antibody and virus. Triplicate may used including toxicity control.
1
2
3
4
5
6
7
8
9
10
11
12

A B C D E
1:16
1:32
1:64
1:128
1:256
1:512
1:1024
1:2048
1:4096
1:8192
1:16384
1:32768

F

G H

A B C D E F G H
1 Back titration Cell control
2 w -1 -2 -3
3
4
5
6
7
8
9
10
11
12

6. Add 50 μL of 1XMEM to plate, except add 100 μL on cell control by using
multichannel pipet (6 or 12 channels).
7. Add 50 μL acitis (Ab) by single channel pipet individually. Then, mix 10 times by
multichannel pipet.
8. Add 50 μL virus (final working dilution).
a. Pour working dilution stock into reservoir.
b. Load with multichannel pipet.
9. Incubate 30 min at 37°C in CO2 incubator.
10. During incubation, prepare cells (use 10% EMEM FSCS).
a. 30 mL for 1 T-75 flask will make 4 plates.
b. 40 mL for 4 T-25 flask will make 4-5 plates.
11. Pour cells in reservoir. Use multichannel pipet.
a. Add 50 μL to plates.
b. Except, add 100 μL to cell control.
12. After 24 hour incubation, add 50 μL of EMEM FSCS to all plates.
13. Stop assay when working dilution (w) is showing 100% CPE.
205

Virus neutralization test (VNT)
Method
1. Inactivate sera at 56°C for 30 min.
2. Put 25 μL of serum diluent (10% GP complement in EMEM 10% FSCS [keep on
ice until needs]) in all wells.
3. Put 25 μL of test serum to the first well of three rows (including row for checking
toxicity*). Dilute with 25 μL multichannel pipet.
4. Add 25 μL of virus (200 TCID50) diluted in EMEM 10% FSCS to all wells
except control (“see cell controls”).
5. Incubate plates at 37°C (5% CO2 incubator). Read after 48 hours, and do final
read at 72 hours.
“Cell controls”: positive or negative sera and virus titration controls
Cell controls: add 50 μL serum diluent to 2 wells.
Serum controls: add 25 μL serum diluent to 1 well/each test serum, add 25 μL test
serum. Known positive or negative serum: set up in same way as test sera.
Virus titration
Add 25 μL serum diluent into each of 4 wells for cell controls (Row#1).
Add 25 μL of working virus dilution to each of 4 wells (Row#2).
Add 25 μL of 1:10 dilution of working virus in EMEM 10% FSCS to each of 4 wells
(Row#3).
Add 25 μL of 1:100 dilution of working virus in EMEM 10% FSCS to each of 4
wells (Row#4).
Add 25 μL of 1:100 dilution of working virus in EMEM 10% FSCS to each of 4
wells (Row#5).
Add 125 μL of trypsinized cells to all 20 wells.
*If serum is toxic in serum control well (1:4 dilution), then repeat test with a row to
check for toxicity.
Reverse SNT for EAV verification – confirmation test
Materials
Known positive serum, inactivated and diluted 1:4 in PBS (should come from field
sample(s), not from vaccinated horses)
Known negative serum inactivated and diluted 1:4 in PBS
Stock virus (Virulent Bucyrus strain)
Unknown virus isolate

Method
1. Add 0.3 mL of known negative serum to 4 tubes for each virus sample to be
tested (including stock virus).
2. Add 0.3 mL of known positive serum to 3 tubes for each virus sample to be tested
(including stock virus).
3. Make up 1:10 dilution of guinea pig complement in EMEM 10% FSCS with
antibiotics (10 mL for each sample).
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4. Make up 10-1 to 10-5 dilutions of all virus samples to be tested using 1.8 mL of
media in #3 and 0.2 mL of virus (It may be necessary to dilute stock virus to 10-3
before starting these dilutions).
5. To positive serum (3 tubes), add 0.3 mL of 10-1, 10-2 and 10-3 virus dilutions.
6. To negative serum (4 tubes), add 0.3 L of 10-3, 10-4 and 10-5 virus dilutions.
7. Incubate serum-virus mixture for 1 hour at 37°C.
8. 14 of T-25 flasks [7 RK-13 (KY) “high passage” and 7 RK-13 (ATCC-CCL37)
“low passage”] are used for each virus to be tested. Aspirate off media from 3-5
day RK-13 flasks and add 0.25 mL of above serum-virus mixture to 2
flasks/dilution.
9. Incubate for 2 hours at 37°C (closed caps, no CO2), rock flasks after 1 hour.
10. Add 10 mL of CMC overlay/flask. Incubate for 4-5 days according to
development of CPE, remove media, and stain with crystal violet plaque stain.
Treatment of serum with toxicity due to (Duvaxyn) antibodies to RK-13 cells
This procedure has been used successfully to eliminate (or reduce to readable at 1:4)
toxicity from serum samples demonstrating the vaccine-induced “European” toxicity at
1:4 and greater in the EAV SNT. These horses have been vaccinated with Duvaxyn EHV
1 and 4 (the EHV-1 component is made in RK-13 cells).
Always treat a known negative and a known positive serum whenever this treatment is
performed on toxic serum specimens. Preferably, use serum that has not been previously
inactivated. Use sterile technique for the following method below.
Method
1. Decant growth media from as flask or 7-10 day old RK-13 (KY) cells (P399-409).
Wash the flask three times by 10 mL of PBS. Add 1 mL trypsin EDTA/flask, rotate
to spread over cell monolayer, then incubate approx. 6-8 min at 37°C.
2. When cells have detached, add 2 mL EMEM with 10% FSCS/flask. Mix well with 5
mL pipet, and then divide between three 1.5 mL microcentrifuge tubes.
3. Spin tubes at 20,000 rpm for 15 sec in microcentrifuge. Use a Pasteur pipet to
remove and discard all supernatant.
4. Add 0.5 mL of toxic serum or control serum per tube; mix with pipet until cells are
resuspended; label tube appropriately. Incubate for 1 hour at 37°C. Flick tubes after
30 min to resuspend.
5. Spin 2,500 rpm for 15 sec. Use a Pasteur pipet to transfer each serum to a new,
labeled 1.5 mL microcentrifuge tube.
6. Inactivate at 56°C for 30 min if serum has not been inactivated previously. Proceed
with EAV SNT test, running sera (toxic, negative, positive) as usual and in preseeded (planted 18-24 hours prior) plates.
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Our standard laboratory protocol for commonly used molecular
biology/recombinant DNA techniques
Primer design
The approach for designing of specific and efficient primers remains somewhat empirical;
there are no hard and fast rules. With experience and by using a good primer designing
program (e.g. MacDNASIS v3.5; Hitachi) the majority of the primers can be made to
work. Following are some guidelines to design specific and efficient primers.
1. Where possible, select primers with an average G+C content of around 50%.
2. Where possible, select primers with a random base distribution. Try to avoid
primers with stretches of polypurines, polypyrimidines, or other unusual
sequences.
3. Melting temperature (Tm) should be between 55-57°C.
Increasing the Tm therefore, the annealing temperature enhances discrimination
against incorrectly annealed primers and reduces misextension of incorrect
nucleotides at the 3′-end of the primers. Therefore, increasing the annealing
temperature will help to increase the specificity. An applicable annealing
temperature is 5°C below the true Tm of the amplification primer. The best
annealing temperatures is in the range of 55-72°C. Quick way to calculate
annealing temperature is:
Annealing temp (°C) = (# of A and T [A+T] x 2 + # of G and C [G+C] x 4)-5°C.
4. Try to design both positive and negative primers with same Tm (1-2°C difference
will not matter).
5. Make sure the primer ends (3′) with a G or C.
6. Primer length should be between 19 and 30 bases (19 to 22 bases are preferred).
7. If possible select a unique area of the genome to design the primer.
8. Avoid sequences with significant secondary structure (computer programs are
very useful for this).
9. Check the primers against each other for complementarily. Avoiding primers with
3′ overlaps will reduce the incidence of “primer-dimer” artifacts.
10. If possible do a simple homology matching (compare the primers with the whole
genome using a computer program) and see whether primer(s) have <50%
homology in the area closer to be amplified (or to be desired area). This will
reduce the number of nonspecific products of same size.
Agarose gel electrophoresis
Materials
Agarose (SEAKEM® LE agarose; FMC BIO PRODUCTS)
50X TAE buffer (Tris Acetate EDTA, pH 8.0)
Gel casting plate
Gel sealing tape
Buffer tank
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Method
1. Make 1,000 mL of 1X TAE, by measuring 20 mL of 50X stock into a 1,000 mL
graduated cylinder and q.s. to 1,000 mL mark with deionized water.
2. Weight 1 g of agarose (for 1% gel) and dissolve it in 100 mL of 1X TAE. Melt
agarose solution in microwave until completely dissolved. Let stand at room
temperature (or at 45°C in a water bath) to remove air bubbles but not enough to
solidify.
3. Prepare gel-casting plate by taping the ends with gel sealing tape. Place the
sample comb in the proper position on the plate.
4. Pour 100 mL of 1% agarsoe on to the gel casting plate slowly and allow it to
solidify (volume of agarose needed depends on the size of the gel casting plate).
The gel should be between 0.3 and 0.5 cm thick. After gel has set, final gelling
carried out at 4°C for 30 min. There should not be any air bubbles in the gel.
5. Remove the tapes and keep the gel plate in the buffer tank. Add 1X TAE buffer
into the reservoirs until it covers the surface of gel at a depth of 3-4 mm.
6. Slowly remove the sample comb and load the samples into the wells (Mix 1-20
μL of RNA or DNA with 6X gel loading buffer; loading volume depends on the
sample and make sure gel loading buffer get diluted to 1X with sample).
7. Voltage 70V for 2-3 hours (95V for 45-60 min) or until the first band has
migrated at least 2.5 inches away from the wells. The voltage must never exceed
100V. For low melt Agarose use low voltage (70V). Always run the gel in
constant voltage.
8. Stain gel in ethidium bromide, letting it sit for 5-10 min. Destain gel by placing in
deionized distilled water for 5 min.
9. Transfer the gel onto a UV light source. Usually, a transilluminator is used to
facilitate this step. Place a piece of plastic wrap between the gel and surface of the
illuminator. Use a face shield, gloves and body shield to minimize the UV
exposure. Take a picture for records.
10. Locate the DNA or RNA bands and excise by using a sharp scalpel blade (e.g. to
obtain the desired band).
11. Range of separation in gels containing different concentrations of agarose.
% agarose (% [w/v]) Efficient range of separation of linear DNA molecules (Kb)
0.3
5-60
0.6
1-20
0.7
0.8-10
0.9
0.5-7
1.2
0.4-6
1.5
0.2-3
2.0
0.1-2
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Viral RNA extraction
Followed manufacturer’s recommended protocol
Total viral RNA extraction
Material
MagMax-96 viral RNA isolation kit (THERMO FISHER# AM1836)
Purpose: Purification of viral RNA (and DNA) from clinical specimens (e.g.) to do
reverse transcription (RT) PCR amplification.
Materials
Kit storage condition
Amount

Component

Storage Temperature (°C)

1 unit
16.0 mL
36.0 mL

Processing Plate & Lid
Lysis/binding concentration
Wash solution 1
(Add 12mL of Isopropanol)
Wash solution 2
(Add 32mL of 100% ethanol)
Elution buffer
RNA binding beads
Carrier RNA
Lysis/Binding Enhancer

Room temperature
Room temperature
4°C

40.0 mL
9.0 mL
1.1 mL
125 μL
1.1 mL

4°C
4°C
4°C
-20°C
-20°C

Required materials that not included with kit
RNase Zap (RNA remover)
100% Ethanol, Isopropanol
96-well plates magnetic stand
96-well U-bottom plate & lids
96-well plates shaker
General use needs (e.g. pipette, tips)
Protocol
1. Prepare your Lysis/Binding Solution preparation:
Specimens

Lysis/Binding
Soln. Conc.

Carrier
RNA

100%
Isopropanol

Total
Volume
(μL)
1703

845
13
845
a. Calculate the total volume of lysis/binding solution per your sample number.
b. Add 13 μL l of lysis/binding solution in each cell by single channel pipet.
2. Prepare your Bead Mix preparation:
Total volume
Per Reaction
Specimens
Component
(μL)
(μL)
RNA Binding Beads
10
130
13
Lysis/Binding Enhancer
10
130
13
a. Make 2 extra per your number of samples.
13
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b. Add 20 μL of bead mix in each cell by single channel pipet on well A
3. Add 150 μL of Wash Buffer 1 into row B and C using by 300 multichannel
pipette.
4. Add 150 μL of Wash Buffer 2 into row D and E using by 300 multichannel
pipette.
5. Add 50 μL of Elution Buffer into row F using by 300 multichannel pipette.
6. Add 50 μL of your RNA sample into row A in the hood room.
7. Turn the machine and add Combs above the plate in the machine.
8. RNA extraction machine takes about 30 min to extract the RNA.
9. Turn off your machine, and aliquot out your RNA in row F.
10. Aliquot out your negative control in each cell at the end of plate. If you are
running negative sample, add your positive sample at the end of plate.
11. Turn on your RNA extraction machine in Sheila's lab, click "start" button twice. It
takes about 30 min to extract your RNA.
MagMax-96 viral RNA isolation kit (THERMO FISHER# AM1836)
Materials
Add 12 mL of 100% isopropanol to the wash solution 1
Add 32 mL of 100% ethanol to wash solution 2
Carrier RNA and Lysis/binding solution are stored at -20°C.
Reagent preparation
Mix 1 μL of carrier RNA + 65 μL of lysis/binding solution + 65 μL of isopropanol / 1
sample
Mix 10 μL of RNA binding beads + 10 μL of lysis/binding enhancer / 1 sample
Method
1. Add 50 μL sample to 130 μL lysis/binding solution.
a. Pipet 130 μL of lysis/binding solution (carrier RNA and isopropanol are
added).
b. Transfer up to 50 μL of sample. Avoid aerosol cross contamination.
c. Shake plate for 1 min on orbital shaker.
2. Add 20 μL beads and mix for 5 min.
a. Vortex bead mix.
b. Add 20 μL of beads. Mix to each sample.
c. Shake the plate for 5 min to lyse viruses and bind RNAs to RNA binding
beads.
3. Capture RNA binding beads and carefully discard the supernatant.
a. Move processing plate to magnetic stand to capture RNA binding beads.
Leave the plate for 3 min. RNA binding beads will form pallets.
b. Carefully, discard the supernatant without disturbing beads.
4. Wash twice with 150 μL of wash solution 1.
a. Add 150 μL of wash solution 1. Shake the place for 1 min.
b. Processing plate on magnetic stand for 1 min.
c. Discard supernatant without disturbing beads carefully.
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d. Remove processing plate off the magnetic stand. Repeat 4a. to 4c. second
time with 150 μL of wash solution 1.
5. Wash twice with 150 μL of wash solution 2.
a. Repeat 4a. to 4d. with wash solution 2.
6. Dry the beads by shaking plate for 2 min to allow remaining from wash solution 2.
If there is residual solution, shake the plate for another 2 min.
7. Elute the RNA/DNA in 20-50 μL of elution buffer.
a. Add 20-50 μL elution buffer, shake vigorously for 3 min.
b. Capture the RNA binding beads. The purified RNA will be in the
supernatant.
c. Transfer the supernatant (contains RNAs) to nuclease-free container. Store
the purified RNA at -80°C.
RNA extraction protocol for Next-generation sequencing prep
Materials
Norgen Biotek Total RNA purification Kit (NORGEN BIOTEK# 17200 - 50 prep)
Buffer RL
40 mL
Wash Solution A
38 mL
Elution Solution A
6 mL
Mini Spin Columns
50
Collection Tubes
50
Elution tubes (1.7 mL)
50
Product Insert
1
Customer-Supplied Reagents and Equipment
Benchtop microcentrifuge
96-100% Ethanol
B-mercaptoethanol (optional)
Protocol
1. Cell Lysate Preparation from Plasma/Serum.
a. 1.0 mL of sample vial centrifuged at 9,000 g force at 4°C (in walk-in room)
for 20 min, discard the pellets.
b. Transfer the supernatant, and then use 200 μL of the sample for RNA
extraction.
c. Add 700 μL of Lysis Solution. Lyse viral-infected cells by vortexing for 15
sec. Ensure that mixture becomes transparent before proceeding to the next
step.
d. Add 400 μL of 100% ethanol and mix by vortex for 10 sec.
2. Binding RNA to Column.
a. Assemble a column with one of the provided collection tubes.
b. Apply up to 600 μL of the lysate with the ethanol (from step 1) onto the
column and centrifuge for 1 min (3,500 x g).
Note: If the entire lysate volume has not passed, spin for an additional minute
at 14,000 x g
c. Discard the flow through. Reassemble the spin column with its collection tube.
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d. Depending on your lysate volume, repeat Step 2b and 2c as necessary.
Optional step: For maximum removal of residual DNA that may affect
sensitive downstream application, use One-Column DNA Removal Protocol
(Norgen's RNase-Free DNase I Kit#25710)
3. Column Wash.
a. Apply 400 μL of 100% ethanol to the column and centrifuge for 1 min.
b. Discard the flow through and reassemble the spin column with its collection
tube
c. Repeat steps 3a and 3b to wash column a second time.
d. Wash column a third time by adding another 400 μL of 100% ethanol.
e. Discard the flow through and reassemble the spin column with its collection
tube.
f. Spin the column for 2 min in order to thoroughly dry the resin. Discard the
collection tube.
4. RNA Elution.
a. Place the column into a fresh 1.7 mL Elution tube provided with the kit.
b. Add 50 μL of Elution Solution A to the column.
c. Centrifuge for 2 min at 200 x g, followed by 1 min at 14,000 x g.
Note: If the entire 50 μL has not been eluted, spin the column at 14,000 x g
for 1 additional min.
5. Storage of RNA. The purified RNA sample may be stored at -80°C for long-term
storage.
cDNA synthesis
Followed manufacturer’s recommended protocol
Synthesis of first cDNA strand with oligo dT
Material
Kit: SuperScript III First-Strand Synthesis System for RT-PCR (THERMO FISHER#
18080-051 LIFE TECHNOLOGY)
Purpose: Use SuperScript III First-Strand synthesis with Oligo (dT) and Gene Specific
Primers (GSP)
Protocol
Template RNA (1 pg-500 ng recommended) - Use about 1,000 ng (1 μg)
Template mix
Components
Olgo dT primer (50 um)
10 mM dNTP
Template RNA
DEPC-treated water

Volume per
reaction (μL)
1.0
1.0
3.0
5.0
10.0
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Number
of
reactions
20
20
20
20

Master
mix
20
20
60
100
200

Aliquot out 10 μL per tube and keep them in ice.
Run the first thermo cycler program: SuperScript III at 65°C for 5 min.

RT Master Mix
Components
10X RT buffer
25 mM MgCl2
0.1 M DTT
RNaseOUT (40 U/μL)
Superscript III RT (200 U/μL)

Voume per
reaction (μL)
2.0
4.0
2.0
1.0
1.0
10.0

Number
of
reactions
20
20
20
20
20

Master
Mix
40
80
40
20
20
200

Add 10 μL of cDNA Synthesis Mix to each RNA/primer mixture, mix gently, and collect
by brief centrifugation. Incubate as follows.
Oligo dT: 60 min at 50 °C
Terminate the reactions at 85 °C for 5 min. Chill on ice.
Collect the reactions by brief centrifugation. Add 1 μL of Rnase H to each tube and
incubate the tubes for 20 min at 37°C.
cDNA synthesis reaction can be stored at -30 to -10°C or used for PCR immediately.
Roche Pure PCR template prep
High Pure PCR Template Preparation Kit Version 20 for 100 isolations (ROCHE# 11
796 828 001)
Preparation of working solution
Proteinase K: Dissolve Proteinase K in 4.5 ml double distilled water, aliquot solution.
Store at -15°C to -25°C. Stable for 12 months. Sample Lysis and DNA Binding Protocol
step 1.
Inhibitor removal buffer: Add 20 mL absolute ethanol to inhibitor Removal Buffer
Lable and date bottle accordingly after adding ethanol. Store at +15°C to +25°C. Stable
through the expiration date printed on label. Washing and Elution protocol step 1.
Wash Buffer: Add 80 mL my absolute ethanol to Wash Buffer Label and date bottle
accordingly after adding ethanol. Store at +15°C to 25°C Stable through expiration date
printed on kit label. Washing and Elution protocol step 2 and 3.
Protocol
1. Thaw 200 μL of EAV KY84 SS cDNA Template x 2vials.
2. Add 200 μL or Binding Buffer. Add, 40 μL Proteinase K, mix immediately,
incubate for 10 min at 70°C in each vial.
3. Add 100 μL isopropanol. Mix well and apply each vial mixture into one High
Pure filter tube.
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4. Centrifuge for 1 min at 8,000 x g.
5. Discard flow through and collection tube.
6. Add 500 μL of inhibitor removal buffer.
7. Centrifuge for 1 min at 8,000 x g.
8. Discard flow through and collection tube.
9. Add 500 μL of Wash Buffer.
10. Centrifuge for 1 min at 8,000 x g.
11. Discard flow through and collection tube.
12. Repeat #9-10.
13. Discard flow through.
14. Centrifuge for 10 seconds at 13,000 x g.
15. Discard collection tube.
16. Add new tube and 200 μL of elution buffer at 70°C E2: 100 μL.
17. Centrifuge for 1 minute at 8,000 x g.
18. Purified Template DNA is ready to go.
Reverse transcription
Followed manufacturer’s recommended protocol
Expand Long Template PCR System (ROCHE# 11 681 834 001)
Preparation
All buffers at + 37°C to +56°C before use. Vortex all other reagents thoroughly.
If the initial reaction produces too many primer dimers, try using two separate master
mixes:
Master Mix 1 contains dNTPs and primers
Master Mix 2 contains buffer, template cDNA and enzyme
Add these two to the tube on ice, then just before starting the reaction.
Protocol
Amplification cDNA. DNA System 3: >12kb
Master Mix 1 (for 10 viruses)
Volume
Components
(μL) per
reaction
10mM dNTP Mix
10.0

Number
of
reactions
5

Master
mix (μL)

Final
concentration

50

500 uM
800 nM
(400 nm)
800 nM
(400 nm)

Downstream

1.0

5

5

Upstream primer
10x PCR Buffer with
MgCl2 (Buffer 3)
Expand Long Tem0.75 μL plate Enzyme
mix
Template DNA after
High Pure PCR Tem

1.0

5

5

5.0

5

25

0.75

5

3.75

5.0

5

25
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Prep Kit
Sterile DW

27.3
50.0

5

136.25
250

DNA quantification (ng/μL)
Qiagen One Step RT-PCR kit (QIGEN# 210210)
Protocol
Component
Volume
Master mix
Rnase-Free
water(provided)
5X Qiagen One Step RT-PCR Buffer
(contains MgCl2)
dNTP Mix
(containing 10 mM of each dNTP)
Qiagen OneStep RT-PCR Enzyme Mix
Rnase Inhibitor (optional, not provided)

Reaction

Master Mix

14.0 μL
5.0 μL

13
13

182
65

1.0 μL

13

13

1.0 μL
0.5 μL
21.0 μL

13
13

13
6.5
279.5

Aliquot out the master mix into tubes (6)
1.0 μL
Primer 1
1.0 μL
Primer 2
Template RNA
Template RNA, added at step 4
1.5 μL
Total
volume
25 μL
Add each forward and reverse primer to master mix tubes (6).

Thermocyclor
Reverse transcription
Initial PCR activation step
3 step
cycling:
Denaturation
Annealing
Extension
Final extension

Duration
30 min
15 min

Temperature
50°C
95°C

30 sec
30 sec
1 min
10 min

94°C
55°C
72°C
72°C

QIAGEN HotStar Taq DNA Polymerase PCR
Volume
Components
(μL)
10X PR Buffer (with 15 mM MgCl2)
5.0
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# Reactions
12

Volume
(μL)
60

25 mM MgCl2 (to get final conc.
2.5 mM)
dNTP Mix (10 mM of each dNTP)
QIAGEN HotStart DNA Polymerase
Nuclease-free water
Master mix
Aliquot out 47 μL into tubes (10).
Forward primer (20 μm)
Reverse primer (20 μm)
Template DNA

2.0
1.0
0.3
38.7
47.0

12
12
12
12

24
12
3.6
464.4
564

1.0 μL
1.0 μL
1.0 μL

Add each forward and reverse primer to master mix tubes (10).
Thermal Cycler Conditions
95°C
15 min
Initial activation step
3-step cycling (40 cycles)
Denaturation
94°C
30 sec
Annealing
55°C
30 sec
Extension
72°C
1 min
Final extension
72°C
10 min
Roche pure PCR purification
Purification of DNA Fragments from Agarose Gel
Protocol
1. Cut desired DNA band from gel using an ethanol-cleaned scalpel or razor blade.
a.
Minimize gel volume by visualizing DNA and cutting the smallest possible
gel slice on a UV light box.
2. Place excised agarose gel slice in a sterile 2.0 mL microcentrifuge tube.
a.
Determine gel mass by first pre-weighting the tube, and then reweighting
with the excised gel slice
3. Add 300 μL Binding Buffer for every 100 mg agarose gel slice to the
microcentrifuge tube.
a.
1 g = 1,000 mg/ 100 mg = 0.1 g.
4. Dissolve agarose gel slice in order to release the DNA.
a.
Vortex the microcentrifuge tube 15-30 sec to resuspend the gel slice in the
binding buffer.
b.
Incubate the suspension for 10 min at 56°C in water bath.
c.
Vortex the tube briefly every 2-3 min during incubation.
5. After the agarose gel slice is completely dissolved.
a.
Add 150 μL isopropanol for every 100 mg agarose gel slice to the tube.
i. 1g = 1,000 mg/ 100mg = 0.1 g
b.
Vortex thoroughly.
6. Insert one high pure filter tube into one collection tube.
a.
Pipette the entire contents of the microcentrifuge tube into the upper
reservoir of the filter tube.
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Do not exceed 700 μL total volume. If mixture is >700 μL, split the volume
and use two separate Filter Tubes for each portion.
7. Centrifuge 30-60 sec at maximum speed in a standard tabletop centrifuge at +15
to +26°C.
8. Discard the flow through solution.
a.
Reconnect filter tube with the same collection tube
9. Add 500 μL wash buffer to the upper reservoir.
a.
Centrifuge 1 min at maximum speed (as above)
10. Discard the flow through solution.
a. Recombine filter tube with the same collection tube.
b. Add 200 μL wash buffer.
c. Centrifuge 1 min at maximum speed.
i. This second 200 μL wash step ensures optimal purity and complete
removal of Wash Buffer from the glass fibers.
11. Discard the flow through solution and collection tube
12. Add 50-100 μL of nucleic acid free water to the paper reservoir of the filter tube
(70 μL E1/ 30 μL E2 at 70°C).
13. The microcentrifuge tube now contains the purified DNA.
a. Either use the eluted DNA directly or store the eluted DNA at +2°C to
+8°C or -15°C to -25°C for later analysis.
b.

5′ RACE System for Rapid Amplification of cDNA ends (THERMO FISHER#
18374-058 Invitrogen (10rxn) LIFE TECHNOLOGY)
Materials
Reagent
Volume
Storage
10X PCR buffer [200 mM Tris-HCl (pH 8.4), 500 mM KCl]
500 μL
-20°C
25 mM MgCl2
500 μL
-20°C
*Note: 10X PCR buffer does not contain MgCl2. Therefore,
MgCl2 must be added to the first strand reaction mix
10 mM dNTP mix [10 mM each dATP, dCTP, dGTP, dTTP]
0.1 M DTT
SuperScript II Reverse Transcriptage (200 units/ μL)
Rnase mix
5X tailing buffer [50mM Tris-HCl (pH 8.4), 125 mM KCl, 7.5
mM MgCl2]
2 mM dCTP
Terminal deoxynucleotidyl transferase (TDT)
5' RACE abridged anchor primer (AAP, 10 μM)
Universal amplification primer (UAP, 10 μM)
Abridged universal amplification primer (AUAP, 10 μM)
DEPC-treated water
Control gene-specific primer 1 (GSP1, 1 μM)
Control nested gene-specific primer 2 (GSP2, 10 μM)
Control PCR primer, gene-specific primer 3 (GSP3, 10 μM)
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100 μL
100 μL
10 μL
10 μL

-20°C
-20°C
-20°C
-20°C

500 μL
50 μL
15 μL
80 μL
40 μL
40 μL
1.25 mL
25 μL
80 μL
20 μL

-20°C
-20°C
-20°C
-20°C
-20°C
-20°C
-20°C
-20°C
-20°C
-20°C

Control DNA (2x104 copies/ μL; ~0.1 pg/ μL)
Control RNA (50 ng/ μL)

DNA Purification System

100 μL
10 μL

Volume
10
columns
10 tubes
30 mL
1 mL

S.N.A.P. Columns
Collection tubes
Binding solution (6M sodium iodide)
Wash buffer concentrate

-20°C
-20°C

Storage
4°C
4°C
4°C
4°C

Additional materials required
Sterilized, RNase-free thin-walled 0.2 or 0.5 mL PCR tubes
Automatic pipettes capable of dispensing 1 to 20 μL and 20 to 200 μL
Sterilized, RNase-free disposable tips for automatic pipettes
Sterilized, distilled water
Absolute ethanol
GSP 1 (cDNA primer, user-defined)
GSP 2 (nested primer for PCR amplification of dC-tailed cDNA, user-defined,
appropriately engineered)
Taq DNA polymerase *Note: Purchased: AccuPrime Pfx DNA Polymerase Cat# 12344024 Invitrogen
37°C, 42°C, 65°C and 70°C water baths or heat blocks (or use thermal cycler)
Microcentrifuge capable of generating a relative centrifugal force of 13,000 x g
Programmable thermal cycler
Mineral oil (if necessary for your thermal cycler)
Method 1
1X Wash Buffer for S.N.A.P. Procedure
*1X wash buffer must be prepared from the wash buffer concentrate.
1. Pipette 1mL (individually wrap) of the wash buffer, concentrate into a 50 ml
conical tube.
2. Add 18 mL of molecular biology grade distilled water and 21 mL of absolute
ethanol. Mix thoroughly.
3. Transfer half into a second 50 mL conical and store and store at 4°C.
70% Ethanol Wash for S.N.A.P. Procedure
1. Add 35 mL of absolute ethanol and 15 mL of molecular biology grade distilled
water to a 50 mL conical tube.
2. Transfer half into a second 50 mL conical and store and store at 4°C.
*Note: Molecular Biology grade distilled water = Nuclease-Free Water
(Cat#AM9937 AMBION)
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Method 2
First Strand cDNA Synthesis
*Add following to a 0.5 mL microcentrifuge tube (or thin-walled PCR tube if using a
thermal cycler)
Number
Components
Voume per
of
Mol
reaction (μL)
reactions
GSP1 (20 um)
1
2
2.5pmoles
Sample RNA (5 μg)
5
2
DEPC-treated water
9.5
2
*** Note: RNA of EAV measurement
Aliquot out each 0.5 mL microcentrifuge tube #1 and #2
*Incubate the mixture 10 min at 70°C to denature RNA. Chill 1min on ice.
Collect the contents of the tube by brief centrifugation and add the following in the order
given:
Number
Voume per
Components
of
reaction (μL)
reactions
10X PCR buffer
2.5
2
25 mM MgCl2
2.5
2
10 mM dNTP mix
1
2
0.1 M DTT
2.5
2
Final volume (8.5)**
8.5
***Total final volume of step 1 and 2: 24 μL
Mix gently, and collect the reaction by brief centrifugation. Incubate for 1 min at 42°C.
Add 1 μL of SuperScript II RT immediately. Mix gently and incubate for 50 min at 42°C.
30 min incubation is usually sufficient for shot (<4 kb) mRNAs.
Longer transcripts require at least 50 min to synthesize enough cDNA for a
consistent signal in long PCR.
Incubate at 70°C for 15 min to terminate the reaction.
Centrifuge 10 to 20 sec and place the reaction at 37°C (at room temp right away).
Add 1 μL of RNase mix gently but thoroughly, and incubate for 30 min at 37°C.
Collect the reaction by brief centrifugation and place on ice or keep the reaction storeed
at -20°C.
* Final composition of the reaction:
20 mM Tris-HCl (PH 8.4)
50 mM KCl
2.5 mM MgCl2
10 mM DTT
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100 nM cDNA primer (GSP1)
400 μM each dATP, dCTP, dGTP,
dTTP
1-5 ug (~40ng/ μL) RNA
200 units SuperScript II RT
Thermocyclor cycle
Denature RNA
Incubation 1
Incubation 2
Incubation 3

Temp
70°C
42°C
42°C
70°C
37°C

Time
10 min
1 min
50 min
15 min
30 min

Method 3
Materials
Collection tube
S.N.A.P. Column (spin cartridge)
40X wash buffer concentration
Binding buffer
S.N.A.P. Column Purification of cDNA
1. Equilibrate the binding solution to room temperature.
2. For each sample to be purified, equilibrate ~100 μL of sterilized, distilled water at
65°C for use in step 9.
3. Add 120 μL of binding solution (6 M Nal) to the first strand reaction.
4. Transfer the cDNA/Nal solution to a S.N.A.P. column. Centrifuge at 13,000 x g for 20
sec.
5. Remove the cartridge insert from the tube and transfer the flow through to a
microcentrifuge tube. Save the solution until recovery of the cDNA is confirmed. Place
the cartridge insert back into the tube.
6. Add 400 μL of cold (4°C) 1X wash buffer to the spin cartridge. Centrifuge at 13,000 x
g for 20 sec. Discard the flowthrough. Repeat this wash step three additional times.
7. Wash the cartridge two times with 400 μL of COLD (4°C) 70% ethanol as described in
step 6.
8. After removing the final 70% ethanol wash from the tube centrifuge at 13,000 x g for 1
min.
9. Transfer the spin catridge insert into a fresh sample recovery tube.
Add 50 μL of sterilized, distilled, water (preheated to 65°C) to the spin cartridge.
Centrifuge at 13,000 x g for 20 sec to elute the cDNA.
Important Note
*Failure to remove all the ethanol can result in poor recovery of the DNA.
** It is very important that the distilled water be at 65°C in order to maximize recovery
of DNA.
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Method 4
TdT Tailing of cDNA
1) Add the following components to each tube and mix gently:
Voume per
Number of
Components
reaction (μL)
reactions
DEPC-treated water
6.5
2
5X tailing buffer
5
2
2 mM dCTP
2.5
2
S.N.A.P.-purified cDNA sample
10
2
Final volume
24
* Aliquot out to PCR tubes #3 and #4
2) Incubate for 2 to 3 min at 94°C. Chill 1 min on ice.
Collect the contents of the tube by brief centrifugation and place on ice.
3) Add 1 μL TdT to the each tubes, mix gently, and incubate for 10 min at 37°C.
4) Heat inactivate the TdT for 10 min at 65°C.
Collect the contents of the reaction by brief centrifugation and place on ice.
*Final composition of the
reaction:
10 mM Tris-HCl (PH 8.4)
25 mM KCl
1.5 mM MgCl2
200 μM dCTP
cDNA
TdT
Thermocyclor cycle
Temp
Time
Incubation 4
94°C
3 min
Incubation 5
37°C
10 min
TdT Inactivation
65°C
10 min
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Method 5
PCR of dC-tailed cDNA
1. Equilibrate the thermal cycler block to 94°C. In most cases, the "good start"
procedure gives specific amplification products. For some target and primer sets,
"hot start" has been reported to improve the specificity of the reaction.
2. Add the following to a 0.2 or 0.5 mL thin-wall PCR tube sitting on ice.
Voume per
reaction (μL)
31.5

Components

Number of
reactions
2

Sterilized, distilled water
10X PCR buffer [200mM Tris-HCl (pH8.4), 500mM
KCl
5
2
25 mM MgCl2
3
2
10 mM dNTP mix
1
2
Nested GSP2 (prepared as 10 μM solution)*
2
2
Abridged Anchor Primer (10 μM)
2
2
dC-tailed (PCR tubes #3 and #4)
5
2
Final volume
49.5
* Aliquot out to PCR tubes #5 and #6
3. Add 0.5 μL of Taq DNA polymerase (5 units/μL) immediately before mixing.
**New enzyme: DNA Taq Polymerase, Native (LIFE TECH#18038-018)
4. Mix the contents of the tube (Taq DNA polymerase is added immediately before
going into the thermal cycler).
Overlay with 50 to 100 μL of mineral oil (if necessary).
*Final composition of the reaction:
20 mM Tris-HCl (PH8.4)
500 mM KCl
1.5 mM MgCl2
400 nM GSP2
400 nM Abridged Anchor Primer
200 μM each dATP, dCTP, dGTP, dTTP
Tailed cDNA
2.5 units Taq DNA polymerase
5. Transfer tubes directly from ice to the thermal cycler preequilibrated to the initial
denaturation temperature (94°C)
6. Perform 30 to 35 cycles of PCR. A typical cycling protocol for cDNA with < 1 kb
amplified region is:
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Thermocycler cycle
Denaturation
Annealing of primers
Primer extension
Final extension
Indefinite hold

Temp
94°C
94°C
55°C
72°C
72°C

Cycle
1
35
1

5°C

Time
2 min
1 min
1 min
2 min
5 min
Until samples are
removed

7. Analyze 5-20 μL of 5' RACE products by agarose gel electrophoresis according to
standard protocols, using appropriate size standards. Either TAE or TBE
electrophoresis buffer may be used for the procedure. The volume of the sample
used for analysis will depend on the volume and thickness of the sample well. If
products will be extracted for reamplification, ultraviolet (UV) visualization of
ethidium bromide-stained products should be performed using either a long
wavelength (356 nm) UV or 302 nm wavelength source to minimize DNA
nicking.
Nested GSP2 (10 uM solution) Preparation
N1V1 = N2V2
(20 uM to 10 μM Dilution)
20 uM : 50 μL = 10 μM:V2
V2= 25μL
Working stock (1:1)
25 μL Nucleic Acid-Free water + 25 μL of 20uM Primer
= Total 50 μL of Nested GSP2 (10 μM solution) of BN 291N
Performing 1% agarose gel electrophoresis
Materials for small box (10 well combs)
Amt. of materials
TAE (1X) Buffer) [diluted from 10X Tris-Acetate-EDTA]
50 mL
Agarose (1%) [Seakem GTG Agarose Cat#50074 Cambrex)
0.5 g
Ethidium Bromide [GIBCO]
2.5 μL
*When you pour the gel, use pipet and get use to the height of the gel.
You can make 100 mL gel stock and can use about 30 mL for small box (10-well
combs)
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Method 6
Nested Amplification
1. Dilute a 5 μL aliquot of the primary PCR (tube# 5 and #6) into 495 μL Nucleic
Acid Free Water
* Aliquote out to PCR tubes #5b and #6b (diluted primary PCR)
2. Equilibrate the thermal cycler block to 94°C.
Add the following to a 0.2 or 0.5 mL thin-wall PCR tube sitting on ice.
Voume
Number
per
Components
of
reaction
reactions
(μL)
Sterilized, distilled water
33.5
2
10X PCR buffer [200 mM Tris-HCl (pH8.4), 500 mM
KCl]
5
2
25 mM MgCl2
3
2
10 mM dNTP mix
1
2
Nested GSP2 (prepared as 10 uM solution)
1
2
UAP (10 μM)
1
2
Dilution of primary PCR product (PCR tubes #5a and
#6a)
5
2
Final volume
49.5
* Aliquot out to PCR tubes #9 and #10
3. Add 0.5 μL of Taq DNA polymerase (5 units/μL) immediately before mixing.
4. Mix the contents of the tube (Taq DNA polymerase is added immediately before
going into the thermal cycler)
Overlay with 50 to 100 μL of mineral oil (if necessary)
*Final composition of the reaction:
20 mM Tris-HCl (pH 8.4)
50 mM KCl
1.5 mM MgCl2
200 nM nested GSP
200 nM UAP or AUAP
200 μM each dATP, dCTP, dGTP, dTTP
Diluted primary PCR product
2.5 units Taq DNA polymerase
5. Transfer tubes directly from ice to the thermal cycler preequilibrated to the initial
denaturation temperature.
6. Perform 30 to 35 cycles of PCR.
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Thermocycler cycle

Temp
94°C
94°C
55°C
72°C
72°C

Denaturation
Annealing of primers
Primer extension
Final extension

Cycle
1

Time
2 min
1 min
1 min
2 min
5 min
Until samples are
removed

35
1

5°C

Indefinite hold

7. Analyze 5 to 20 μL of the amplified sample, using agarose gel electrophoresis,
ethidium bromide staining, and the appropriate molecular size standards.
3′ RACE System for
FISHER#18373-019)
Materials

Rapid

Amplification

of

cDNA

Contents
10X PCR buffer [200 mM Tris-HCl (pH 8.4), 500 mM KCl]
25 mM MgCl2
10 mM dNTP mix (10mM each dATP, dCTP, dGTP, dTTP)
0.1M DTT
SuperScript II Reverse Transcriptase (RT, 200units/ μL)
Adapter primer (AP, 10 μM)
Universal amplification primer (AUAP, 10 μM)
Abridged universal amplification primer (AUAP, 10μM)
E. coli RNASE H (2units/ μL)
DEPC-treated water
Control RNA (50ng/ μL)
Control gene-specific primer (GSP, 10 μM)
Additional preparations
GSP (user-defined, appropriately engineered)

ends

(THERMO

Amount
(μL)
500
500
100
100
20
20
20
20
20
1.2 mL
10
20

Method 1
First Strand cDNA Synthesis
This procedure converts 1 to 5 μg of total RNA into first strand cDNA. Poly (A) RNA
may be used in this protocol.
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1. Mix and quickly centrifuge each component before use.
2. Combine 1-5 μg of total RNA or 50 ng of poly (A) RNA and DEPC-treated water to a
final volume of 11 μL in a 0.5 mL microcentrifuge tube.
3. Add 1 μL of the 10 μM AP solution, (adapter primer) mix gently, and collect reaction
by brief centrifugation.
4. Heat the mixture to 70°C for 10 min and chill on ice for at least 1min.
Collect the contents of the tube by brief centrifugation and add the following:
Volume
Components
(μL)
Reaction Mastermix
10X PCR buffer
2
5
8
25 mM MgCl2
2
5
8
10 mM dNTP mix
1
5
4
0.1 M DTT
2
5
8
Total
7
28
Aliquot out 7 μL into 4tubes (#1-4)
Final composition of the reaction:
20 mM Tris-HCl (pH 8.4 at 22℃)
50 mM KCl
2.5 mM MgCl2
10 mM DTT
500 nM AP
500 μM each dATP, dCTP, dGTP,
dTTP
1-5 μg (<50 ng/μL) of RNA
5. Mix gently and collect the reaction by brief centrifugation. Equilibrate the mixture to
42°C for 2 to 5 min.
6. Add 1 μL of SuperScript II RT. Incubate the tube in a 42°C water bath or heat block
for 50 min.
7. Terminate the reaction by incubating at 70°C for 15 min.
8. Chill on ice. Collect the reaction by brief centriugation. Add 1 μL of RNase H to the
tube. Mix, and incubate for 20 min at 37°C before proceeding to Protocol 2.
9. The reaction mixture may be stored at -20°C and STOP or continue the Method 2.
Method 2.
Amplification of the Target cDNA
1. To a fresh 0.5 mL microcentrifuge tube, add the following:
Component
Volume (μL) Reaction
10X PCR buffer
25 mM MgCl2
Autoclaved, distilled water
10 mM dNTP mix
GSP (prepared as 10 uM solution)
UAP (10 μM)

5
3
36.5
1
1
1
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5
5
5
5
5
5

Master Mix
25
15
182.5
5
5
5

Taq DNA polymerase (2 to 5 units/μL)
Total

0.5
48

5

2.5
240

Final composition of the reaction:
20 mM Tris-HCl (pH 8.4)
50 mM KCl
1.5 mM MgCl2
200 nM GSP
200 nM AUAP or UAP
200 μM each dATP, dCTP, dGTP,
dTTP
0.04 to 0.1 unit/ μL Taq DNA
polymerase
2. Add 2 μL from the cDNA synthesis reaction to the tube. Collect the reaction
briefly by centrifugation.
3. Perform 20 to 35 cycles of PCR, using the protocol accompanying Taq DNA
polymerase.
Temp
94°C
94°C
55°C
72°C
72°C
4°C

Cycle
1
35
1

Time
3 min
45 sec
30 sec
1 min 30 sec
10 min
Until samples are removed

4. Analyze 10 to 20 μL of the amplified sample, using agarose gel electrophoresis
and ethidium bromide staining, and the appropriate molecular size standards. If
the positive control RNA was used, a single 720 bp band will be visible.
Method 3.
Gel purification.
Follow previous protocol.
Miniprep
Followed manufacturer’s recommended protocol
QIAprep Spin Miniprep Kit (QIAGEN# 27104)
***Note: Optional: Add LyseBluse reagent to Buffer P1 at a ratio of 1 to 1,000.
Add the provided Rnase A solution to Buffer P1, mix, and store at 2-8°C.
(*Total 20 mL of Buffer P1 + 20 μL of Lyseblue + 200 μL of RNase solution)
Add ethanol (100%) to Buffer PE before use.
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All centrifugation steps are carried out at 13,000 rpm (~17,900) in a conventional
tabletop microcentrifuge.
Method
1. Take the bacterial culture tubes out from shaker incubator overnight (37°C, 200
rpm).
2. Using 2 mL pipet, aliquot out 1.5 mL of bacterial growth in 2 mL microcentrifuge
tubes.
3. Centrifugation the tubes at >800 rpm (6,800 x g) for 3 min at room temperature.
4. Discard supernatant without disturbing pelleted bacterial cells.
5. Add 250 μL of Buffer P1 and scratch the tube on the rack to mix thoroughly.
Solution will turn cloudy.
6. Add 250 μL of Buffer P2 and mix thoroughly by inverting the tube 4-6 times
(gently flipping the tube) until the solution becomes clear. Do not allow the lysis
reaction to proceed for more than 5 min. If using LyseBlue reagent, the solution
will turn blue. Solution turns blue, then clear
7. Add 350 μL of N3 Buffer and mix thoroughly by inverting the tube 4-6 times
(gently flipping the tube). If using LyseBlue reagent, the solution will turn
colorless. Solution will be cloudy.
8. Centrifuge for 10 min at 13,000 rpm (~17,900 x g) in a tabletop microcentrifuge.
9. Aliquot out all the supernatant without disturbing pellet (bacterial DNA, no
needed) and try to avoid to pipetting white floating stuff. You only want the
supernatant into Qiaprep spin column by decanting or pipetting.
10. Add 500 μL of PB buffer to wash the QIAprep spin column. Centrifuge for 30-60
sec and discard the flow through, or apply vacuum to the manifold to draw.
Centrifuge for 30-60 sec and discard the flow through, or apply vacuum to the
manifold to draw the solution through the QIAprep spin column and switch off
the vacuum source.
11. Wash the QIAprep spin column by adding 750 μL Buffer PE. Centrifuge for 3060 sec and discard the flow through, or apply vacuum to the manifold to draw the
solution through the QIAprep spin column and switch off the vacuum source.
Transfer the QIAprep spin column to the collection tube.
12. Centrifuge hard for 1 min to remove residual wash buffer.
13. Place the QIAprep column in a clean 1.5 mL microcentrifuge tube. To elute DNA,
add 50 μL Buffer EB (10mM Tris-HCl, pH 8.5) or nucleic acid-free water to the
center of the QIAprep spin column, let it stand for 1min, and centrifuge for 1 min.
14. Do DNA quantification.
Preparation of Restrict Enzyme Reaction
Reagent
Amount
Nucleic Acid Free water
7 μL
10X FD (fast digest) Buffer
2 μL
Miniprep DNA (Elute 2)
10 μL
Eco R1 (Restriction Enzyme)
1 μL
20 μL
Incubate the tubes in 37°C water bath for 15 min. Then, ready to load the gel.
229

Cloning
Followed manufacturer’s recommended protocol
Generating Blunt Ends
Materials
T4 DNA Polymerase THERMO FISHER# 18005-016
1. To a Sterile 1.5 mL microcentrifuge tube on ice, add:
Component
Amount
5X T4 DNA polymerase buffer
20 μL
0.5 mM dNTP mix
20 μL
DNA [5' Race Final PCR product
pooled
6 μL
(Tube#9,10,11,12)]
T4 DNA polymerase (5U/μL)
2 μL
Autoclaved, distilled water
52 μL
Total
volume:
100 μL
2. Mix gently, and incubate at 11°C for 15 min.
3. Place reaction on ice. Store at -20°C.
4. Terminate reaction by phenol extraction, chloroform extraction and ethanol
precipitation.
Heat inactivation is not recommended, as heat inactivation may cause ends to
"breathe" and be more susceptible to 3' to 5' exonuclease activity.
Phenol extraction, chloroform extraction and ethanol precipitation
1. Extract the sample twice with phenol/chloroform/isoamyl alcohol (25:24:1).
Increase the volume of the sample to about 300 μL by adding sterile deionized
water into the sample. For each extraction, mix the DNA sample with an equal
volume of phenol/chloroform/isoamyl alcohol (25:24:1) until an emulsion is
formed.
2. The centrifuge the tube(s) at 12,000 x g for approximately 15 sec at room
temperature. The upper aqueous phase contains the DNA and should be
transferred to a fresh sterile microcentrifuge tube after each extraction.
3. Add sodium chloride (to a final concentration of 0.1M; use 20 μL of 5M NaCl) or
sodium acetate (final concentration, 0.25 M) to the sample. Then, precipitate the
DNA by adding a 2.5 volume of cold absolute alcohol (750-800 μL). Incubate for
30-45 min at -70°C, then centrifuge (12,000 x g) for 10 min at 4°C.
4. Discard the supernatant, dry DNA pallet under vacuum (or in a 37°C oven) and
resuspend the pellet in a convenient volume (20-200 μL) of sterile deionized
water and measure the optical density of the solution. Calculate the concentration
of the plasmid and the total amount of DNA obtained. DNA is ready for
restriction enzyme digestion and PCR analysis.

230

Zero Blunt TOPO PCR Cloning
Materials
Zero Blunt TOPO PCR Cloning Kit THERMO FISHER# K2800-020SC
Produce Blunt PCR Product
1. Set up the following 6 μL TOPO Cloning reaction
Reagent
Amount*
Fresh PCR Product
0.5-4 μL
Salt Solution
1 μL
Add to a total volume of 5
Sterile Water
μL
PCR Blunt II TOPO
1 μL
Total
6 μL
*For transformation of chemically competent E. coli only
2. Mix gently and incubate for 5 min at room temperature
3. Place tubes on ice. Proceed to Transformation and
Analysis.
Transformation
1. Thaw 1 vial of One Shot E. coli cells on ice for each transformation.
2. Add 2 μL of the TOPO Cloning reaction to each vial of One Shot cells to be
transformed, and mix gently.
3. Incubate the vials on ice for 5-30 min.
4. Heat-shock the cells for 30 sec at 42°C without shaking.
5. Add 250 μL of room temperature S.O.C. medium to the cells.
6. Cap the tubes and shake them at 37°C for 1 hour.
7. Spread 10-50 μL from each transformation on pre-warmed LB plates containing
50 μg/mL kanamycin or pre-warmed Low Salt LB plates containing 25 μg/mL
Zeocin selective antibiotic.
Refer to the Zero Blunt TOPO PCR Cloning Kit manual for a Low Salt LB
medium recipe.
8. Incubate plates overnight at 37°C.
An efficient TOPO Cloning reaction should produce several hundred colonies. Pick
~10 colonies for analysis. Proceed to Analyze Positive Clones.
Analyze Positive Clones
1. Culture the 10 colonies overnight in LB medium containing 50 μg/mL kanamycin
or low Salt LB medium containing 25 μg/mL Zeocin selective antibiotic.
2. Isolate plasmid DNA using your method of choice. For ultrapure plasmid DNA,
we recommend the PureLink HQ Mini Plasmid Purification Kit (Cat# K2100-01).
3. Analyze the plasmid by restriction analysis or by sequencing to confirm the
presence and orientation of the insert.

NGS data analysis command line coding method
Protocol from Dr. Ganwu Li’s laboratory at Iowa State University
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1. In DataAnalysis file, separate each sample file.
2. Choose individual file to work on.
3. Turn on Terminal
4. Type ls : view files
5. Type cd Desktop: enter to desktop
6. Type ls : view files on desktop
7. Type cd DataAnalysis to enter into the folder
8. Type ls : to view files in DataAnalysis
9. Choose EAV folder and Type cd (EAV-folder name) : to enter into the folder
10. Type ls : to view files in EAV file
11. Choose a sample folder and Type cd (sample folder name)
12. Create sample_list file : bash namelist.sh
13. View sample_list file : less sample_list
14. Trim the raw NGS data materials : bash batch_trim_Truseq.sh
a. First batch use the program: Trueseq.sh
b. Second batch use the program: Nextera.sh
c. You can check the condition of trimmed data looking at surviving %
15. Enter to cd trimmed/ : new folder
16. Type ls to view the trimmed folder
17. Type mkdir other : create other folder to keep unnecessary sample files
18. Type mv sample name R1 and R2 /others/ : to move two unnecessary sample files
to other folder
a. D107_S20_FUP_L001_R1_001.fastq.gz ./others/
b. D107_S20_RUP_L001_R2_001.fastq.gz ./other/

19. Create sample_list file in trimmed folder : bash namelist.sh
20. View sample_list file to check the right sample name : less sample_list
21. Copy EAVKY84.fasta file and paste into Trimmed folder in each sample folder
22. Do partial De Novo assembly to collect reads : bash general102314.sh
EAVKY84.fasta
a. To complete de Novo assembly, you need four different programs
including Seqman pro (commercial). But in my case, I don’t do complete
de novo assembly in my data analysis..
23. Enter into a folder cd (trimmed_sample name)
24. Type ls to view the folder (trimmed_sample name)
25. Type cd single_id txt .. : Copy single_id txt file in trimmed sample name folder
26. Type cd .. : to come out of trimmed sample name folder
27. Type ls : to view trimmed sample name folder and see if there is folder (single_id
txt)
28. Use seqtk subseq to get the reads Type and create two files (sample_R1 and
R2.fastq) :
a. seqtk subseq trimmed_S-S-D107_S20_L001_R1_001.fastq.gz single_id.txt >
sample_R1.fastq
b. seqtk subseq trimmed_S-S-D107_S20_L001_R2_001.fastq.gz single_id.txt >
sample_R2.fastq

29. Finally, you will do mapping of sample_R1 & R2.fastq and EAVKY84 with bwa
program :
a. EAVKY84 will be your reference EAV sequence
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b. Otherwise, you can use 33 EAV full length genome sequences for the
reference sequence
c. To do mapping, you can change the parameter for reads (how long or short
you want). But right now, I stick with one parameter to be simple
d. Create Index : bwa index EAVKY84.fasta
e. Then Type and create sam file : bwa mem -M EAVKY84.fasta sample_R1.fastq
sample_R2.fastq > sample.sam
f. Now it will do mapping

30. You need to convert sam file to bam file to visualize in IGV :
a. Type and convert sam to bam file : samtools view -hbS sample.sam >
sample.bam

b. Type and create sorted bam file : samtools sort sample.bam >sample.sorted.bam
c. Type : samtools index sample.sorted.bam
i. Samtools index for bam file is different from bwa index
ii. After sorting you will have (sample.sorted.bam.bai)
iii. Sample.sorted.bam is your final bam file that visualize via IGV program

31. Now you can view in IGV
a. First, you need to convert your EAVKY84.fasta into genome file
b. Press genome and click create genome file
i. Load EAVKY84.fasta
ii. Name and describe the file
iii. Save EAVKY84.genome in sample folder
c. Second, click load from file, then you load sample.sorted.bam file
d. You can see % at the ambiguous sites (ambiguity)
32. Now, type below to create consensus sequence :
a. samtools mpileup -uf EAVKY84.fasta sample.sorted.bam |bcftools call -c |
vcfutils.pl vcf2fq > cns.fq

b. To view your consensus sequence type : less cns.fq
c. To convert your consensus sequence from fastq to fasta, type : seqtk seq -a cns.fq
> cns.fasta

33. To find the numbers and location of your ambiguous sites, type :
a. perl ~/Desktop/boracode/ambcount.pl cns.fasta

At ISU, Ying helped me to download these below software programs and set up PATH
through command line (terminal) to do NGS data analysis: Also I need Ying’s self
written script to run these programs (boracode folder)
Trimmomatic.0.36 : for trim, clean the data to run the batch_trim_TruSeq or Nextera
IGV: visualizing for map
BWA : mapping
SAM tools : manipulate the mapping files SAM file will convert to BAM file
Seqtk: manipulate the fastq files
BWA (not Abyss and SeqPro): to run the de novo assembly
Lofreq: Variants calling software find the variant percentages
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17. GenBank accession # MG137443 – EAV KY84-L137B-BC6
18. GenBank accession # MG137444 – EAV KY84-L137B-NS6
19. GenBank accession # MG137445 – EAV KY84-L137B-S5
20. GenBank accession # MG137446 – EAV KY84-L137B-S9
21. GenBank accession # MG137447 – EAV KY84-L137B-S107
22. GenBank accession # MG137448 – EAV KY84-L138C-BC6
23. GenBank accession # MG137449 – EAV KY84-L138C-NS6
24. GenBank accession # MG137450 – EAV KY84-L138C-S5
25. GenBank accession # MG137451 – EAV KY84-L138C-S9
26. GenBank accession # MG137452 – EAV KY84-L138C-S107
27. GenBank accession # MG137453 – EAV KY84-L139D-BC6
28. GenBank accession # MG137454 – EAV KY84-L139D-NS6
29. GenBank accession # MG137455 – EAV KY84-L139D-S5
30. GenBank accession # MG137456 – EAV KY84-L139D-S9
31. GenBank accession # MG137457 – EAV KY84-L139D-S107
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